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Background: Mental health disorders represent a major public health problem in most 
countries around the world. In South Africa, the lifetime prevalence of psychiatric disorders 
is 30.3%, with substance-use disorders and mood disorders being the second and third most 
prevalent classes of lifetime disorders, respectively. Bipolar disorder (BD) has a lifetime 
prevalence of 1.4% and alcohol use disorder (AUD) a lifetime prevalence of 30.3%, and they 
are frequently comorbid. Both of these disorders have a relatively high heritability, yet the 
exact genetic basis of each remains unknown. Genetic variants within the hypothalamic-
pituitary-adrenal (HPA)-axis and glutamatergic pathways have previously been implicated in 
both phenotypes. The aim of this project was to investigate the aetiology of BD and AUD, 
using high-throughput genomic technologies, bioinformatics, brain-imaging and 
environmental measures. An additional aim was to assess the genetic aetiology of BD-AUD 
comorbidity. 
 Methods: For the genetic analysis underlying BD, a South African ‗Afrikaner‘ family was 
investigated. Whole-genome sequencing (WGS) and whole-genome linkage analysis was 
performed for individuals with BD Type I (BDI) and unaffected family members using the 
Illumina HiSeq2000 and Affymetrix AxiomTM Genome-wide CEU 1 Array, respectively. For 
the AUD analysis, two groups were investigated; a South African adolescent group 
comprising 80 individuals with AUD and 80 controls, and a group of 8123 individuals from 
the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. The South 
African group of adolescents were genotyped using the Illumina Infinium iSelect custom 
6000 BeadChip, childhood trauma data was obtained and brain magnetic resonance images 
were collected for a subset of this group. Genotype data on HPA-axis genes were obtained 
from a previous study for the ALSPAC cohort. The fourth group of individuals investigated 
in this thesis comprised 233 individuals with BD-AUD comorbidity from the Systemic 
Treatment Enhancement Program for BD (STEP-BD). Genotype data for genes from the 
glutamatergic and HPA-axis pathways were obtained from a previous study conducted on 
these individuals.  
Results: The chromosomal regions 6p25, 10p14-10p15.1, 11q23-11q25, and 13q21-22 
scored the highest LOD scores for BD and the most over-represented pathway in the affected 
family members was the T-cell receptor signalling pathway. In the South African adolescent 




alcohol use in adolescence. The gene-imaging analysis identified a SNP in the glutamate 
receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B) gene as being associated with brain 
volume in the left orbitofrontal cortex and posterior cingulate. HPA-axis genes did not show 
an association with AUD and no significant gene x environment interactions were detected 
for AUD in the ALSPAC cohort. Single variants in the glutamatergic genes and HPA-axis 
were not associated with BD-AUD comorbidity. However, from the gene-based analysis, the 
glutamatergic gene PRKCI was associated with BD-AUD comorbidity.  
Conclusions: It appears that disruption in immune-related genes may contribute to the 
development of BD in an Afrikaner family. No significant gene x environment interactions 
were detected for adolescent AUD. The circadian pathway and childhood trauma may play a 
role in the development of adolescent AUD. Differential brain volume and BD-AUD 
comorbidity may be characterised by variation in the glutamatergic pathway. These pathways 


















Investigating any single psychiatric disorder is a challenge, as revealed in the literature.  In 
this exploratory study the candidate investigates two distinct but related (and often co-
morbid) phenotypes (bipolar disorder and alcohol use disorder), using a range of 
methodologies.  It was hoped that the candidates exposure to these psychiatric phenotypes, 
and examination of her own data generated through genomic analyses, and access to data 
from other international studies, provide her with skills, and access to resources for future 
work in the challenging area of psychiatric genetics/genomics.   
This thesis consists of six chapters. Chapter 1 is an introduction, which includes descriptions 
and the epidemiology of the two psychiatric phenotypes under investigation, namely bipolar 
disorder and alcohol use disorder. Chapter 2 presents the investigation of the genetic basis of 
bipolar disorder in an Afrikaner family using whole-genome sequencing and whole-genome 
linkage analysis. Chapter 3 includes the investigation on alcohol use disorder in a local 
adolescent group using genetic, environmental and brain imaging measures. Brain imaging 
and gene-imaging analyses were performed in collaboration with Dr Samantha Brooks from 
the Department of Psychiatry and Mental Health at UCT. Chapter 4 provides an investigation 
of alcohol use in a European birth cohort, specifically investigating the HPA-axis. Chapter 5 
includes the investigation of the glutamate and HPA-axis pathways in a bipolar disorder 


















The Guest House  
 
This being human is a guest house.  
Every morning a new arrival.  
 
A joy, a depression, a meanness,  
some momentary awareness comes  
as an unexpected visitor.  
 
Welcome and entertain them all!  
Even if they're a crowd of sorrows,  
who violently sweep your house  
empty of its furniture,  
still, treat each guest honorably.  
He may be clearing you out  
for some new delight.  
 
The dark thought, the shame, the malice,  
meet them at the door laughing,  
and invite them in.  
 
Be grateful for whoever comes,  
because each has been sent  
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Chapter 1: Introduction  
Background 
South Africa has a history steeped in violence and oppression. For this reason, it is thought 
that this population group may be at higher risk of developing mental disorders [Williams et 
al., 2008]. Studies have shown the lifetime prevalence of psychiatric disorders is 30.3% in 
this country, with substance-use disorders (13.3%) and mood disorders (9.8%) being the 
second and third most prevalent classes of lifetime disorders, respectively [Herman et al., 
2009]. It has been projected, that in 2030, depression will be one of the top three burdens of 
disease [Mathers and Loncar, 2006]. An emphasis needs to be placed on mental health 
research in South Africa, in order to improve the understanding of the biology and 
environmental factors contributing towards the development of psychiatric diagnoses which, 
in turn, may aid in the development of effective treatment and/or management strategies. 
In this chapter the psychiatric phenotypes bipolar disorder and alcohol-use disorder, the foci 
of this study, are described in terms of the diagnostic classification and epidemiology of each 
disorder.  
1.1 Epidemiology of Psychiatric Disorders: Worldwide and in South Africa 
Mental health disorders represent a major public health problem in most countries around the 
world [Kessler et al., 2009]. In 2007, a study was conducted based on a cross-national 
epidemiological survey (Composite International Diagnostic Interview- CIDI) on 17 
participating countries including South Africa, Belgium, Colombia, France, Germany, Israel, 
Italy, Japan, Lebanon, Mexico, Netherlands, New Zealand, Nigeria, China, Spain, Ukraine, 
and the United States of America (USA), to determine the age of onset, projected lifetime 
risk (an estimation of the proportion of the population group who will have the investigated 
disorder by the end of their life) and lifetime prevalence (an estimation of the proportion of 
the population group who have been diagnosed with the investigated disorder by the time of 
interview) of mental health disorders [Kessler et al., 2007]. For this survey, data on 
psychiatric illnesses for South Africa was obtained from the South African Stress and Health 
(SASH) study which is the largest population-based mental health epidemiological study 
conducted in South Africa, consisting of 4351 adults of all ethnic groups [Stein et al., 2008; 




The results of the survey indicated that the lifetime prevalence for having one or more of the 
investigated classes of disorders varied considerably between countries.  For example, the 
USA and Nigeria had a lifetime prevalence of 47.4% and 12.0%, respectively, for having one 
or more of the disorders. South Africa lies roughly in-between the two above-mentioned 
countries, with a reported lifetime prevalence of 30.3% for any mental disorder (investigated 
in the study). Anxiety disorders were the most prevalent diagnoses in ten of the 17 countries 
(including South Africa) and impulse control disorders were the least prevalent. Unlike 
lifetime prevalence estimates, the distributions of age of onset were similar across the 
surveyed countries. Impulse control disorders had the lowest age of onset for most countries, 
and mood disorders had a similar age of onset (i.e. 29-43 years) as generalised anxiety 
disorder (GAD), panic disorder and post-traumatic stress disorder (PTSD). South Africa has a 
projected lifetime risk of 47.5% for any disorder, as of the age of 75 years.  Thus, nearly half 
of the South African population will develop a mental disorder in their lifetime. Countries 
with the highest rates of sectarian violence e.g. Israel, Nigeria and South Africa; had the 
highest risk-to-prevalence ratios of any mental disorder [Kessler et al., 2007].  
Mental health disorders place a considerable burden on the economy due to direct costs such 
as hospitalisation and treatment, and indirect costs such as loss of income due to 
unemployment [Insel, 2008]. In South Africa, it has been estimated that the annual loss in 
income due to depression and anxiety disorders for individuals affected with these conditions, 
is approximately $3.6 billion [Lund et al., 2013]. This data highlights the importance of 
mental health research in South Africa to improve the understanding of the biology and 
environmental factors contributing towards the development of psychiatric diagnoses which, 
in turn, may aid in the development of effective management strategies, thus reducing the 
burden of disease.   
1.2 Classes of Psychiatric Diagnoses 
One of the most prominent classification systems in clinical and research practice is the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) which is published by the 
American Psychiatric Association [American Psychiatric Association. Task Force on DSM-
IV, 1994], the most recent being the fifth edition (i.e. DSM-5), which was released in May, 
2013.  For the purpose of this thesis, all psychiatric diagnoses will be based on the DSM-IV 
classification. The DSM-IV is a tool for psychiatrists to assess their patients based on a 
multiaxial classification system which consists of five axes [American Psychiatric 




Axis I- Clinical Disorders: used for reporting on all conditions except Personality Disorders 
and Mental Retardation 
Axis II: Personality Disorders and Mental Retardation 
Axis III: General medical conditions which may be useful or relevant in the treatment of the 
individuals‘ mental illness 
Axis IV: Psychosocial and environmental issues which could be useful in the understanding, 
treatment and prognosis of the individual with the mental illness 
Axis V: Global functioning assessed by the clinician  
1.3 Mood Disorders 
Mood disorders are classified as Axis I disorders. In South Africa, mood disorders have a 
lifetime prevalence of 9.8% [Stein et al., 2008].  The development of effective therapies for 
mood disorders has been hampered by the lack of understanding of the pathophysiology of 
the disease and the mechanism by which current treatment strategies work [Sanacora et al., 
2008]. One of the most severe and prevalent mood disorders is bipolar disorder (BD).  
1.3.1 Bipolar Disorder– A Historical Perspective 
The concept of BD was reportedly first recognised by the French Psychiatrist, Jean-Pierre 
Falret in 1851 who termed this disorder as ―folie circulaire‖ or ‗circular madness‘ [Sedler, 
1983]. He observed that this disorder was characterised by episodes of mania followed by 
melancholia with ―symptom-free‖ periods in between the two mood states. Three years later, 
in 1854, another French psychiatrist, Jules Baillarger, described BD as ―folie à double forme‖ 
or ‗dual form insanity‘. In the 1890s, the renowned German psychiatrist Emil Kraeplin, 
described these symptoms as a ―double attack‖ [Angst and Sellaro, 2000]. Today, the 
diagnosis of BD is based on the classification by the DSM-IV [American Psychiatric 
Association. Task Force on DSM-IV, 1994] criteria, or, the more recently revised DSM-5.  
Based on different symptomatic criteria, there are several types of BD distinguishable in the 
population: i) BD type I (BDI), ii) BD type II (BDII), iii) Cyclothymia, and iv) ―BD not 
otherwise specified‖ (BDNOS) [American Psychiatric Association. Task Force on DSM-IV, 





1.3.2 Diagnostic Classification of BDI 
According to the DSM-IV, BDI is a recurrent mood disorder, characterized by the presence 
of one or more manic or mixed episodes (see Table 1 for diagnostic criteria of each mood 
episode). Manic episodes are typified by a period of abnormally elevated (euphoric) or 
irritable mood, feelings of grandiosity, reduced need for sleep and increased participation in 
pleasurable activities. The occurrence of one or more major depressive episodes (MDE) may 
also be a feature. Depressive episodes, as the name suggests, are characterised by depressed 
mood and a lack of interest in pleasurable activities. The mania associated with BDI should 
not be due to a Substance-Induced Mood Disorder or Schizoaffective Disorder. During severe 
manic episodes, violent or abusive behaviour may be experienced. On average, untreated BDI 
patients experience four episodes each decade [American Psychiatric Association. Task Force 
on DSM-IV, 1994]. There are no differences in BDI prevalence across gender and ethnicity. 
However, it has been noted that females have a later onset of mania and have more 
depressive episodes than males [Robb et al., 1998]. Most individuals return to an improved or 
functional state between episodes [American Psychiatric Association. Task Force on DSM-
IV, 1994]. 
1.3.1.2 Epidemiology 
BD is estimated to have a lifetime prevalence of 1.4% [Merikangas et al., 2011]. The lifetime 
prevalence of BDI and BDII are estimated at 0.6%-1% and 0.4%, respectively [Merikangas et 
al., 2007; Merikangas et al., 2011]. BDI affects males and females at equal frequencies and 
disease onset is usually during early adulthood [Miller, 2006]. Approximately 25% of those 
affected with BDI have attempted suicide [Merikangas et al., 2011]. 
BD is associated with significant social impairment, such that affected individuals have 
greater difficulty in sustaining interpersonal relationships and have trouble maintaining 
employment compared to those without mood disorders: a total of 54% of affected 
individuals were dismissed from their jobs compared to 29% of a matched unaffected group 
[Calabrese et al., 2003]. Studies have also showed that individuals suffering from the disorder 
have difficulty abiding by the law and they have a significantly higher chance of being 
arrested for crimes [Calabrese et al., 2003; Daff and Thomas, 2014]. Violent behaviour is 
often observed during manic episodes [American Psychiatric Association. Task Force on 
DSM-IV, 1994]. In 1991, the total economic burden of BD in the USA was estimated at 
US$45 billion. This cost is attributed to medication, hospitalisation, misdiagnosis, and the 




recent study conducted in the United Kingdom (UK) estimated the total cost to the National 
Health Service, attributable to BD, at GB£342 million [Young et al., 2011].    
BD is often accompanied by various other comorbidities. For example, approximately 65% of 
patients with BD have comorbidities such as an anxiety, substance abuse/use or eating 
disorder. Individuals with comorbidity usually have an earlier age of onset and a more severe 
phenotype [McElroy et al., 2001]. Yasseen et al. (2009) reported that 25% of BD patients 
also suffered alcohol abuse as a comorbidity. The United Nations Office on Drugs and Crime 
(UNODC) reported that an individual diagnosed with a mental disorder is three times more 
likely to be dependent on an illicit substance [http://www.unodc.org/unodc/en/data-and-
analysis/WDR-2010.html, UNODC World Drug Report, 2010]. Large epidemiological 
studies in the USA have shown that, compared to other Axis I psychiatric disorders, BD had 
the highest association with alcohol and substance use [Salloum and Thase, 2000]. This may 
suggest common aetiological pathways and genes underlying BD and substance abuse or 
dependence.  
1.4 Substance-Related Disorders 
Substance-related disorders are classified as Axis I disorders. Substance use and abuse is a 
major public health problem worldwide and in South Africa. The lifetime prevalence of 
substance use disorders (SUD) is 13.4% (the second most prevalent class of disorders), and 
the median age of onset is 24 years in South Africa [Stein et al., 2008]. In 2010, mental 
disorders and SUDs accounted for approximately 7.4% of all disability-adjusted life years 
(DALYs) for the top ten causes of total disease burden, worldwide, and are the primary cause 
of years lived with disability. The DALYs differed by age whereby adolescents and young 
adults had the largest percentage of DALYs. Alcohol-use disorder (AUD) accounted for 
approximately 9.6% of the DALYs attributable to the class ‗mental disorders and SUDs‘ 
[Whiteford et al., 2013]. 
The World Health Organisation (WHO) states that alcohol is a ―psychoactive substance‖ with 
―dependence–producing properties‖ which has been extensively used across many cultures 
for centuries [http://www.who.int/substance_abuse/publications/global_alcohol_report/en/]. 
Since the arrival of European settlers in South Africa, alcohol has played a major and often 
controversial role in the history of the country. Alcohol was the method of payment for cattle 




The Western Cape region has the highest reported prevalence of an overall community 
population of foetal alcohol syndrome (FAS) in the world [May et al., 2000]. Alcohol is the 
most abused substance at most speciality treatment centres across South Africa [Plüddemann 
et al., 2008]. Therefore, it is of great interest to investigate the intrinsic factors which place 
some individuals at greater odds of developing alcoholism than others, in a highly ―at risk‖ 
environment.   
1.4.1.1 Diagnostic Classification of Alcohol Use Disorder 
According to DSM-IV, AUD consists of alcohol abuse (AA) and alcohol dependence (AD). 
AUD is defined as the presence of three or more of the symptoms outlined in Table 2, in a 12 
month period. Abuse is defined as the continued use of a substance resulting in adverse 
consequences. However, the diagnosis of ‗abuse‘ differs from ‗dependence‘ in that it does not 
include the criterion of ‗tolerance‘ (criterion 1), ‗withdrawal‘ (criterion 2) and ‗compulsive 
usage‘ (criterion 3) of the substance (DSM-IV).  
1.4.1.2 Epidemiology 
Alcoholic beverages are consumed by individuals worldwide. The psychoactive ingredient of 
alcohol is ethanol which has the ability to induce feelings of euphoria and relaxation. The 
effect of alcohol is characterised by a biphasic pattern whereby the initial ―positive effects‖ 
(euphoria and relaxation, etc.) are followed by hangover, exhaustion, depression and 
sometimes vomiting and loss of consciousness [Oscar-Berman and Marinković, 2007]. The 
WHO reported, in 2012, 3.3 million deaths (5.9%) per year globally, were as a result of the 
harmful effects of alcohol [http://www.who.int/substance_abuse/en/].  
The lifetime prevalence of any AUD is approximately 30.3% [Hasin et al., 2007]. The WHO 
reports that the 12 month prevalence of AUD in South Africa in 2010 was 10% in males, 
1.5% in females and 5.6% in both sexes 
[http://www.who.int/substance_abuse/publications/global_alcohol_report/en/].  AA has been 
shown to be one of the most prevalent mental disorders in South Africa with an annual 
prevalence of 4.5% [Williams et al., 2008] and lifetime prevalence of 11.4% [Herman et al., 




Table 1: Diagnostic criteria for mood episodes characteristic of BD [American Psychiatric Association. 
Task Force on DSM-IV, 1994] 






Episode (MDE)  
a) Five or more of the following symptoms 
 Depressed or irritable (children and adolescents) mood 
 Decreased interest or pleasure in almost all activities 
 Significant changes in body weight 
 Insomnia or hypersomnia  
 Psychomotor agitation 
 Fatigue and decrease in energy 
 Feelings of worthlessness and excessive guilt 
 Diminished concentration and increased indecisiveness 
 Increased thoughts of death and suicidal ideation 
b) Symptoms do not meet criteria for mixed episode 
c) Symptoms cause functional impairment 
d) Symptoms not a result of physiological effect of substance 
e) Symptoms not as a result of bereavement and are present for longer than 






a) Period of abnormally elevated or irritable mood lasting at least one week 
b) Three or more of the following symptoms are present to a significant 
degree 
 Inflated self-esteem or grandiosity 
 Decreased need for sleep 
 Talkative 
 Racing thoughts 
 Easily distractible 
 Increased goal-directed activity or psychomotor agitation 
 Excessive participation in pleasurable activities with potential for painful 
consequences 
c) Symptoms do not meet criteria for mixed episode 
d) Symptoms cause functional impairment 
e) Symptoms not a result of physiological effect of substance 
 
Mixed Episode 
a) Criteria met for both Major Depressive Episode and Manic Episode nearly 
every day during a one week period 
b) Symptoms cause functional impairment 







a) Period of abnormally elevated or irritable mood lasting at least four days 
b) Three or more of the following symptoms are present to a significant 
degree 
 Inflated self-esteem or grandiosity 
 Decreased need for sleep 
 Talkative 
 Racing thoughts 
 Easily distractible 
 Increased goal-directed activity or psychomotor agitation 
 Excessive participation in pleasurable activities with potential for painful 
consequences 
c) Change in functioning  
d) Disturbance in mood observable by others 
e) Episode not severe enough to caused marked functional impairment 







Table 2: DSM-IV criteria for AUD diagnosis [American Psychiatric Association. Task Force on DSM-IV, 
1994] 
Criterion DSM-IV Definition 
1 Tolerance: The need for increasing volumes of the substance to reach intoxication or significant 
decrease of intoxication with continued use of the same volume 
2a Withdrawal: A maladaptive change in behaviour with physiological and cognitive features as a 
result of a decrease in tissue or blood concentrations of the substance, after extended and heavy 
usage of the substance 
2b When the individual maintains substance use to alleviate the symptoms of withdrawal 
3 Compulsively taking the substance at high volumes or for a prolonged period of time 
4 The individual expresses an intention to decrease or discontinue substance usage often with 
unsuccessful results 
5 The individual spends a great portion of his/her time obtaining, using and recovering from the 
effects of the substance 
6 The individual‘s daily routine revolves around the use of the substance, often resulting in not 
participating in important occupational, social or recreational activities  
7 The individual continues to use the substance even though he/she is aware of the detrimental effects 
the substance has on the individuals mental and physiological health 
 
In the Western Cape, the majority of the population is of mixed ancestry (ethnicity) and it is 
estimated that in this group, 3618 per 10 000 individuals have been treated at substance abuse 
centres. In comparison, the Black African, Caucasian, and Indian groups have 100, 504, and 1 
per 10 000 individuals treated for substance abuse, respectively. In terms of the proportion of 
individuals treated for AA, 48% are of mixed ancestry (ethnicity), 45% are Caucasian, 7% 
are Black African and less than 1% are Asian or Indian [Plüddemann et al., 2008]. AD has 
been estimated to be the most expensive psychiatric disorders with costs exceeding US $225 
x 109 per year [Sullivan et al., 2012]. According to the WHO, globally, the total number of 
deaths and DALYs due to alcohol-related diseases and injury are 5.1% 
[http://www.who.int/mediacentre/factsheets/fs349/en/]. In comparison, in South Africa, the 
total number of deaths and DALYs due to alcohol harm was estimated at 7.1% and 7.0%, 
respectively [Schneider et al., 2007]. 
1.4.1.3 Adolescent Alcohol Use Disorder 
Adolescence is defined as the transitional period from childhood to adulthood, approximately 
between the ages of 12-18 years. During this developmental stage, exploration and 
experimentation is at its peak [Phillips, 2008] and increases in social and novelty-




occurrence of psychiatric diagnoses [Paus et al., 2008]. During this critical period of 
development, alcohol is one of the most used substances which in turn is associated with an 
increased likelihood of nicotine and drug use, academic failure, delinquency and pregnancy 
[Saraceno et al., 2009]. Studies have shown that alcohol use in adolescence is a predictor of 
AD in adulthood [Grant and Dawson, 1997; Grant et al., 2006]. An earlier age of onset (mean 
age = 18.7 years) for AD is associated with more severe symptoms, comorbidity and family 
history of AD, compared to individuals with a later age of onset (mean age= 31.9 years) 
[Chen et al., 2011].  
A study involving high school learners from three sites in South Africa (Johannesburg, 
Durban and Cape Town) found that alcohol was the most abused substance, with cannabis 
being the most abused illicit substance [Parry et al., 2004].  Another study found that lifetime 
and current alcohol use was 57.8% and 37.7%, respectively, amongst female adolescents in 
the Western Cape [Phillips, 2008]. Alcohol usage has a detrimental effect on normal brain 
development during this time which may result in negative effects on cognition and 
emotional behaviour [Squeglia et al., 2009].  
Typically, adolescents who abuse alcohol are more likely to be addicted to illicit substances 
in adulthood [Rohde et al., 2001]. Therefore, they are an ideal group to investigate in terms of 
alcohol use as they are the ideal target group for the development of preventative strategies 
[Zimmermann et al., 2007].   
1.5 Overlap of Psychiatric Diagnoses 
Most psychiatric disorders are found to cluster in families and have a relatively high 
heritability [Kendler, 2013]. In this study, the genetic aetiologies of two psychiatric 
phenotypes were investigated. It remains unknown to what extent the genetic aetiology is 
unique for a particular disorder or is shared with other psychiatric diagnoses, particularly 
since diagnoses are classified based on clinical symptoms and not pathophysiology (as this is 
still largely unknown) [Kendler, 2013]. A recent study by the Cross Disorder Group of the 
Psychiatric Genomics Consortium (PGC) investigated the genetic aetiology, using genome-
wide SNP data, of the following psychiatric disorders: autism spectrum disorder (ASD), 
attention deficit-hyperactivity disorder (ADHD), BD, major depressive disorder (MDD) and 
schizophrenia (SCZ). The genetic correlation was high between SCZ and BD and moderate 
between SCZ and MDD; BD and MDD; ADHD and MDD [Cross-Disorder Group of the 




polymorphisms shared an association across all five of the above-mentioned disorders. Two 
of the four polymorphisms are found in genes encoding subunits of L-type voltage-gated 
calcium channels [Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013b]. 
These studies suggest that there is considerable overlap in the genetic aetiologies (and 
therefore the underlying pathophysiology) of various psychiatric disorders. 
In psychiatry, comorbidity between diagnoses is often observed [Merikangas et al., 1998a]. In 
an epidemiological study conducted in the USA, more than 40% of 12 month DSM-IV 
diagnoses had comorbidity, with comorbidity associated with disorder severity [Kessler et al., 
2005]. Another study found that 37% of individuals with an AUD had mental disorder 
comorbidity [Regier et al., 1990]. Psychiatric comorbidity is defined as ―the presence of a 
concurrent psychiatric syndrome in addition to the principal diagnosis…‖. Comorbidity is 
common in mental health disorders particularly in psychotic and major affective disorders. 
Much of the costs for treatment in mental health is attributed to comorbidity as comorbidity 
complicates diagnoses and hence treatment [Hirschfeld and Vornik, 2005].   
1.5.1 Overlap in BD and AUD 
BD has a high rate of comorbidity (65%) with other Axis I disorders [McElroy et al., 2001]. 
It has been established that BD and AUD are strongly comorbid [Hsieh et al., 2012; Schoepf 
and Heun, 2014]. Approximately half of patients diagnosed with BD have an AUD, and BD-
affected individuals are three times more likely to have an AUD than someone from the 
general population [Hirschfeld and Vornik, 2005; Oquendo et al., 2010]. Individuals affected 
with both disorders have a more severe outcome, characterised by an earlier age of onset, 
overall poorer functioning and increased suicide attempts [Cardoso et al., 2008; Oquendo et 
al., 2010]. It has also been shown that there are gender differences in the prevalence of BD-
AUD comorbidity, with BD-affected men more likely to have AUD comorbidity than 
females [Frye et al., 2003; Cardoso et al., 2008]. However, the direction of causality is as yet 
unknown. It has also been shown that individuals with a family history of a mood or AUD 
have three-fold higher prevalence of comorbidity than individuals with no family history of 
mental illness [Mantere et al., 2012]. It is also known that both of these psychiatric disorders 
have a high heritability [McGuffin et al., 2003; Epps and Holt, 2011]. Due to the substantial 
genetic component for both BD and AUD; and the high rate of comorbidity between the two 
disorders, it could be postulated that both BD and AUDs have common causative genetic 
variants. It has recently been proposed that investigating comorbid subtypes of BD, such as 




[Kerner et al., 2011; Hu et al., 2013].  Indeed, BD with comorbid AUD has been shown to be 
a strong familial sub-phenotype [Saunders et al., 2008].   
1.6 Project Aims and Objectives 
The aim of this project, in its entirety, was to investigate the aetiology of two psychiatric 
phenotypes, namely, BD and AUD using bioinformatics, high-throughput genomic 
technologies, brain-imaging and environmental measures. An additional aim was to assess 
the genetic aetiology of BD-AUD comorbidity.  
1.6.1 Objectives  
The objectives of this entire study were as follows: 
1) The genetic aetiology of BD was investigated using whole-genome sequencing and whole-
genome linkage analysis in an Afrikaner family. 
2) The aetiology of AUD was investigated by integrating high-throughput genotyping data 
with brain-imaging and environmental measures in a South African adolescent group and in a 
European birth cohort. 
3) The genetic aetiology of BD-AUD comorbidity was assessed by investigating the 
glutamatergic pathway and hypothalamic-pituitary-adrenal (HPA)-axis using publically-












Chapter 2: An Investigation of the Genetics Underlying Bipolar 
Disorder  
Abstract  
Family, adoption and twin studies strongly suggest that BD has a genetic component, with 
heritability estimates as high as 85%. The aim of this study was to identify BD susceptibility 
variants using whole-genome technologies in a large Afrikaner family affected with BD. 
Whole-genome sequencing was performed on four related individuals with BDI from a large 
Afrikaner family, using the Illumina HiSeq2000TM Sequencer. Additional family members 
were genotyped using the AxiomTM Genome-wide CEU 1 Array. Quality control of 
sequencing data was performed using FastQC, mapping to the reference sequence using the 
Burrows Wheeler Aligner program and post-alignment processing and variant calling was 
performed using SAMtools and the Genome Analysis Toolkit. Whole-genome linkage 
analysis was performed using the program Superlink Online SNP 1.1. The chromosomal 
regions 6p25, 10p14-10p15.1, 11q23-11q25, and 13q21-22 showed the highest LOD scores, 
and these genomic regions containing immune–related genes and pathways were the most 
over-represented in BD. These findings need to be validated in other Afrikaner families (as 
well as other BD cohorts) and the exact disease-causing variants identified. Whole-genome 
sequencing data may contribute to understanding which genetic variants underlie complex 
disorders such as BD.  
2.1 Introduction 
BD is a severe psychiatric illness, characterised by extremes in mood with affected 
individuals experiencing episodes of mania and depression. The understanding of the 
aetiology of this devastating disorder has been hampered by clinical and genetic 
heterogeneity. With the advancement of next generation sequencing (NGS) technologies, it is 
anticipated that details of the underlying pathophysiology of BD will become clearer.  
2.1.1 Genetic Basis of BD  
Family, adoption and twin studies strongly suggest that BD has a genetic component [Smoller 
and Finn, 2003]. First degree relatives and half-siblings of an affected individual are at a 
higher risk of developing the disorder [Müller-Oerlinghausen et al., 2002; Lichtenstein et al., 
2009]. Heritability estimates (a measure of the phenotypic variance attributable to the 




2003].  A recent study showed that the offspring of individuals with BD also have a higher 
rate of other mood (~35%) and anxiety (~43%) disorders [Vandeleur et al., 2012].  
Despite the high heritability of BD, the underlying genetic aetiology is still unknown. 
Linkage analysis, candidate gene association and genome-wide association studies (GWAS) 
have been conducted for BD in various populations, the details of which are outlined below.  
However, it is evident from the results of these past studies, due to the lack of a replicable 
genetic signal, that it is unlikely that just a single gene or single variant will confer a 
predisposition towards developing BD. The onset of BD is likely to be determined by 
common variants of small effect within numerous genes [Purcell et al., 2009], possibly 
interacting with the environment [Uher, 2014].  
2.1.1.1 Linkage Studies  
Linkage analysis is used to identify chromosomal regions which contain disease genes. This 
technique measures the recombination fraction between genetic markers and is based on the 
observation that genes which are physically close to each other co-segregate after meiosis. 
The measure of linkage is the logarithm of odds (LOD) score which is defined as the 
logarithm of the odds that the loci are linked divided by the odds that the loci are unlinked 
[Pulst, 1999]. Once the chromosomal region has been identified, fine mapping is used to 
identify the disease-causing gene/s.  
Regions on almost every chromosome have been found to be linked to BD i.e. the strongest 
evidence of linkage for BD has been shown for the following chromosomal regions: 1p34-
p36 [Schumacher et al., 2005]; 3p14 [Etain et al., 2006]; 4q31-q32 [Ekholm et al., 2003; 
Schumacher et al., 2005]; 6q [Dick et al., 2003; Middleton et al., 2004; Pato et al., 2004; 
Schumacher et al., 2005]; 8q24 [Cichon et al., 2001]; 10p12 [Cheng et al., 2006]; 10q25 
[Cheng et al., 2006]; 12q24.3 [Ewald et al., 2002]; 13q32 [Detera-Wadleigh et al., 1999]; 
16q24 [Cheng et al., 2006]; 16p13 [Cheng et al., 2006]; 16p12 [Ekholm et al., 2003; Cheng et 
al., 2006]; 17q [Dick et al., 2003]; 18p [Stine et al., 1995]; 20p11.2 [Radhakrishna et al., 
2001]; 22q13 [Kelsoe et al., 2001]. There has not been much consistency in terms of the top 
regions identified across studies, which could possibly be due to false positive and negative 
findings. False negatives occur because of under-powered studies [Segurado et al., 2003] and 
5% of all reported significant linkage findings are likely false positives [Lander and 
Kruglyak, 1995]. In an attempt to overcome this, meta-analyses have been used to identify 




Several meta-analyses of whole-genome linkage scans for BD have been conducted and have 
shown the most significant regions of the genome to be 6q [McQueen et al., 2005], 8q 
[McQueen et al., 2005], 13q [Badner and Gershon, 2002] and 22q [Badner and Gershon, 
2002]. Segurado et al. (2003) found nominal significance in the regions 9p and 18p-q. Again, 
there is not much consistency across these findings suggesting that alternate approaches to 
linkage be utilised or to combine linkage analysis with other techniques and technologies, 
such as NGS. 
2.1.1.2 Candidate Gene and Genome-Wide Association Studies  
The candidate gene approach investigates genes which have been reported to be linked to 
disease in previous research, or focuses on loci based on their purported role in the biology of 
the disorder. Numerous candidate gene association studies have been conducted for BD, 
however as with many other psychiatric disorders, results from these studies have been 
inconclusive [Sullivan et al., 2012]. Most association signals have not been able to be 
replicated and much of the missing heritability is still unexplained. The greatest disadvantage 
of association studies is that they are highly influenced by confounding factors such as 
ethnicity, which may result in findings of spurious significance [Risch, 2000].  
More recently, instead of candidate gene analysis, researchers have adopted more high-
throughput approaches such as GWASs. Candidate gene based association studies are more 
cost-effective than GWAS but require a hypothesis regarding the relationship of the gene to 
disease [Hirschhorn and Daly, 2005]. GWAS is an a priori association method which utilises 
high-throughput genotyping methods, on very large cohorts of subjects/patients and controls, 
to determine whether genetic variants, such as single nucleotide polymorphisms (SNPs) 
spread across the genome, have an association with disease status compared to equally large 
numbers of controls [Hirschhorn and Daly, 2005].  
The first GWAS for any disorder was published in 2005 and since then, as many as 1000 
associations have been identified for approximately 200 genetic traits [Olfson and Bierut, 
2012]. Initially, GWASs have had limited success in identifying causative loci for psychiatric 
disorders. However, with considerably large increases in sample size, replicable signals have 
been identified. For example, a recent SCZ GWAS consisting of approximately 13 000 cases 
and 18 000 controls (with a replication sample of 7 413 cases; 19 762 controls and 581 
parent-offspring trios), found 22 loci with genome-wide significance [Ripke et al., 2013]. 




which met genome-wide significance, 83 of which were novel loci. A large proportion of 
these significant genes are expressed in tissues involved in the immune system 
[Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014].   
To date, approximately 38 GWASs, with a minimum of 100 000 SNPs assayed, have been 
conducted for BD [http://www.genome.gov/gwastudies/]. Results from each of these studies 
have been variable, with few of the findings being replicable. Most BD GWAS studies were 
unable to find genome-wide significant hits, but instead report on findings below threshold 
that have biological plausibility. Most GWASs have been conducted on Caucasian and 
European population groups. Several BD GWASs comprise individuals from large consortia 
such as the PGC. The aim of the PGC, which was started in 2007, was to conduct meta-
analyses for psychiatric GWASs. This consortium, which is one of the biggest in psychiatry, 
consists of more than 80 institutions from 25 countries. The main focus of the PGC is to 
investigate the genetics underlying ASD, ADHD, BD, MDD and SCZ 
[https://pgc.unc.edu/index.php].  
Some of the many interesting findings from BD GWAS over the last several years include 
ankyrin 3 (ANK3); calcium channel, voltage-dependent, L type, alpha 1C subunit 
(CACNA1C), and diacylglycerol kinase, eta (DGKH) [Sklar et al., 2008; Ferreira et al., 2008; 
Liu et al., 2011b; Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; 
Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013b; Mühleisen et al., 
2014; Ruderfer et al., 2014]. A list of the top findings of each of the 38 BD GWASs is listed 
in Table 3 (several of these GWASs have overlapping datasets). The largest BD GWAS to 
date, which was a meta-analysis conducted exclusively on BD, investigated 2.3 million SNPs 
in 9 747 BD affected individuals and 14 278 controls. This study identified two new loci 
associated with BD, adenylate cyclase 2 (ADCY2) located at 5p15.31 and the region 6q16.1, 
and was able to replicate previous associations found in the genes ANK3, odd Oz/ten-m 
homolog 4 (ODZ4) and tetratricopeptide repeat and ankyrin repeat containing 1 (TRANK1) 
[Mühleisen et al., 2014]. 
As results from linkage and association studies have been inconclusive regarding the BD 
phenotype, recent studies have focused on stratifying affected individuals by comorbidity 
[Kerner et al., 2011], symptom dimensions [Labbe et al., 2012], or clinical subtypes 




symptom dimension of ―negative mood delusions‖ and the chromosomal region 3q26.1 




Table 3: List of GWASs conducted for BD 




Ancestry Genotyping Platform 
Genome-wide Significant/Top 
Findings 
Genome-wide association study 
of 14,000 cases of seven common 





BD 2000 cases, 3000 controls Caucasian Affymetrix GeneChip 500K 16p12 
A genome-wide association study 
implicates diacylglycerol kinase 
eta (DGKH) and several other 
genes in the etiology of bipolar 
disorder 







Caucasian Illumina HumanHap550 DGKH (13q14.11) 
Collaborative genome-wide 
association analysis supports a 
role for ANK3 and CACNA1C in 
bipolar disorder1 






6209 controls Caucasian Affymetrix GeneChip 500K 
ANK3 (10q21) 
CACNA1C (12p13.3) 
Whole-genome association study 
of bipolar disorder 
[Sklar et al., 
2008] 
 




association study of bipolar 
disorder in the Japanese 
population 
























DEC1 (9q32), IRF2(4q34.1), 
VEPH1(3q24), EXTL1(1p36.1), 
PCDH15 (10q21.1), MYT1L (2p25.3), 
CSMD1(8p23.2), DYNC1I1 (7q21.3), 
PCSK5 (9q21.3), OLFM3 (1p22), 
PLXNA2 (1q32.2), KCNMB2 (3q26.2), 





A genomewide association study 
of response to lithium for 
prevention of recurrence in 
bipolar disorder 







1177 cases Caucasian Affymetrix GeneChip 500K rs10795189 (10p15) 
Genome-wide association and 
meta-analysis of bipolar disorder 
in individuals of European 
ancestry1 
[Scott et al., 
2009] 
 
BDI 2076 cases, 1676 controls Caucasian Illumina HumanHap550 
1p31.1, 3p21 (ITIH1, GNL3 NEK4, 
ITIH3), 5q15(MCTP1), 
Genome-wide association study 
of bipolar disorder in European 
American and African American 
individuals1 
















Affymetrix SNP 6.0 




Singleton deletions throughout 
the genome increase risk of 
bipolar disorder 
[Zhang et al., 
2008] 
 
BDI, SABP 1001 cases, 1033 controls Caucasian Affymetrix SNP 6.0 Singleton deletions increased in BD 
A genome-wide association study 
of bipolar disorder in Norwegian 
individuals, followed by 




BD 194 cases, 336 controls Caucasian Affymetrix SNP 6.0 
DLEU2, 
GUCY1B2, PKIA, CCL2, CNTNAP5, 
DPP10, and FBN1 
A genome-wide meta-analysis 
identifies novel loci associated 
with 
schizophrenia and bipolar 
disorder1 
[Wang et al., 
2010a] 
 
BD, SCZ 653 cases, 1034 controls Caucasian Affymetrix SNP 6.0 rs11789399 (9q33.1) 
Genome-wide Association Study 
Identifies Genetic Variation 
in Neurocan as a Susceptibility 
Factor for Bipolar Disorder1 
[Cichon et al., 
2011] 
 




Case-case genome wide 
association analysis reveals 
markers 
differentially associated with 
schizophrenia and bipolar 
disorder 
and implicates calcium channel 
genes 




506 cases, 523 
SCZ, 
505 controls 
Caucasian Affymetrix GeneChip 500K, Affymetrix SNP 5.0 CACNG5-rs17645023 
Propensity Score-Based 
Nonparametric Test Revealing 
Genetic 





BD 1998 cases, 3004 controls Caucasian Affymetrix GeneChip 500K rs420259, rs9378249, rs12938916 
Genome-Wide Association Study 
in Bipolar Patients 
Stratified by Co-Morbidity 






1034 controls European Affymetrix SNP 6.0 rs1039002 near PDE10A (6q27) 
Genome-wide association study 
of bipolar I disorder in the 
Han Chinese population 
[Lee et al., 
2011] 
 
BD 1000 cases, 1000 controls Hans Chinese Illumina HumanHap550-Duo 
Near to ST8SIA2- rs2709736, 
rs8040009, KCTD12- rs2073831, 
CACNB2- rs11013860 
Meta-Analysis of Genome-Wide 
Association Data of Bipolar 
Disorder and Major Depressive 
Disorder1 
[Liu et al., 
2011b] 
 
BD, MDD 4387 cases, 6209 controls Caucasian Affymetrix GeneChip 500K CACNA1C-rs1006737, rs7297582 
Genome-wide association 
analysis of age at onset and 
psychotic symptoms in bipolar 
disorder1 
[Belmonte 






2744 controls Caucasian 






association analysis of bipolar 
disorder identifies a new 









BD 7481 cases, 9250 controls 
European-
American 
Affymetrix 500K, Affymetrix 
5.0, Affymetrix 6.0 
and Illumina HumanHap 500 
CACNA1C, ODZ4 
Genome-Wide Association of 
Bipolar Disorder Suggests 
an Enrichment of Replicable 
Associations in Regions near 
Genes 
[Smith et al., 
2011a] 
 
BD 2191 cases, 1434 controls European Affymetrix SNP 6.0 Near CACNA2D-  rs2367911 
Genome-wide association study 
on bipolar disorder 








Genome-wide association study 
in a Swedish population yields 
support for greater CNV and 
MHC involvement in 
schizophrenia 
compared with bipolar disorder1 
[Bergen et al., 
2012] 
 
BD, SCZ 2343 cases, 2093 controls European 
Affymetrix SNP 6.0, 
Affymetrix SNP 5.0 MHC region for SCZ 
Genome-wide association of 
mood-incongruent 
psychotic bipolar disorder1 







8148 controls European 
Affymetrix SNP 6.0, 
Affymetrix SNP 5.0 
PRSS35/SNAP91-rs1171113 (6q14.2), 
TRANK/LBA1- rs9834970 (3p22.2), 
NUMB -rs2333194 (14q24.2) 
Genome-wide Association Study 
of Temperament in Bipolar 
Disorder Reveals Significant 














association between a 
‗negative mood delusions‘ 
dimension in bipolar 
disorder and genetic variation on 
chromosome 3q26.1 














A genome-wide association study 
of attempted suicide1 










Affymetrix SNP 6.0, Illumina 
HumanHap550 rs300774 (2p25) 
Genome-wide association study 
meta-analysis of 
European and Asian-ancestry 
samples identifies three 
novel loci associated with bipolar 
disorder1 










Affymetrix SNP 6.0, Illumina 
HumanHap550 near TRANK1-rs9834970 
Genome-Wide Association Study 
of Irritable vs. Elated 
Mania Suggests Genetic 
Differences between Clinical 








1434 controls European Affymetrix SNP 6.0 33 SNPs (13q31) 
A genome-wide association study 
of seasonal pattern mania 
identifies 
NF1A as a possible susceptibility 
gene for bipolar disorder 












Genetic Predictors of Risk and 
Resilience in Psychiatric 
Disorders: A Cross-Disorder 
Genome-wide Association Study 
of Functional Impairment in 
Major Depressive Disorder, 








765 cases European American 
Affymetrix GeneChip Human 
Mapping 500K, Affymetrix 
SNP 5.0 
ADAMTS16 
GWAS meta-analysis identifies 
TSNARE1 as a novel 
Schizophrenia / 










Illumina 1MDuoV3, Illumina 
HumanHap550 or 610 Quad TSNARE1- chr8q24.3 
Identification of risk loci with 
shared effects on five major 









BD 6990 cases, 4820 controls European Multiple platforms 
3p21, 10q24, 
CACNA1C and CACNB2 
Cross-disorder genomewide 
analysis of schizophrenia, bipolar 
disorder, and depression1 
[Huang et al., 
2014] 
 
BDI, BDII 1575 cases, 1204 controls Caucasian Affymetrix GeneChip 500K ADM-rs6484218 
Identification of novel loci for 
bipolar I disorder in a multi-stage 
genome-wide association study 
[Kuo et al., 
2014] 
 
BD 200 cases, 200 controls Taiwanese 
Illumina 
HumanOmni1-Quad rs7619173 
Genome-wide association study 
reveals two 




















Genetic Relationships Between 
Suicide Attempts, 
Suicidal Ideation and Major 
Psychiatric Disorders: 
A Genome-Wide Association and 
Polygenic Scoring Study1 














Polygenic dissection of diagnosis 
and clinical dimensions of 





BD and SCZ 19779 cases, 19423 controls Caucasian 





Illumina Human 610-Quad, 
Illumina 300K, 
Illumina 650 
CACNA1C, IFI44L, MHC, TRANK1, 
MAD1L1, PIK3C2A 
Genome-wide association study 
of bipolar disorder accounting 
for effect of body mass index 










American Affymetrix SNP 6.0 TCF7L2- rs12772424 
Genome-wide association study 
of bipolar 
disorder in Canadian and UK 
populations 
corroborates disease loci 
including SYNE1 
and CSMD1 
[Xu et al., 
2014] 
 
BD 950 cases, 950 controls Caucasian 
Illumina- 
Sentrix Human Hap550 
BeadChip, Affymetrix 5.0 
SYNE1, PPP2R2C, ZNF659, CNTNAP5, 
CDH13 
1 Indicates a meta-analysis. BD- bipolar disorder, BDI- bipolar disorder type I, BDII- bipolar disorder type II, BMI- body mass index, MDD- major depressive disorder, 




2.1.2 Next Generation Sequencing Technologies and Complex Disorders 
Since its discovery in 1977 [Sanger et al., 1977], Sanger sequencing, also known as first 
generation sequencing, has been the gold-standard in deoxyribonucleic acid (DNA) 
sequencing [Tsiatis et al., 2010]. The automation of Sanger sequencing led to the completion 
of the sequenced human reference genome [Metzker, 2010] at a cost of approximately $1 
billion [Bentley, 2006]. However, over the years a demand arose for faster and cheaper 
sequencing methods which ushered in the era of second generation or NGS technologies. 
Most NGS platforms amplify isolated DNA and have removed the bacterial cloning step 
characteristic of traditional Sanger sequencing [von Bubnoff, 2008].  Since 2005, the use of 
this technological advancement has become widespread and offers an approximately four 
times reduction in cost compared to traditional Sanger sequencing [Bamshad et al., 2011]. 
NGS technologies have been relatively successful in identifying rare causal variants in 
‗simple‘ Mendelian disorders [Ku et al., 2011]. In addition, NGS ―success‖ stories include 
the rapid diagnosis  of genetic diseases (approximately 50 hours) in neonates [Saunders et al., 
2012], and the use of whole genome sequencing (WGS) has allowed the identification of a 
locus at chromosomal region 8q24 as having an association with prostate cancer in 
individuals of Icelandic origin  [Gudmundsson et al., 2012].  
In terms of the applicability of NGS in psychiatric disorders, using whole-exome sequencing 
(WES) (includes only coding regions of the genome), several de novo mutations in sporadic 
cases of SCZ were detected. Non-synonymous, protein altering mutations were more 
common in SCZ cases than controls [Xu et al., 2011]. Similarly, the use of WES of 
individuals with ASD have identified de novo and inherited mutations of large effect size 
[Sanders et al., 2012; Yu et al., 2013].  To date, only a handful of studies have interrogated 
the genetic aetiology of BD using NGS. One of these studies employed WES in a Caucasian 
familial cohort with BD, to determine whether rare variants predispose individuals to having 
a good response to lithium, a BD sub-phenotype. The most notable finding was that a 
missense variant in the gene zinc finger protein 259 (ZNF259) segregated completely with 
affected family members in one of the families [Cruceanu et al., 2013]. Another WES study 
which examined BD with comorbid anxiety spectrum disorder in a Caucasian family found 
that rare heterozygous variants in the genes IQ motif and ubiquitin domain containing 
(IQUB), jumonji domain containing 1C (JMJD1C), growth arrest and DNA-damage-
inducible, alpha (GADD45A), golgin B1 (GOLGB1), phospholipid scramblase family, 




(MESDC2), and FGGY carbohydrate kinase domain containing (FGGY) were exclusively in 
the affected family members but not in the unaffected members or 200 additional controls. 
These genes all play a role in various intracellular-signalling pathways important for neuronal 
and synaptic plasticity, cognition, and response to chronic stress [Kerner et al., 2013]. The 
mitogen-activated protein kinase (MAPK) signalling pathway was associated with BD in a 
separate WES study [Chen et al., 2013b]. A WES study conducted on Old Order Amish 
families found that a missense variant (c.1181G>A) in the potassium channel, voltage gated 
eag related subfamily H, member 7 (KCNH7) gene had an association with BD (Strauss et al., 
2014). Another study investigating Old Order Amish families combined WGS data with 
whole-genome linkage analysis and family-based association analysis in a group of 18 
parent-child trios [Georgi et al., 2014]. This study showed several linkage peaks, which 
included chromosomal regions 7q21 and 18p11. However, the combination of the results of 
the three types of analyses in the affected families was not able to identify convergent risk 
loci or pathways for BD.  Another WGS study was conducted on 99 individuals affected with 
BD in a European population group. Variants within the ANK3 and CACNA1C genes with 
significantly different allele frequencies between cases and 1000 Genomes Project data were 
validated in a separate BD case-control cohort. From this study, the most significant SNPs 
identified were CACNA1C rs79398153 and ANK3 rs139972937 [Fiorentino et al., 2014]. It 
can be noted that there is not much overlap between each of the above-mentioned NGS 
studies. However, since the studies were generally conducted on families, it is possible that 
the identified variants or regions were family or population specific. Therefore, in terms of 
NGS analysis, family-based study designs with large pedigrees may be ideal in detecting 
possible candidate genes for BD in specific population groups.  
Although NGS offers many interesting and exciting avenues of exploration for researchers, 
there are still several challenges associated with the use of this technology. One of these 
challenges is the generation of short sequence reads which is a characteristic of several 
platforms including Illumina. Short sequence reads complicate sequence assembly and 
mapping to a reference sequence particularly in ‗repeat-rich‘ regions. Another challenge is 
that certain areas of the genome are more difficult to sequence (for e.g. GC-rich regions) 
which results in low coverage in those particular regions. Each of the NGS platforms has an 
associated error rate which presents another challenge in the data analysis [Hui, 2014].  
Besides the technical difficulties related to sequencing, the bioinformatics analysis poses 




identification of novel disease-causing genes or variants from the many thousands of benign 
variants and sequencing errors [Bamshad et al., 2011].  One method of controlling for this is 
by the use of discrete filtering. In most instances the ―novelty‖ of a gene or variant is 
assessed by filtering against databases of known variants such as dbSNP and 1000 Genomes 
Project or unaffected members of the population. This method is based on the premise that 
the disease-causing variant/s are not present in the ―filter set‖ [Bamshad et al., 2011].  
2.1.2.1 Illumina NGS Platform 
Illumina manufactures  one of the most used NGS platforms [Metzker, 2010]. The first step 
in sequencing on most NGS platforms is library preparation. Genomic DNA is randomly 
fragmented and ligated to common adapters [Shendure and Ji, 2008]. Most sequencing 
technologies are incapable of detecting single fluorescent molecules, therefore all fragments 
of interest need to be amplified before sequencing can occur. The Illumina WGS platform 
makes use of a solid phase amplification system known as bridge amplification or 
―clustering‖. This is achieved by the amplification of target DNA by forward and reverse 
primers covalently attached to a glass slide. The single molecule target DNA is firstly primed 
and extended, thereafter bridge amplification occurs, resulting in approximately 1000 copies 
of a single DNA molecule [Shendure and Ji, 2008; Metzker, 2010].  
2.1.3 Aims and Objectives 
The aim of this investigation was to identify susceptibility genes and variants for BD in a 
large Afrikaner family.  
2.1.3.1 Objectives 
The objectives of this investigation were as follows: 
1) To identify novel BD variants and genes present in BDI affected family members using 
WGS. 
2) To filter the variants and genes identified using whole-genome linkage analysis. 





2.2 Materials and Methods 
2.2.1 Research Group 
The research group consisted of members of an Afrikaner family who were affected with BDI 
and their unaffected family members. Additionally, publically-available genetic data for the 
Dutch background population were used as controls. Details regarding each of these groups 
are outlined below.  
2.2.1.1 Family 30 
The BD research project, based in the Division of Human Genetics at the University of Cape 
Town (UCT) was first granted institutional ethics approval on the 30th of May 1996. The 
focus was on investigating the molecular basis of BD. To date, a total of 919 individuals from 
221 families have been recruited from all over South Africa. These individuals are of 
Caucasian (British, Afrikaner, Portuguese, Greek, and Ashkenazi Jewish), mixed ancestry, 
Indian and African ethnicity. Each individual has provided blood or saliva samples for DNA 
studies and undergone numerous neuropsychological tests, including the Structured Clinical 
Interview for the DSM-IV (SCID) [First et al., 1996]. As the name suggests, SCID is a semi-
structured questionnaire which allows for the diagnosis of DSM-IV axis disorders. The most 
prevalent diagnoses present in the archive includes mood disorders (BDI, BDII, MDE) (with 
BDI being the primary diagnosis), borderline personality disorder, PTSD and AA. For the 
purposes of this study, only one family from the BD genetics repository was investigated.  
Family 30 is one of the largest families in the BD research project, consisting of 74 
individuals. A subset of this family tree (consisting of two family branches) can be found in 
Appendix 1 (Family tree). A total of five individuals have been diagnosed with BDI, one 
individual with BDNOS, 17 individuals with recurrent MDE, and 11 with single episode 
MDE. The rest of the family members do not have a psychiatric diagnosis. This family is 
relatively well characterised and of Afrikaner ancestry. The Afrikaner population group of 
South Africa are considered to be genetically distinct from other groups in the country. This 
population group are mainly the descendants of Dutch settlers (approximately 1000-2000) 
who arrived in the Western Cape Province from 1652, onwards. European immigration to 
South Africa continued  in the 17th Century by the French, and in the 18th and 19th centuries 
by the Dutch, German and British [Botha and Beighton, 1983]. Subsequently, the Afrikaners 
moved inland where they formed and maintained geographically isolated communities 




three million individuals, and due to language barriers, lack of immigration, and endogamy in 
the earlier generations, have remained relatively genetically isolated [Abecasis et al., 2004]. 
Afrikaner families have a high prevalence of rare Mendelian disorders such as porphyria 
variegata, Fanconi anaemia and Huntington Disorder [Greeff, 2007] and have been shown to 
have conserved haplotypes around disease-causing genes, suggesting strong genetic ‗founder‘ 
effects. Due to these factors, individuals of Afrikaner descent have often been described as 
ideal candidates for molecular studies [Abecasis et al., 2004].  
For the purposes of this study, for which updated ethical approval was obtained (UCT Human 
Research Ethics Committee (HREC) reference number 023/2012), five individuals with BDI 
and 15 family members without a BDI diagnosis were investigated. One of the BDI affected 
family members had committed suicide prior to blood collection; however permission was 
obtained for genetic analysis from the surviving family members. 
2.2.1.2 Control Group  
The Genome of the Netherlands (GoNL) forms part of the Biobanking and Biomolecular 
Research Infrastructure-Netherlands (BBMRI-NL) which is a national network of biobanks in 
the Netherlands and a node of the bigger European biobanking initiative. The aim of the 
GoNL was to characterise DNA sequence variation in a Dutch population group by the use of 
WGS. The group consisted of 250 family trios which were sequenced with the Illumina 
HiSeq2000 at approximately 13x coverage [Boomsma et al., 2014; Genome of the 
Netherlands Consortium, 2014]. The summary counts of the SNVs and small indels (<20bp) 
for all chromosomes (release 5) for the parents (n=498) of the GoNL was accessed on the 
22nd of  August 2014 
[https://molgenis26.target.rug.nl/downloads/gonl_public/variants/release5/]. Variants from 
this dataset were called using the Genome Analysis Toolkit (GATK) UnifiedGenotyper v1.4, 
using the data from all individuals together.  
2.2.2 Genetic Analysis  
Blood samples were obtained from members of Family 30 with the appropriate informed 
consent (see Appendix 1- Example of Patient Consent Form) and DNA was isolated using the 
Gentra PuregeneTM DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). The 
protocol involved the following steps: the lysis of red blood cells (RBCs) and nucleated cells, 
protein precipitation, DNA precipitation, recovery, and rehydration. Following rehydration in 




or -80°C (for long term storage). A more detailed protocol is included in Appendix 1 (DNA 
Isolation Protocol). Integrity of the DNA was verified by spectrophotometric quantification 
using the Nanodrop 1000 spectrophotometer (Nanodrop Technologies Inc., Wilmington, DE, 
USA) and 1% agarose gel electrophoresis (Appendix 1-DNA Integrity Check). All DNA 
samples were deemed to be of sufficient concentration and integrity for downstream genetic 
analysis. 
2.2.2.1 Whole-Genome Sequencing 
WGS for four of the BDI affected members in Family 30 was carried out at the University of 
Southern California using the Illumina HiSeq2000 (San Diego, California, USA) system. 
This technology is based on a proprietary reversible terminator-based method which is able to 
detect single nucleotides as they are incorporated into growing DNA strands. The WGS 
protocol consisted of the following steps: i) library creation; ii) clustering; and iii) 
sequencing. Briefly, these steps are described below and a more detailed protocol can be 
found in Appendix 1 (WGS Protocol). 
2.2.2.1.1 Library Creation 
A total of 1 microgram (µg) of genomic DNA in Tris-ethylenediaminetetraacetic acid 
(EDTA) (TE) buffer was used for the library creation.  DNA was randomly sheared with the 
Covaris Focused Ultrasonicator (Woburn, Massachusetts, USA) yielding double-stranded 
fragments of approximately 300-400bp in length, with 3‘ and 5‘ overhangs. This process 
occurred at a temperature between 3-4°C for a duration of 40 seconds. The Covaris Focused 
Ultrasonicator is able to shear DNA by the process of Adaptive Focused AcousticsTM. This 
process generates bursts of high frequency ultrasonic acoustic energy which is able to be 
focused on a sample immersed in a water bath [http://covarisinc.com/technology/how-it-
works/]. End repair was performed using the Illumina End Repair mix (Illumina, Inc., San 
Diego, California, USA) which removes 3‘ and 5‘ overhangs to create fragments with blunt 
ends. The blunt-ended fragments were then cleaned with the Agencourt AMPure XP 
polymerase chain reaction (PCR) purification system (Beckman Coulter Genomics, Danvers, 
Massachusetts, USA). The 3‘ ends of the fragments were then adenylated with a single 
adenine nucleotide to prevent the fragments from binding to one another at the adapter 
ligation step. The adenine nucleotide binds to the complementary thymine nucleotide found 
on the 3‘ end of the multiple-indexing adapter which allows for fragment-adapter binding. 
The adapter-bound fragments were then cleaned with the Agencourt AMPure XP PCR 




fragments were then further purified on an InvitrogenTM E-Gel® (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), which allows for the removal of un-ligated adapters, 
adapters bound to one another, and to size select fragments of the appropriate length for 
clustering. The adapter-bound fragments of the correct size were then selectively amplified 
by PCR to increase the amount of DNA. This PCR contained primers which specifically 
annealed to the adapters. The PCR products were then cleaned with the Agencourt AMPure 
XP PCR purification system (Beckman Coulter Genomics, Danvers, Massachusetts, USA). 
The concentration, size, and molar concentration of the purified PCR products were then 
determined by spectrophotometric quantification using the Nanodrop 1000 spectrophotometer 
(Nanodrop Technologies Inc., Wilmington, DE, USA) and the Agilent 2100 Bioanalyser 
(Santa Clara, California, USA). The purpose of this process was to ensure high quality DNA 
libraries. All of the samples were at the required concentrations and fragment size. For cluster 
generation a starting molar concentration of 10 nanomolar (nM) was required.  
2.2.2.1.2 Clustering 
The aim of this step was to clonally amplify the fragments by a process of bridge 
amplification, resulting in millions of clusters. This was achieved by the hybridisation of the 
DNA fragments to oligonucleotides attached on a flow cell, which are complementary to the 
adapter sequences. Firstly, the fragments were denatured using 2N Sodium hydroxide 
(NaOH) and incubated at room temperature for five minutes. A serial dilution was performed 
and the PhiX viral control genome was added to each tube.  The samples were then placed on 
the Illumina cBot (San Diego, California, USA) where cluster generation occurred.  
2.2.2.1.3 Sequencing 
The paired-end sequencing reaction was performed on the Illumina HiSeq 2000 which is 
based on the sequencing-by-synthesis chemistry. This entails the use of four reversible 
terminator nucleotides, each with a different, cleavable, fluorescent dye and chemically 
blocked hydroxyl group.  Primers were hybridised to the amplified, covalently bound DNA 
templates on the flow cell and the labelled nucleotides and DNA polymerase were washed 
over the flow cell. Thereafter, chain elongation occurs whereby the fluorescently-labelled 
nucleotides compete for incorporation into the growing DNA strand. Once a complementary 
nucleotide was incorporated, chain termination occurred. The incorporated fluorescent 
nucleotide was excited by a laser, displaying a characteristic fluorescence which was detected 
and recorded in an imaging step by a charge-coupled device.  The fluorescent dye was then 




continue. This process was repeated several times, the result of which were a series of images 
which were interpreted by the HiSeq control system and Realtime Analyser software [Mardis, 
2008; Liu et al., 2012]. As each reaction contained all four fluorescently-labelled terminator-
bound nucleotides, there was no incorporation bias. 
2.2.2.2 Microarray Genotyping  
A total of 18 family members (three with BDI and 15 unaffected) from Family 30 were 
genotyped using the AxiomTM Genome-wide CEU 1 Array Plate (Affymetrix, Santa Clara, 
California, USA) at the Centre for Proteomic and Genomic Research (CPGR) (Cape Town, 
South Africa). This array consists of 587 353 markers which cover both common and rare 
variants specifically designed for European populations.  These variants were selected from 
the dbSNP [http://www.ncbi.nlm.nih.gov/SNP/], 1000 Genomes Project [1000 Genomes 
Project Consortium, 2012] and the Axiom Genomic databases 
[http://www.affymetrix.com/support/technical/sample_data/axiom_db/axiomdb_data.affx]. 
A total of 50 nanograms (ng) of DNA sample was used in the assay. Each sample was 
processed in accordance with the Affymetrix AxiomTM protocol. The target preparation 
included the following workflow: DNA amplification, fragmentation and precipitation, 
sample drying, re-suspension and quality control (QC). QC was performed using a Nanodrop 
spectrophotometer and gel electrophoresis with a 4% gel. All samples met the QC criteria for 
hybridization to the array which required a total sample yield of greater than 1000µg and 
DNA fragments between 25 and 125bp. The fragmented DNA sample was loaded onto the 
GeneTitan® Multi-Channel instrument for denaturation, hybridisation to the array, ligation, 
staining and scanning.   
Following scanning, the output files generated by Affymetrix GeneChip® Command 
Console® were analysed with the Affymetrix® Genotyping Console version 4.2.0.26. All the 
samples met the default QC thresholds, which were a dish QC (sample quality metric) greater 
than or equal to 0.82 and a call rate greater than 97%. 
2.2.3 Statistical and Bioinformatic Analyses 
2.2.3.1 Bioinformatic Analysis of WGS Data 
In order to derive useful information from the WGS data, the appropriate bioinformatic 




were performed using facilities provided by UCT‘s ICTS High Performance Computing team 
[http://hpc.uct.ac.za]. Outlined below is the workflow and programs used in the analysis:  
2.2.3.1.1 Quality Control 
The raw sequence reads were obtained from the sequencer in ‗fastq‘ format. The files were 
divided in terms of lane number or run number (each sample comprised 5 runs), direction 
(forward and reverse), and read number (each lane and direction file consisted of 26 or 27 
reads). Therefore, each individual sample consisted of a minimum of 260 raw sequence files. 
The program FastQC [http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/] was used to 
ensure that the quality of the raw sequencing data was sufficient for downstream analysis. 
This program allows for the visual inspection of the read quality and statistics. Included in the 
output are the following: 
 Basic statistics: contains details about the file, the Illumina system used, the total and 
filtered number of sequences, the sequence length and percentage GC content   
 Per base sequence quality: quality score for each of the bases 
 Per sequence quality scores: a plot of the quality scores for each of the sequences 
 Per base sequence content: base content across all sequences 
 Per base GC content: percentage GC content across all bases 
 Sequence GC content: plot of percentage GC content across all sequences 
 Per base N content: percentage N content across all bases 
 Sequence length distribution: distribution of sequence length across all sequences 
 Sequence duplication levels: percentage duplicate compared to unique sequences 
 Over-represented sequences: presence of over-represented sequences 
 K-mer content: relative enrichment of K-mers across read length   
 
2.2.3.1.2 Alignment to Reference Genome 
The Burrows-Wheeler Aligner (BWA) (bwa- 0.5.9) [Li and Durbin, 2009] tool was used to 
align the short sequence reads to the reference human genome sequence (hg19 assembly). 
The BWA-backtrack algorithm was implemented as this algorithm is able to align relatively 
short sequence reads to a long reference sequence. Alignments were run on each read for 




2.2.3.1.3 Post-Alignment Processing and Variant Calling 
SAMtools [Li et al., 2009], Picard [http://broadinstitute.github.io/picard/] and GATK 
[McKenna et al., 2010] were used for post-alignment processing and for variant calling. Post-
processing includes the sorting and indexing of the binary alignment map (BAM) file.    
Firstly, the combined aligned reads were sorted using SAMtools (samtools-0.1.17), which 
created a binary SAM file called a BAM file. Statistics for the sorted BAM file were 
obtained, duplicates were removed, and the BAM file was indexed. Picard (picard-tools-1.51) 
is a java–based program with command line functionality allowing for the manipulation of 
SAM and BAM files. This program was used to obtain various metrics regarding the aligned 
sequence, such as an alignment summary and quality score distribution. Qualimap [Garcia-
Alcalde et al., 2012] was used to determine the sequence coverage, percentage GC content, 
percentage of the reads which were successfully mapped and the read length. Indel 
realignment was performed using GATK (gatk v1.2). Insertion/deletion (indel) realignment 
consists of two steps, firstly the identification of target intervals, and secondly, the actual 
realignment process using the IndelRealigner utility in GATK. To ensure that all mate-pair 
information was correct across reads, the FixMateInformation utility was used in Picard 
(picard-tools-1.51).  
At this point of the data analysis, the quality scores of each of the bases sequenced were 
recalibrated from the aligned BAM file using GATK. This process is performed since the 
quality scores assigned by various sequencers are often inaccurate and biased. Thus the base 
quality score recalibration (BQSR) process assigns quality scores based on the actual 
probability that the base mismatches the reference genome. Also, this process is able to 
improve the variation in quality with machine cycle and sequence context. This is achieved 
by examining the covariation of the base based on the following features 
[http://www.broadinstitute.org/gatk/guide/article?id=44]: 
i) Reported quality score 
ii) Position within the read 
iii) Preceding and current nucleotide 
In order to call variants from the aligned sequence, the UnifiedGenotyper in GATK was used. 
Once the variants were called, variant quality score recalibration (VQSR) was performed. 




variants (known and novel) in a variant call list 
[http://www.broadinstitute.org/gatk/guide/article?id=39]. It is achieved by the development 
of a continuous, covarying estimate of the relationship between SNP call annotations and the 
probability that a variant is truly a variant as opposed to a sequencing or data analysis error. 
This is a two-step process whereby the following two options are used: VariantRecalibrator 
and ApplyRecalibration. The former generates a recalibration file based on a Gaussian 
mixture model which assesses the annotation values over a high quality subset of the input 
call set and then evaluates all input variants. This model is based on data from ―known sites‖ 
or ―true sites training resource‖ such as HapMap 3.3 [Gibbs et al., 2003], dbSNP 132 and the 
Omni 2.5 SNP human microarray.  The HapMap resource is a SNP call set with a very high 
degree of confidence assigned to each of the variants. GATK will select the variants in this 
resource as representative of true sites and will use these variants to train the recalibration 
model [http://www.broadinstitute.org/gatk/guide/article?id=1259]. The result of this is a 
variant call format (VCF) file which is a text file containing a list of the variants called. 
Thereafter, the variant list was filtered to only include variants with a high quality and high 
coverage.  
2.2.3.1.4 Variant Annotation 
The latest version of ANNOVAR [Wang et al., 2010b] was used to annotate the variant list. 
Variants were assigned to their respective genes and were classified according to their 
respective locations (intronic, exonic, intergenic, upstream, downstream, 3‘ untranslated 
region (UTR), 5‘ UTR, etc.).  The hg19 sequence build was used as a reference and the 
refGene database [Pruitt et al., 2005]  was used to assign genes.   
2.2.3.2 Whole-Genome Linkage Analysis 
Linkage analysis is commonly used to identify rare susceptibility variants, for a particular 
disorder, in an affected family. In this study, a narrow definition of the phenotype was used 
whereby only individuals with BDI were considered affected. Any individuals with a 
psychiatric diagnosis other than BDI were coded as unaffected. Genotype data was available 
for 587 352 variants (SNPs and insertions/deletions (indels)). Using the Affymetrix® 
Genotyping ConsoleTM, the variants were filtered by including only those variants with a 95% 
call rate, a minor allele frequency (MAF) of greater than 0.1, and any variants on the X-
chromosome were excluded. All of the short indels and any variants without a dbSNP 
identifier were removed. After filtering, the variant list consisted of 293 047 SNPs. A two-




[Silberstein et al., 2013]. Chromosomes which obtained LOD scores greater than the genome-
wide maximum LOD, score as calculated by the program were filtered by 2 centimorgan 
(cM) to reduce linkage disequilibrium (LD) [Smith et al., 2011b]. These chromosomes were 
also ‗cleaned‘, which is a process of removing erroneous markers, Mendelian errors, 
genotyping errors and uninformative markers. The two-point linkage analysis was now 
repeated on these regions of interest with the penetrance set at 0.8 and the disease allele 
frequency at 0.01 [Cheng et al., 2006]. As the genetic model of BD is unknown, the LOD 
scores were calculated for a recessive and dominant model. The base pair positions of these 
chromosomal locations were identified using NCBI dbVar Genome Browser 
[http://www.ncbi.nlm.nih.gov/dbvar/browse/] (Homo sapiens: GRCh38).  
2.2.3.3 Principal Component Analysis 
Principal component analysis (PCA) is used to reduce the dimensions in a large dataset. In 
this study, PCA was used to determine whether the Dutch population group would be a 
suitable control for the affected Afrikaner individuals, based on genome-wide genotype data. 
PCA was performed using the BD WGS data for the four affected individuals together with 
GWAS data for a Dutch control population group and data from the 1000 Genomes Project 
[1000 Genomes Project Consortium, 2012] as reference populations. The Dutch GWAS data 
was obtained from PGC for SCZ which consisted of 637 control individuals from the 
Netherlands genotyped with the Illumina 550K microarray. The 1000 Genomes Project data 
(phase 3) for 26 different populations for all chromosomes was accessed on the 22 August 
2014 [ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502]. This dataset consisted of 
SNPs, indels, complex short substitutions and structural variant classes. The following six 
population groups were selected for the analysis: Han Chinese (CHB), Yoruba (YRI), British 
(GBR), Finnish (FIN), Toscani in Italy (TSI) and Iberian populations in Spain (IBS). The 
genotype data from a total of 615 unrelated individuals from the above-mentioned population 
groups were used in downstream analysis.  
Prior to the PCA analysis, the variants were filtered using Plink (version 1.9) 
[https://www.cog-genomics.org/plink2/] [Purcell et al., 2007] whereby the overlapping 
variants (number of variants= 148 788, number of individuals from the combined datasets= 1 
256) between the datasets were identified and subsequently used. PCA was conducted using 
the package SNPRelate [Zheng et al., 2012] implemented in the statistical environment R 
3.0.0 [http://www.r-project.org/]. Prior to this; variants in LD were pruned at an LD threshold 




than 5% were discarded. The PCA plots were subsequently viewed and edited using the 
software Genesis 0.3 (http://www.bioinf.wits.ac.za/software/genesis/downloads.html).  
2.2.3.4 Comparison of Case with Control Samples 
For the BD samples, a list of 870 875 variants was obtained for which each of the BD 
affected individuals shared the same genotype (either heterozygous or homozygous for the 
alternate allele). A total of 625 965 of these variants were present in the GoNL dataset, thus 
leaving a list of 221 703 variants which were present exclusively in the BD group (23 207 
variants were located in the mitochondrial genome or were labelled as part of the random 
chromosomes). This list was further filtered to include only those regions of interest as 
identified from the linkage analysis (i.e. only variants in the chromosomal regions 6p25, 
10p14-10p15.1, 11q23-11q25, and 13q21-22 were retained for analysis).  
To determine whether there were any pathogenic variants in the list, ANNOVAR [Wang et 
al., 2010b] was used to generate SIFT and Polyphen2 scores, with the hg19 human genome 
build. Sift predicts whether an amino acid substitution is tolerant or intolerant to the 
respective protein, based on sequence homology [Ng and Henikoff, 2001]. Polyphen2 is 
similar to SIFT but differs in that it uses a structure-based approach in addition to the 
sequence homology to determine whether a missense mutation has a pathogenic effect 
[Adzhubei et al., 2010]. The web-based program ConsensusPathDB [Kamburov et al., 2009] 
was used to determine which pathways were over-represented in BD. Within this program, 
enrichment analysis was performed using the pathway-based, gene ontology (GO)-based and 
enriched protein complex-based sets. The minimum overlap for each set analysis was set at 
two genes and the p-value cut-off was set at 0.01.  For the protein complex-based set 
analysis, the minimum complex size was set at two.  
2.3 Results 
2.3.1 Research Group 
2.3.1.1 Family 30 
A total of 20 family members were genetically analysed. Four of the affected individuals 
were males and the other was female. The average age of the affected group was 65 years 
(SD=16.3 years) and the mean age of symptom onset was 25 years (SD=16.7 years). Table 4 
describes the number of depressive episodes, as well as number of hospitalisations for the 




and six were male. Two of the individuals in the unaffected group had MDE (one with 
recurrent MDE and the other with a single episode). The average age of the unaffected family 
members was 63 years (SD=16.2 years), and the youngest and oldest members were 43 and 
84, respectively. As all of the unaffected family members were older than the mean age of 
onset for the affected family members, it was thought unlikely that any of these individuals 
would develop BDI later in life. 













30_8 19 unknown 0 2 
30_10 55 unknown 0 2 
30_29 16 unknown 0 2 
30_30 16 unknown 0 3 
30_50 21 2 0 7 
 
2.3.2 Statistical and Bioinformatic Analyses 
2.3.2.1 Bioinformatic Analysis of WGS Data 
2.3.2.1.1 Quality Control 
Based on the results of FastQC, overall all four samples had a passable quality in terms of per 
base sequence quality, per sequence quality scores, per base sequence content, per base GC 
content, per sequence GC content, per base N content, sequence length distribution, sequence 
duplication levels, over-represented sequences, and kmer content. As an example, Appendix 




2.3.2.1.2 Post-Alignment Processing and Variant Calling 
The four BDI samples had an average coverage of approximately 29X. The average 
percentage of reads mapped to the reference was approximately 94%. The mean GC 
percentage across all four samples was approximately 39% and the mean read length was 
101. Table 5 outlines the values for the above-mentioned variables per sample.  














30_10 39.73 25.59 93.49 101 4 759 614 669 438 
30_29 38.8 36.66 93.57 101 4 746 223 686 403 
30_30 39.4 23.76 93.65 101 4 824 753 666 561 
30_50 39.44 30.04 93.83 101 4 872 249 688 696 
 
2.3.2.1.3 Variant Annotation 
The average number of variants called across all four samples was 4 800 710 (SNPs and short 
indels). The average number of intronic and exonic variants was 1 649 268 and 22 420, 
respectively. The number of intronic, exonic and regulatory variants for each of the samples 
is listed in Table 6. 
2.3.2.2 Whole-Genome Linkage Analysis 
Eighteen of the family members were genotyped with the genome-wide microarray (three of 
these individuals were affected with BDI). To include the two other BDI affected individuals 
in the linkage analysis, genotype data for the microarray variants were obtained from the 
WGS data. Therefore, 20 family members with genetic data were included in the linkage 
analysis. None of the chromosomal regions obtained a LOD score of greater than three, the 
traditional threshold for significant linkage, indicating that the odds that the loci are linked is 
1000 times greater that the odds that the loci are not linked [Nyholt, 2000]. A total of four 
chromosomal regions, 6p25, 10p14-10p15.1, 11q23-11q25, and 13q21-22, reached the 
maximum LOD score (marked with a green line) as indicated by the figures below (Figures 
1-8). The SNPs corresponding to these regions with the respective LOD scores are reported 














30_10 4 759 614 31 518 4 782 1 796 177 22 238 2 822 732 82 167 
30_29 4 746 223 31 399 4 484 1 585 912 21 906 2 806 951 295 571 
30_30 4 824 753 31 710 4 392 1 602 586 22 401 2 863 885 299 779 
30_50 4 872 249 32 398 4 723 1 612 396 23 134 2 899 020 300 578 
Total 19 202 839 127 025 18 381 6 597 071 89 679 11 392 588 978 095 
ncRNA- non-coding ribonucleic acid 
 
Table 7: Top LOD scores across four regions of interest 
Chromosome Region Marker LOD score Gene Genetic Model 
6p25.1 rs9392683 0.9866 FARS2 Recessive 
6p25.2 rs160701 1.2062 WRNIP1 Dominant 
10p15-p14 rs2961611 1.0950 AKR1C1 Dominant 
10p14 rs570825 0.9957/1.3340 Intergenic Recessive and dominant 
11q25 rs2027784 1.3146 NTM Dominant 
11q23.3 rs1712789 0.7236 Intergenic Recessive 
13q21.2 rs9538758 1.4009/1.4062 Intergenic Recessive and dominant 









Figure 1: Two-point linkage results for chromosome 6 




Figure 2: Two-point linkage results for chromosome 6 
with a dominant model. 
 
Figure 3: Two-point linkage results for chromosome 10 




Figure 4: Two-point linkage results for chromosome 10 






Figure 5: Two-point linkage results for chromosome 11 




Figure 6: Two-point linkage results for chromosome 11 
with a dominant model. 
 
 
Figure 7: Two-point linkage results for chromosome 13 




Figure 8: Two-point linkage results for chromosome 13 










2.3.2.3 Principal Component Analysis 
Figure 9 is a graphical plot of PCA 1 and PCA2 for the BD, Dutch and all the population 
groups from the 1000 Genomes Project dataset, which includes the CHB and YRI. The CHB 
and YRI cluster separately from the other groups illustrating that these groups are genetically 
distinct from the European population groups. Figure 10 is a is a graphical plot of PCA 1 and 
PCA2 for the BD, Dutch and only the European population groups from the 1000 Genomes 
Project dataset. It can be seen that the BD individuals (red circles) cluster more closely with 
the Dutch individuals (green circles) and the GBR individuals (blue triangles) than any of the 
other European population groups. This suggests that the BD affected individuals are 
genetically closer to the Dutch and British populations than any of the other European groups 
included in this analysis. 
 
 
Figure 9: Population group structure for autosomal variants for PCA1 and PCA2. BD-bipolar disorder, 
CHB- Han Chinese from Beijing, GBR- British in England and Scotland, FIN- Finnish in Finland, IBS- Iberian 





Figure 10: European and Afrikaner population group structure for autosomal variants for PCA1 and 
PCA2. BD-bipolar disorder, GBR- British in England and Scotland, FIN- Finnish in Finland, IBS- Iberian 
populations in Spain, TSI-Toscani in Italy. 
 
2.3.2.4 Comparison of Case with Control Samples 
A list of WGS variants which were present in all four affected individuals and not the Dutch 
control group was generated. This list was then filtered to only include variants which are 
located in the regions identified by the whole-genome linkage analysis (6p25, 10p14-
10p15.1, 11q23-11q25, and 13q21-22). This list consisted of 5386 variants and around 279 
genes. A total of 18 of the 5386 variants were exonic and seven of these were non-
synonymous. Table 8 lists the details of the non-synonymous polymorphisms, most of which 
are located on chromosome 11. None of these SNPs were predicted to be deleterious or 
intolerant by either SIFT or Polyphen2 (Table 8). A SIFT score of less than 0.05 is indicative 
of a deleterious variant. Polyphen2 scores of greater than or equal to 0.957 is indicative of a 
probably damaging variant and a score greater than or equal to 0.453 and less than or equal to 
0.956 denotes a possibly damaging variant.  
For the enrichment analysis, 238 out of the 279 genes were mapped.  From the pathway-
based enrichment analysis, 49.6% of the input genes were able to be mapped to at least one 
pathway and the most significant pathway was the T-cell receptor (TCR) signalling pathway 
(q-value=0.148, p-value=0.0004, pathway source= Wikipathways), with six of the genes 
forming part of this pathway (pathway consists of 92 genes).  From the GO-based enrichment 
analysis 79.4% of the genes formed part of at least one of the GO categories and the most 




second and third most significant GO terms were also involved in interleukin production. A 
total of 41.6% of the genes are present in at least one protein complex. The most significant 
protein complex was CD3 epsilon: CD3 gamma with phosphorylated ITAM (p-value=0.0002, 
q-value=0.003, complex source= Reactome). Other protein complexes include 
TCR/CD3/MHC II/CD4/LCK/ZAP-70/CBL/SLAP-2/Ubiquitin and HTR3:5HT. Appendix 1 
(Enrichment Analysis Results) lists the results for all the significantly enriched pathways, GO 
terms and protein complexes and Figure 11 is a visual representation of the interactions 
between the significantly enriched pathways. 
Of the 5 386 variants, 216 were novel, i.e. not reported in dbSNP. None of the novel variants 
were located in exonic regions and were therefore not predicted to be pathogenic. A full list 




















Figure 11: ConsensusPathDB output for the over-representation analysis (enriched pathway-based set).  













Sift prediction score 
and category 
Polyphen2 prediction 
score and category 
10 7763661 ITIH2 rs7075296 c.A788G p.N263S 0.27-Tolerated 0.04-Benign 
11 112088499 BCO2 rs2217401 c.A1423C p.I475L 1.0-Tolerated 0.0- Benign 
11 117160347 BACE1 rs539765 c.T1366C p.C456R 0.4-Tolerated 0.0- Benign 
11 121437819 SORL1 rs1699107 c.C3220G p.Q1074E 1.0-Tolerated 0.0- Benign 
11 123754844 TMEM225 rs10893099 c.A401G p.N134S 1.0-Tolerated 0.0- Benign 
11 130780225 SNX19 rs681982 c.G1854T p.L618F 1.0-Tolerated 0.0- Benign 










2.4 Discussion  
The aim of this chapter was to identify susceptibility variants for BD in a large Afrikaner 
family using whole-genome technology. Although no chromosomal regions obtained a 
significant LOD score, the four chromosomal regions which obtained the highest LOD 
scores, namely 6p25, 10p14-10p15.1, 11q23-11q25, and 13q21-22 were further investigated. 
Interrogation of WGS data, filtering for these four regions, identified variants and pathways 
which may a play a role in the aetiology of BD. The TCR signalling pathway was the most 
enriched pathway in individuals with BD.  
The four chromosomal regions obtained the highest LOD scores in both the dominant and 
recessive model analyses. This has been observed in a previous linkage analysis for BD, 
where positive LOD scores were detected for chromosome 5 using a dominant and recessive 
model [Homer et al., 1997].  The hypothesis is that if the difference in the maximum LOD 
scores between the two models is greater than 1.5, then the higher LOD score of the two 
inheritance patterns is the true method [Greenberg and Berger, 1994]. In this study, a 
difference of greater than 1.5 was not observed for any of the four chromosomal regions, 
therefore, the above hypothesis does not hold true for this particular study. It may be 
speculated that the true mode of inheritance could be determined by the genotyping of 
successive generations as biological material is not available for the first parental generation.   
Previous linkage studies have not found evidence for the region 6p25 for the BD diagnosis. 
However, this region has been suggestively linked to the psychosis sub-phenotype in 
individuals affected with BD [Cheng et al., 2006]. In this study, the SNPs which obtained the 
highest LOD score in this region were rs9392683 and rs160701. Neither these SNPs nor the 
genes in which they located in, namely, phenylalanyl-tRNA synthetase 2, mitochondrial 
(FARS2) and Werner helicase interacting protein 1 (WRNIP1), respectively have previously 
been implicated in BD. However, these genes should not be discounted in terms of playing a 
role in the pathophysiology of BD as other SNPs within FARS2 and WRNIP1 have previously 
been associated with cognitive deficit in other psychiatric disorders, i.e. SCZ and ADHD, 
respectively [Jablensky et al., 2012; Franke et al., 2009].  
Chromosome 10 is thought to harbour susceptibility variants for psychiatric disorders such as 
BD and SCZ [Wildenauer et al., 1999]. The region 10p14 has been linked to BD and 
suggestively linked to ADHD features in subjects with BD [Lambert et al., 2005; Joo et al., 




rs2961611 and rs570825. The SNP, rs2961611, is located within the gene aldo-keto 
reductase family 1, member C1 (AKR1C1). The SNP, rs570825, is located in an intergenic 
region close to the genes protein kinase C, theta (PRKCQ) and Scm-like with four mbt 
domains 2 (SFMBT2). PRKCQ forms part of glutamatergic signalling, a pathway previously 
implicated in BD [McCullumsmith and Meador-Woodruff, 2002; Hashimoto et al., 2007; 
McCullumsmith et al., 2007]. Also, this gene has been shown to have reduced expression in 
the temporal cortex of patients with MDD [Aston et al., 2005]. Mice treated with the mood-
stabilising drug, valproate, showed increased expression of SFMBT2 in the brain, suggesting 
a role for this gene in the pathophysiology of BD [Chetcuti et al., 2006].   
Copy number variation (CNV) has been observed in the chromosomal region, 11q23-11q25, 
in individuals with BD and major depression [Baysal et al., 2002; Böhm et al., 2006; Reardon 
et al., 2007; Ye et al., 2012]. Also, this region has been shown to interact with the 
chromosomal region 2p15-12 in families with BD [Fullerton et al., 2010]. The SNPs which 
obtained the highest LOD score in this region were rs2027784 and rs1712789. The SNP, 
rs2027784, is located within the gene neurotrimin (NTM) which encodes a protein that 
stimulates neurite outgrowth and cell adhesion [Gil et al., 1998]. NTM, has not previously 
been associated with BD, but variation within this gene has been associated with IQ [Pan et 
al., 2011], which in turn has been shown to be associated with BD [Mancuso et al., 2015]. 
The other SNP, rs1712789, is located in an intergenic region close to the gene, neurexophilin 
and PC-esterase domain family, member 2 (NXPE2).  This gene has not been associated with 
BD before.  
The 13q region has previously been linked to BD, including in a meta-analysis of whole 
genome linkage scans [Stine et al., 1997; Badner and Gershon, 2002; Liu et al., 2003; Potash 
et al., 2003; Cheng et al., 2006]. Specifically, 13q21 has been shown to be linked to psychotic 
features in families with BD [Goes et al., 2007]. Also, an epistatic relationship between 
13q21 and 20p12 was observed in families with BD [McInnis et al., 2003]. The 
polymorphisms which obtained the highest LOD score in this region were the intergenic 
SNPs rs9538758 and rs1536399, neither of which has shown an association to BD or any 
other psychiatric disorder, previously.  The SNP, rs9538758, is located close to the gene, 
tudor domain-containing 3 (TDRD3). This gene has previously been associated with variation 
in size of the mid-saggital area of the corpus collosum, an area implicated in BD [Newbury 




From the enrichment analysis, the most over-represented pathway was the TCR signalling 
pathway, the most over-represented GO-term was interleukin production and the most over-
represented protein complex was (cluster of differentiation 3) CD3 epsilon. Each of these 
entities are involved in the body‘s immune system, suggesting a role of this system in the 
pathophysiology of BD. Psychiatric disorders such as SCZ have previously been significantly 
associated with disruption in immune function [Maes et al., 1995; Theodoropoulou et al., 
2001; Steiner et al., 2010].  
The immune system comprises two parts: the innate and adaptive response. The innate 
immune system provides an immediate response (considered as the ―first line of defence‖ to a 
pathogen) and includes physical, chemical and microbiological barriers [Parkin and Cohen, 
2001; Strous and Shoenfeld, 2006]. The cellular component of the innate response includes 
monocytes/macrophages, granulocytes and natural killer cells. The humoral part of the innate 
system consists of acute phase proteins and the complement system [Strous and Shoenfeld, 
2006]. The adaptive immune system provides a slower response to infection but has a higher 
degree of specificity compared to the innate system. The adaptive system is characterised by 
a cellular component consisting of antigen-specific receptors present on the T-lymphocytes 
(T-cells) and B-lymphocytes (B-cells) and a humoral component consisting of antibodies 
[Parkin and Cohen, 2001; Strous and Shoenfeld, 2006].  The TCRs bind to CD3, a T-cell co-
receptor consisting of four subunits (which includes CD3 epsilon), to form the TCR/CD3 
complex, involved in antigen/major histocompatibility complex (MHC) recognition [San José 
et al., 1998]. Upon presentation of an antigen, the TCR complex elicits a cytotoxic or 
inflammatory response [Parkin and Cohen, 2001]. Another integral part of the immune 
system is the cytokine component, which comprise of small molecular weight compounds 
released from a particular cell to change the actions/functions of either the cell itself, or that 
of other cells. Interleukins are a type of cytokine which are secreted from white blood cells 
and mainly affect the behaviour of other white blood cells [Parkin and Cohen, 2001].  
Disruption in the immune system in terms of BD has been described previously [Breunis et 
al., 2003; Ortiz‐Domínguez et al., 2007; Brietzke et al., 2009; Drexhage et al., 2011; Wieck et 
al., 2013; Barbosa et al., 2014]. Studies have found increased levels of activated T-cells in the 
blood of BD patients compared to healthy controls [Breunis et al., 2003; Drexhage et al., 
2011; Wieck et al., 2013]. However, findings are sometimes conflicting as another study 
found reduced T-cells in BD affected individuals [Barbosa et al., 2014]. During manic phases 




observed in the serum of patients with BD [Brietzke et al., 2009]. The inverse interleukin 
levels were shown during the depressive phase [Ortiz‐Domínguez et al., 2007]. The 
administration of the cytokine interferon-alpha, used to treat hepatitis C and certain cancers, 
has been shown to result in neuropsychiatric side effects, including mania and depression 
[Capuron and Ravaud, 1999; Constant et al., 2005].  There has also been genetic evidence for 
a link between the immune system and BD. Association between polymorphisms and 
differential expression patterns of immune-related genes have been reported in BD [Papiol et 
al., 2004; Padmos et al., 2008; Dieset et al., 2014; Yoon and Kim, 2012; de Baumont et al., 
2014]. Also, drugs with anti-inflammatory effects are used to treat BD [Dean et al., 2012].  
There is a close, bi-directional relationship between the immune system and the central 
nervous system (CNS) [Wrona, 2006]. In the brain, the microglial cells are the macrophages 
of the CNS [Hanisch and Kettenmann, 2007]. The exact mechanism as to how a disruption of 
the immune system results in an altered mental state is still unknown, however it is thought to 
possibly occur via several pathways, including the HPA-axis and various neurotransmitter 
pathways [Dantzer et al., 2008]. 
Although this investigation was able to identify several interesting candidate genetic regions 
and pathways for BD, this study had several limitations. As illustrated by the PCA plot from 
this study, the Afrikaner individuals clustered with the Dutch control group as well as 
individuals of British descent. The use of the GoNL dataset was not ideal as Afrikaner 
individuals are not purely of Dutch descent, but are of British, French and German ancestry 
[Botha and Beighton, 1983]. However, at the time of analysis, the researchers of this study 
only had access to the WGS data for the Dutch group. Future studies should consider 
including other European population groups, such as the French, British and Germans, and 
determine whether these individuals also cluster with the Afrikaner family members. WGS 
data should have been obtained for the unaffected family members as these individuals would 
have served as the ideal controls in this type of analysis. 
Another limitation of this study is that CNVs and novel variants were excluded from the 
linkage analysis. This was done so that the input files met the requirements of the linkage 
program. However, it is possible that these regions harboured disease-causing variants which 
were excluded. Also, the list of potential susceptibility variants identified was present in the 
affected individuals but not in the Dutch control individuals. Thus, susceptibility variants 




limiting factor was that two of the unaffected family members had an MDE diagnosis. 
Depression is a hallmark of BD and the inclusion of these two relatives could have biased the 
linkage results. However, the aim was to determine variants which were segregating with 
BDI, therefore a narrow diagnostic model was employed in the linkage analysis. It should 
also be noted that disruption in the immune system could be unrelated to the BD phenotype 
and may be due to the presence of immune-related diseases present in this family. BD 
affected family members should be further assessed in terms of immune function. 
This study identified four regions which may be linked to BD and suggests that the immune 
system may possibly underlie the aetiology of BD in an Afrikaner family. These findings 
need to be validated in other Afrikaner families (as well as other BD cohorts) and the exact 
disease-causing variants identified. If validated, immunotherapy may be a key to an effective 
treatment regime for BD.  
The following chapter of this thesis investigates the aetiology of AUD in a South African 

















Chapter 3: An Investigation of AUD in a Group of South African 
Adolescents  
Abstract  
In South Africa, AUD is a serious mental and public health issue. AUD has a considerable 
genetic influence and the heritability is estimated to be between 40-60%. However, the 
genetic basis remains unknown. Endophenotypes, such as differential brain volume, may be 
useful in determining the genetic aetiology of AUD. Besides biological factors, 
environmental risk factors can also determine whether an individual will be more at risk for 
an AUD. The aim of this investigation was to determine whether variants previously 
implicated in other psychiatric disorders have an association with adolescent AUD and 
differential brain volume in AUD. An additional aim was to determine whether these genetic 
factors interact with childhood trauma to result in adolescent AUD. Genotyping was done 
using the Illumina Infinium iSelect custom 6000 BeadChip for 80 adolescents with AUD and 
80 matched controls. Statistical analysis was performed using SPSS, Plink and SPM8.  No 
single SNP was associated with adolescent AUD, after correction for multiple testing. The 
circadian rhythm genes nuclear receptor subfamily 1, group D, member 1 (NR1D1) and basic 
helix-loop-helix family, member e41 (BHLHE41) were associated with AUD in a gene-based 
analysis. Childhood trauma was shown to be higher in adolescents with AUD compared to 
matched controls. No significant gene-environment interactions were found for lifetime 
alcohol units. The gene-imaging analysis identified a SNP in the glutamate receptor, 
ionotropic, N-methyl D-aspartate 2B (GRIN2B) gene as being associated with brain volume 
in the left orbitofrontal cortex (uncorrected p-value < 0.05) and posterior cingulate 
(uncorrected p-value < 0.05). Findings from this study imply that the onset of AUD in 
adolescents may be as a result of dysfunction in the circadian and glutamatergic pathways. 
Both of these pathways have previously been implicated in BD and suggest a common 
pathophysiology between AUD and BD.   
3.1 Introduction 
AUD, consisting of AA and AD, is a serious mental and public health issue, worldwide and 
in South Africa. Of particular concern is the growing number of adolescents in the country 




identify the biological and environmental risk factors which predispose individuals to an 
AUD and to understand the possibly complex way in which these factors interact. This may 
ultimately aid in the identification of ―at risk‖ individuals and enable the tailoring of effective 
interventions and treatment strategies.  
3.1.1 Addiction and the Neurobiology Underlying Alcohol Use 
Addiction is the ―loss of control over drug use‖ [Nestler, 2005]. Each drug of abuse has its 
own chemistry and mechanism of action, resulting in distinct behavioural and physiological 
outcomes. Despite this, after acute and chronic administration, most drugs of abuse have a 
common effect whereby they are acutely rewarding, resulting in repeated use and eventually, 
in some individuals, to addiction [Nestler, 2005]. It has been established that most drugs of 
abuse exert their effects on the brain limbic system [Nestler, 2005]. The limbic system 
consists of the following brain structures: the amygdala, hippocampus, hypothalamus, 
anterior thalamic nuclei, parts of the basal ganglia, epithalamus and septal nuclei [Maclean, 
1954; Ganong, 1995]. Most addictive substances are known to increase the extracellular 
amount of the neurotransmitter, dopamine (DA), in the limbic system of the brain. This 
increase in DA is associated with the reinforcing properties of the addictive substance [Wise, 
1996; Volkow et al., 2009].  
Alcohol is a simple organic molecule (CH3CH2OH) which, upon consumption, is able to 
enter nearly all biological compartments within the body [Costin and Miles, 2014] through 
absorption from the stomach and intestine. Alcohol is able to cross the blood-brain-barrier 
where it exerts its effects on neurotransmitters, receptors, enzymes and various other 
molecules [Most et al., 2014]. Human and animal studies have not shown a specific effect of 
alcohol on the brain but rather that it affects a variety of brain systems [Palmer et al., 2012], 
including the reward and stress response systems via several neurotransmitter pathways. 
These include, but are not limited to, the DA, opioid, gamma-aminobutyric acid (GABA), 
glutamate, serotonin, and corticotropin-releasing hormone (CRH) systems.  
As shown in studies conducted on rats and humans, alcohol exerts some of its effects on the 
brain by increasing the secretion of DA and serotonin in the nucleus accumbens [Boileau et 
al., 2003]. Furthermore, upon withdrawal of alcohol, the levels of these neurotransmitters 
(DA and serotonin) are reduced [Weiss et al., 1996]. The opposite effect is true for the 
neurotransmitter, glutamate. At increasing concentrations, alcohol inhibits glutamate 




neurotransmission is observed [Tsai et al., 1998]. Alcohol also affects GABAergic signalling, 
with a post-mortem study showing increased GABA receptors in the brains of individuals 
with AD [Tran et al., 1981]. Also, alcohol stimulates the release of opioid peptides in the 
nucleus accumbens [Olive et al., 2001] and opioid receptor antagonists such as naltrexone 
have been shown to be effective in reducing alcohol intake [Davidson et al., 1999; Morris et 
al., 2001]. Alcohol also has an effect on the CRH as consumption of alcohol increases 
expression of the CRH receptors in the hypothalamus [Lee and Rivier, 1997] and it has been 
shown that ethanol-preferring rats have dyrsegulated secretion of CRH in the amygdala 
compared to control rats [Richter et al., 2000]. The interaction of alcohol with the above-
mentioned systems results in the acute reinforcing effects of this substance, and after chronic 
exposure, results in sensitization, tolerance, withdrawal and dependence [Gilpin and Koob, 
2008].  
Alcohol use is characterised by both positive and negative reinforcement [Cooper et al., 
1995]. Reinforcement is defined as a response or behaviour which is governed by a previous 
experience. Positive reinforcement, mediated by the reward network (DA, GABA and opioid 
peptides), is when the probability of a certain response is strengthened (e.g. alcohol–seeking 
behaviour) by a rewarding stimulus or experience such as alcohol-induced euphoria. Negative 
reinforcement, mediated by the stress system (CRH and norepinephrine), is characterised by 
an increase in the probability of a particular response (e.g. alcohol-seeking behaviour) if this 
response allows the individual to avoid or alleviate an aversive stimulus (e.g. alcohol 
withdrawal). Positive reinforcement is usually observed in the early stages of alcohol use and 
negative reinforcement during the transition of use to dependence, or when the individual has 
a psychiatric comorbidity [Gilpin and Koob, 2008]. This principle is illustrated by Figure 12 
which shows the systems which alcohol acts upon during positive and negative 
reinforcement, and the differences between non-dependence and dependence.  
3.1.1.1 Genetic Basis of AUD 
Certain individuals are more at risk of developing an AUD than others. The use of twin 
studies have been extremely useful in showing that AUD has a considerable genetic influence 
[Prescott and Kendler, 1999], whereby the heritability is estimated to be between 40-60% 
[Prescott and Kendler, 1999; Epps and Holt, 2011]. In the USA, a total of 22% of adults have 
at least one biological parent with an AUD [Yoon et al., 2013]. Children of an individual with 
AUD are more likely to develop AUD themselves; although this could be due to both genetic 




parent affected with an AUD have a 2.5 fold increased lifetime odds of developing an AUD 
themselves [Yoon et al., 2013]. In addition, those individuals with two affected parents have 
a 4.4 fold increase in the odds of developing a lifetime AUD, and females are more 
vulnerable (than males) to the effect of a parent with an AUD [Yoon et al., 2013]. With the 
use of family-based linkage analysis, candidate gene-based association and GWASs, previous 




Figure 12:  A simplified representation of the transition of the brain reward system from alcohol non-dependence to 
dependence [Gilpin and Koob, 2008].   
 
3.1.1.1.1 Linkage Studies 
In Chapter 2, the aim of a linkage study is described. Over the years, numerous linkage 
studies have been conducted for AUD. As with BD, findings have been variable, with a 
region on nearly every chromosome being implicated: chromosome 1 [Reich et al., 1998; 
Turecki et al., 1999; Foroud et al., 2000; Nurnberger Jr et al., 2001; Dick et al., 2002], 2 
[Turecki et al., 1999]; 4p [Long et al., 1998], 4q22-32 [Prescott et al., 2006], 7 [Reich et al., 
1998; Foroud et al., 2000]; 8 [Turecki et al., 1999]; 9q [Bergen et al., 2003], 10q23 [Gelernter 
et al., 2009], 11p [Long et al., 1998], 16 [Foroud et al., 2000], 19 [Turecki et al., 1999], 21 
[Turecki et al., 1999]. Results from linkage analyses indicate that it is possible that multiple 
chromosomal regions are responsible for individuals developing AUD. Thus instead of single 
genomic regions, gene networks and relevant pathways should be considered and investigated 




3.1.1.1.2 Candidate Gene and Genome-Wide Association Studies 
Many candidate gene association studies have been performed to determine the aetiology of 
AUD. Table 9 lists some of the most commonly associated genes in AUD. Each of the listed 
genes is involved in either neurotransmission or alcohol metabolism. However, as with BD, 
findings have been conflicting and in most instances non-replicable. Therefore, more recent 
studies have performed GWASs with relatively large sample sizes.  
Approximately 26 GWASs have been published for the diagnosis of AD and related 
phenotypes [http://www.genome.gov/gwastudies/]. Table 10 lists the details of these GWASs 
and the main findings. Many of the reported GWASs were conducted on samples from large 
consortia such as the Collaborative Studies on Genetics of Alcoholism (COGA), Study of 
Addiction: Genetics and Environment (SAGE), and the Australian twin-family study of 
alcohol use disorder (OZ-ALC). COGA was first initiated in 1989, and has collected data on 
more than 300 extended families with alcoholism [Edenberg et al., 2005]. SAGE consists of 
unrelated individuals of European-American and African-American descent, a subset of 
which are from the COGA consortium [Bierut et al., 2010]. OZ-ALC consists of Australian 
twins and their extended families [Heath et al., 2011]. The aims of each of these consortia are 
to determine the genetic factors predisposing to AUD. 
The first GWAS for AD, conducted on the COGA cohort, was published by Johnson et al. 
(2006). They identified SNPs involved in cell signalling, gene regulation, cellular adhesion, 
development and those involved in Mendelian disorders, associated with AD, and concluded 
that this phenotype is a result of polygenic inheritance [Johnson et al., 2006]. Similarly, the 
conclusions from subsequent GWASs were that AD is likely to be as a result of the combined 
small effects of hundreds of variants [Heath et al., 2011; Yang et al., 2014]. Using a process 
of genome partitioning, a recent GWAS on a group of African-Americans with AD, found 
that variants within 10-20kb of all genes, on all chromosomes, have an effect on the AD 
phenotype [Yang et al., 2014].  Considering all of the best results from the GWASs, no 
obvious chromosomal region, gene or variant seems to be common in all of the studies. 
Therefore, instead of examining genetics in isolation, it may be necessary to consider the 
aetiology of AUD in a more holistic manner by examining other biological factors or 




3.1.1.2 Brain Volume as Endophenotype for AUD 
Differential brain volume, as measured by various imaging techniques, is a prime example of 
an intermediate phenotype or endophenotype for AUD. It has been postulated that the power 
to detect aetiological factors of complex disorders, such as AUD, would be to investigate 
endophenotypes which represent ―mediating factors of behaviour‖ and which are likely to be 
affected by variations in overlapping sets of genes [Lesch, 2005]. Several studies have had 
success in identifying candidate genes for AD by the genetic investigation of endophenotypes 
such as brain oscillations and subjective level of response to alcohol [Edenberg et al., 2004; 
Wang et al., 2004; Wall et al., 2005]. A particular trait needs to meet the following criteria to 
be considered as an endophenotype: it should (i) be associated with a disorder in the 
population; (ii) be heritable; (iii) be evident in individuals whether the disorder is active or 
not; (iv) co-occur with disease within families; and v) manifest in non-affected family 
members of affected individuals at a higher frequency than in the general population 
[Gottesman and Gould, 2003].  
Brain-imaging studies have shown that various brain regions are altered in individuals with 
AD. For example, individuals who are alcohol dependent are more likely to have smaller 
prefrontal cortical volumes [Bellis et al., 2005; Medina et al., 2008], smaller right and left 
hippocampal volumes [Agartz et al., 1999; De Bellis et al., 2000; Nagel et al., 2005], smaller 
grey and white matter volumes [Gazdzinski et al., 2005] and reductions in brain regions, such 
as the amygdala, involved in the reward network, [Makris et al., 2008], compared to healthy 
controls. Previous research, conducted by our group on adolescents with alcohol exposure, 
found that the pattern of grey matter density differences was limited to regions in the left 
lateral frontal, parietal and temporal lobes [Fein et al., 2013].  
Brain development is influenced by genetic factors, and twin studies have shown that brain 
structural differences have considerable heritability [Posthuma et al., 2000; Baaré et al., 2001; 
Thompson et al., 2001]. However, exactly which genes are responsible for brain volume 
variation is largely unknown.  In this regard, examining specific mental disorders may help to 
elucidate the association between genes and disordered phenotypes. Several gene-imaging 
studies have focussed on AD and alcohol-related phenotypes in adults. For example, a 
missense mutation in the superoxide dismutase 2 (SOD2) gene had an association with grey 
matter loss in AD individuals [Srivastava et al., 2009]. A study by Ramchandani et al. (2010), 
using positron emission tomography (PET), reported that a functional polymorphism within 




administration in social drinkers. Several gene-imaging studies have focussed on adolescents, 
either with AUD, or who were at a high risk for alcoholism. One such study investigated the 
effects of variation within the corticotrophin-releasing hormone receptor 1 (CRHR1) gene 
and found that individuals homozygous for the rs110402 had greater activation in the right 
ventrolateral prefrontal cortex in adolescents and young adults at high risk for alcoholism 
[Glaser et al., 2014]. Other such studies have found that variations within the serotonin 
transporter (5-HTT), gamma-aminobutyric acid A receptor, alpha 2 (GABRA2), brain-
derived neurotrophic factor (BDNF), catechol-O-methyltransferase (COMT), and dopamine 
receptor D2 (DRD2) genes had an association with brain structure and function [Hill et al., 
2009; Hill et al., 2011; Hill et al., 2013]. 
3.1.1.3 Environmental Measures 
Besides biological factors, studies have shown that early environmental risk factors can 
determine whether an individual will be more susceptible to psychiatric disorders later on in 
life [Schmidt, 2007]. In this regard, some studies have shown that marital status has an 
influence as to whether individuals consume more or less alcohol. Some reports observed that 
unmarried individuals are heavier alcohol drinkers compared to their married counterparts 
[Black and Markides, 1993; Bobak et al., 1999] and another study found the opposite to be 
true [Moore et al., 2005].  Religion, education level, alcohol availability, parental control and 
peer influences have also been shown to play an important role in the level of alcohol 
consumption [Dielman et al., 1987; Black and Markides, 1993; Loveland-Cherry et al., 1996; 
Kendler et al., 1997; Bobak et al., 1999; Moore et al., 2005; Enoch, 2006; Latvala et al., 
2011].  
Some of the more severe environmental factors influencing alcohol use include parental 
emotional and physical abuse, experience/exposure to violence and sexual abuse [Brietzke et 
al., 2012]. Individuals who have experienced childhood abuse and neglect are at an elevated 
risk for substance use and AD [Duncan et al., 1996; Felitti et al., 1998; Dube et al., 2006; 
Khoury et al., 2010; Nelson et al., 2010; Copeland et al., 2011; Sartor et al., 2013]. Childhood 
abuse and neglect are interactions with a child which are considered abnormal which results 
in the actual or potential harm of the child. The abuse and neglect has a negative effect on the 





Table 9: Candidate gene studies for AUD 
Gene Polymorphism Description Sample number Reference 
DRD2 
(11q23) 
-141C Ins/Del allele was significantly different between alcoholic and control subjects 130 cases, 251 controls [Konishi et al., 2004] 
rs1800497 A1 allele higher in early onset alcoholics 100 cases, 93 controls [Kono et al., 1997] 
DRD4 







p.Met158 allele associated with higher drinking activity when there was 
less parental supervision 285 adolescents [Laucht et al., 2012] 
p.Met158 allele associated with an increased risk of suicide in male 
alcoholics 
393 cases with alcohol dependence, 







p.Met66 allele associated with alcohol use in older men 68 cases, 232 controls [Shin et al., 2010] 













SNP associated with alcohol dependence meta-analysis-9638 cases, 9517 controls [Li et al., 2011] 
SNP associated with flushing, alcohol consumption and alcohol 
dependence 4597 subjects from 2618 families 
[Macgregor et al., 
2009] 














SNP associated with decreased alcohol metabolic rates 250 participants [Martínez et al., 2010] 




SNP associated with decreased alcohol metabolic rates 250 participants [Martínez et al., 2010] 








short allele preferentially transmitted to alcoholics 92 triads [Lichtermann et al., 2000] 
short allele predicted a greater alcohol consumption over time 202 non-regular adolescent drinkers [van der Zwaluw et al., 2010] 
predicted alcohol consumption 200 participants [Nilsson et al., 2005] 







SNP associated with alcohol dependence COGA [Edenberg et al., 2006] 
SNP associated with alcohol dependence 226 cases, 110 controls [Liu et al., 2011a] 
SNP suggestively associated with alcohol consumption 4597 subjects from 2618 families [Macgregor et al., 2009] 
GABRA2 
(4p12) 
rs9291283 Associated with alcohol dependence 291 cases, 295 controls [Soyka et al., 2008] 
rs279858, 
rs279826 SNPs associated with alcohol dependence 173 families 





Table 10: GWASs conducted for AUD 
Study Title Reference Phenotype 
Initial1 Sample Size 







Pooled association genome scanning for alcohol dependence 
using 104,268 SNPs: validation and use to identify alcoholism 
vulnerability loci in unrelated individuals from the 
collaborative study on the genetics of alcoholism 
[Johnson et 









Genome-wide Association Study of Alcohol Dependence [Treutlein et al., 2009] AD 
Cases: 487 
Controls: 1358 European 
Illumina Human-
Hap 550 121 SNPs 










Genome-Wide Association Study of Alcohol Dependence 













A genome-wide association study of nicotine and alcohol 
dependence in Australian and Dutch populations1 [Lind et al., 2010] AD 
Cases: 1124 
Controls: 1162 
Australian Illumina Infinium 1M 
CTBP2- rs12761801 
(chr 10q26) 
Genome-wide association studies identify genetic loci related 
to alcohol consumption in Korean men 








Human SNP array 
5.0 




A quantitative-trait genome-wide association study of 








Australian Illumina 370K TMEM108, ANKS1A 
Association Analysis of Symptoms of Alcohol Dependence in 









Affymetrix 6.0 KCNMA1, AKAP9, PIGG, CEACAM6 
Confirmation of prior evidence of genetic susceptibility to 
alcoholism in a genome-wide association study of comorbid 
alcoholism and bipolar disorder 














Genome-wide association and genetic functional 
studies identify autism susceptibility candidate 2 gene 













A meta-analysis of two genome-wide association studies 










Genome-wide significant association between alcohol 












Genome-wide association study identifies 5q21 and 9p24.1 













Genome-Wide Association Study of Alcohol Dependence 






(COGA and SAGE) 
Illumina Human 
1M KIAA0040 
Genome-wide search for replicable risk gene regions in alcohol 











Human 1M SH3BP5-NR2C2 
A meta-analysis of two genome-wide association studies to 
identify 












Illumina Human 1 
M 
rs9523562(13q31.1), 
rs67666182 (chr8),  
LMO1, PLCL1 
A Genome-Wide Association Study of Behavioral 







Caucasian Illumina Human 660W-Quad 13 SNPs 
Genome-wide association studies of maximum number of 















Extended genetic effects of ADH cluster genes on the risk 
of alcohol dependence: from GWAS to replication [Park et al., 2013] AD 
Cases: 117 
Controls: 279 
Korean Illumina Human660 W 
ADH gene cluster, 
ALDH 
A genome-wide association study of alcohol-dependence 












NKAIN1-SERINC2 is a functional, replicable and genome-
wide 
significant risk gene region specific for alcohol dependence in 
subjects of European descent 












Genome-wide significant association signals in IPO11-HTR1A 









1M IPO11, HTR1A 
Genome-wide association study of alcohol dependence: 
significant findings in African- and European-Americans 
including novel risk loci 
[Gelernter et 
al., 2014] AD 











ALDH2 Is Associated to Alcohol Dependence and Is the 
Major Genetic Determinant of ―Daily Maximum Drinks‖ 










595 Chinese Illumina Cyto12 ALDH2 
Family-Based Association Analysis of Alcohol Dependence 












Exploring the genetic architecture of alcohol dependence 
in African‐Americans via analysis of a genome-wide set of 
common 
variants 




African American Illumina Omni 1-Quad chr4 




3.1.1.4 Gene x Environment Interactions 
Environment together with genetics plays an important role in the development of AD 
[Lesch, 2005]. Classical genetic studies, which include GWASs, assume that the effects of 
the identified risk gene/variant is the same across changing environmental conditions and that 
environmental risk factors have the same effect across different genotypes [Sher et al., 2010].  
A gene x environment interaction occurs when the above assumptions are not met [Duncan 
and Keller, 2011]. In other words, the effects of the genes and environment on the phenotype 
are dependent on each other or when genes and environment ―act together‖ [Dick and 
Kendler, 2012]. Gene x environment interactions are particularly pertinent in adolescent 
alcohol use, as there is still a certain degree of environmental control by the parent or adult 
guardian. Also, for an AUD to occur there has to be an initial exposure to alcohol. If alcohol 
is unavailable or restricted in a particular environment, any genotypic effects on the 
phenotype will be minimal or non-existent [Dick and Kendler, 2012]. 
Gene x environment interactions can be investigated in 2 ways: i) via latent genetic effects, 
based on a ―genome‖ approach. This type of approach is exemplified by twin or relative 
studies, ii) molecular or biological perspective via a specific molecular variant. The 
advantage of the latter approach is that it provides an understanding of the biological 
aetiology of the phenotype in question [Kendler et al., 2011b].   
In terms of the molecular perspective, there are three types of gene x environment effects: i) 
an additive effect is one whereby there is no significant interaction between the genes and 
environment of interest. In other words, there is a main effect of genes on the phenotype and 
a main effect of the environment on the phenotype but no interaction between the two. The 
effects of the genes and environment add together. This type of gene x environment effect is 
exemplified by Panel A in Figure 13, ii) a fan-shaped interaction is one whereby the effect of 
the genes and environment on the phenotype is dependent on each other. This type of 
interaction (Panel B in Figure 13) is characterised by the fact that genes have more of an 
effect on the outcome or the phenotype of interest in more adverse environments than in 
―normal‖ environments, and iii) a cross-over interaction is one in which the order of the 
genetic effect changes as a function of the environmental effect i.e. individuals at the lowest 
genetic risk in an benign environment will be at the highest genetic risk in the most adverse 




One of the first few gene x environment interaction type studies, conducted by [Caspi et al., 
2002] found that a polymorphism within the monoamine oxidase A (MAOA) gene interacted 
with childhood maltreatment to determine anti-social behaviour during adulthood. A 
subsequent study by the same authors found that the level of depression was moderated by an 
interaction between the 5-HTT gene and stressful events [Caspi et al., 2003]. In the last 
couple of years, there has been a dramatic increase in the number of gene x environment 
(usually candidate genes) interaction-type studies, as opposed to the classical candidate-gene 
association studies. Kaufman et al. (2007) demonstrated that abused or neglected children are 
seven times more likely to abuse alcohol compared to those not abused during childhood. 
Also, that childhood maltreatment together with the 5-HTT variant (5-HTTLPR) predicted 
risk of early alcohol use [Kaufman et al., 2007].  In another study, examining the circadian 
gene PER2, carriers of the G-allele of the SNP rs56013859 interacted with stressful life 
events to result in lower alcohol consumption than those individuals who were homozygous 
for the A-allele [Blomeyer et al., 2013]. Many other studies have also found significant gene 
x environment interactions for alcohol consumption [Nilsson et al., 2005; Covault et al., 
2007; Ducci et al., 2007; Nilsson et al., 2007; Nelson et al., 2010; Miranda et al., 2013; Sartor 
et al., 2014; Kim et al., 2015]. 
One of the disadvantages of gene x environment interactions is that the power to detect an 
interaction is significantly less than detecting a main effect [Duncan and Keller, 2011]. Also, 
statistical interactions are not the same as biological interactions [Dick and Kendler, 2012]. 
Gene x environment interactions have been met with a lot of scepticism in the psychiatric 
genetic community as most of the previous significant findings had not been successfully 
replicated [Duncan et al., 2014]. One of the recommendations for future gene x environment 
interaction type studies is to employ a genome-wide by environment interaction approach- 
instead of investigating one or two candidate genes, and to investigate multiple variants 
spread across the genome [Duncan et al., 2014].    
3.1.2 Aims and Objectives 
AUD is a multifactorial disorder with unknown causative factors. The aim of this 
investigation was to determine whether variants previously implicated in other psychiatric 
disorders have an association with adolescent AUD and differential brain volume in AUD. 
An additional aim was to determine whether these genetic factors interact with childhood 





The objectives of this investigation were as follows: 
1) Using Illumina BeadChip technology, determine whether variants previously 
associated with other psychiatric disorders, have an association with AUD. 
2) Determine whether differential brain volumes predict AUD and whether the selected 
genetic variants have an association with brain volumes. 
3) Determine whether there are interactions between the selected genetic variants and 







Figure 13: Representation of the three types of gene-environment interactions. The lines (in different colours) represent 
different genotypic risks to develop trait Y. The X-axis represents the environment, where level 1 is a benign environment 




3.2 Materials and Methods 
3.2.1 Research Group 
The research cohort investigated in this study was originally recruited as part of a 
collaborative project entitled ‗Effects of heavy alcohol abuse on adolescent brain structure 
and function’ conducted at the University of Stellenbosch, for which ethical approval was 
obtained (ethics reference number: N06/07/128). In addition, for the purposes of the current 
study, ethical approval was obtained from the local institutional (UCT) HREC (REF 
023/2012). Subjects were recruited from 19 schools within the Cape Flats region of the Cape 
Town metropole. All participants were either English or Afrikaans speaking and were from 
moderately low socioeconomic backgrounds. Eligibility was assessed after a detailed medical 
history was taken, and physical and psychiatric examinations were undertaken. In addition, 
participants underwent urine analysis and breathalyser testing to ensure they were not 
intoxicated during the testing period. Written informed assent was obtained from each of the 
study participants and written informed consent was obtained from their parents or guardians. 
The consent form contained full details of all study-related activities in the language 
understandable by the study population [Fein et al., 2013]. 
 
Exclusion criteria for study participation included diagnoses of mental retardation, lifetime 
DSM-IV Axis I other than AUD, lifetime dosages exceeding 30 cannabis joints or 4 
methamphetamine doses, current use of sedative or psychotropic medication, signs or history 
of fetal alcohol syndrome or malnutrition, sensory impairment, history of traumatic brain 
injury with loss of consciousness exceeding 10 minutes; presence of diseases that may affect 
the CNS, less than 6 years of formal education, and lack of proficiency in English or 
Afrikaans. Blood samples (3-4ml) were collected by venepuncture for all of these individuals, 
with the appropriate informed consent. 
The final cohort consisted of 80 adolescents with DSM-IV AUD, and 80 age- and gender-
matched light (lifetime dosage not exceeding 80 units of alcohol)/non-drinking controls (HC). 
All subjects (AUD and HC) were of mixed ancestry ethnicity. The Cape mixed ancestry 
population are a genetically admixed group, in fact, it is reported to have the highest level of 
intercontinental genetic admixture compared to other global populations [Tishkoff et al., 
2009]. The ancestral composition of this unique population group is 32-43% Khoesan, 20-




3.2.2 Clinical Measures 
Psychiatric Diagnoses and Alcohol Use 
To determine whether any of the participants had current or past psychiatric symptoms, the 
Schedule for Affective Disorders and Schizophrenia for School Aged Children (6–18 years) 
Lifetime Version (K-SADS-PL) [Kaufman et al., 1997], a semi-structured, clinician 
administered, diagnostic interview was used. In addition to the K-SADS-PL, the Timeline 
Followback (TLFB) procedure, a semi-structured, clinician administered assessment, was 




Measures of childhood trauma were obtained for each of the study participants using the 28-
item Childhood Trauma Questionnaire-Short Form (CTQ-SF) [Bernstein et al., 2003] 
(Appendix 2-Childhood Trauma Questionnaire) which is a reduced version of the initial 70-
item Childhood Trauma Questionnaire (CTQ) [Bernstein et al., 1994]. The CTQ-SF is a self-
report questionnaire consisting of five subscales, each measuring a specific dimension of 
childhood maltreatment, including: physical abuse  (―bodily assaults on a child by an adult or 
older person that posed a risk of or resulted in injury‖), sexual abuse (―sexual contact or 
conduct between a child younger than 18 years of age and an adult or older person‖), 
emotional abuse (―verbal assaults on a child‘s sense of worth or well-being or any 
humiliating or demeaning behaviour directed toward a child by an adult or older person‖), 
physical neglect (―the failure of caretakers to provide for a child‘s basic physical needs, 
including food, shelter, clothing, safety, and health care‖), and emotional neglect (―the failure 
of caretakers to meet children‘s basic emotional and psychological needs, including love, 
belonging, nurturance, and support‖). Each clinical dimension consists of five items which 
covers the necessary content from the original questionnaire and has sufficient reliability. 
Participants answer the questions in the context of ―when you were growing up‖. The scores 
range from one to five for each question, with one corresponding to ―never‖ and five to ―very 
often‖, thus the CTQ subscale scores range between five and 25 [Bernstein et al., 2003]. The 
CTQ total score is a summation of the five subscales. A dichotomised clinical cut-off score 
which differentiates between significant abuse and neglect was generated for each of the 
subscales and were defined by the following: sexual abuse (CTQ-SA), physical abuse (CTQ-




EA) a score equal to ten or more, and emotional neglect (CTQ-EN) a score of 15 or more 
[Bevilacqua et al., 2012]. 
3.2.3 Genetic Analysis 
DNA from the AUD and HC groups were extracted using the Maxwell® 16 Blood DNA 
purification kit (AS1010) (Promega) using the Maxwell 16 instrument (Promega) at the 
CPGR (Cape Town, South Africa). Each of the samples was genotyped using the Illumina 
Infinium iSelect custom 6000 BeadChip (Illumina Inc., San Diego, California, USA). This 
assay is based on a dual colour, single-base extension protocol and allows the user to prepare 
the DNA sample in a single tube without involving PCR or ligation steps. Briefly, this 
method consists of four main components: i) PCR-free whole genome amplification is 
performed and the DNA is fragmented, ii) array-based hybridization capture, whereby the 
unlabelled DNA fragment is hybridised to a 50-mer probe on the array, iii) an enzymatic 
single base, allele-specific primer extension, and iv) amplified signal detection [Steemers et 
al., 2006].  
The Illumina Infinium iSelect custom 6000 BeadChip comprised approximately 5000 SNPs 
covering haplotype-tagging and previously reported SNPs in 295 candidate genes (genes 
involved in neurotransmitter and neuroendocrine systems) for PTSD, and 319 SNPs and 
CNVs which generally yielded statistically ―significant hits‖ in previous psychiatric GWASs. 
The bead chip was run on the Illumina BeadStation 500G System at the University of 
Michigan DNA Sequencing Core (Michigan, USA). AUD and HC samples were analysed 
together. Standard clustering algorithms were utilised in the GenomeStudio software 
(Illumina) to make genotype calls.  
The genotypes of three variants (BDNF-rs6265, COMT-rs4680 and neuregulin 1 (NRG1)-
rs6994992) were validated using the TaqMan® SNP Genotyping Assay, which were run on 
the AB7900HT qPCR instrument (Life Technologies) at the CPGR (Cape Town, South 
Africa). Assay QC measures included a no template control and a positive control. The 
TaqMan® method, which is based on the 5‘ exonuclease activity of Taq polymerase, consists 
of two locus-specific PCR primers and two allele-specific probes. The TaqMan® probe 
contains a fluorescent reporter dye at the 5‘ end and a non-fluorescent quencher dye at the 3‘ 
end. When the probe is unbound, reporter dye emission is inhibited by the quencher dye. 
However, when extension of the product of interest occurs, the exonuclease activity of the 




fluorescent reporter dye. With each cycle of PCR, the reporter dye fluoresces only if the 
probe is annealed to the allele of interest [De la Vega et al., 2005]. 
3.2.4 Imaging Analysis 
Magnetic Resonance Imaging (MRI) is able to provide a high resolution, three-dimensional 
view of soft tissues. The main advantage of this technique is its relative safety as it is non-
invasive and does not involve any ionizing radiation [Leondes, 2005]. The MRI is obtained 
by the use of a tomograph. The main constituent of this instrument is a large cylindrical coil 
which functions as a magnet. There are additional coils which form part of an electric circuit, 
whereby the electrical current within the magnet is able to produce a steady magnetic field. 
The subject is placed inside the cylindrical coil and exposed to the magnetic field [Hennel et 
al., 1997]. 
MRI data was obtained for a subset of the cohort (58 AUD and 58 HC), as part of a previous 
study, on a 3T Siemans Magnetom Allegra Headscanner using Syngo MR software (Siemens 
Medical Solutions) [Fein et al., 2013]. The scanner is situated at the Cape Universities Brain 
Imaging Center (CUBIC) at the Stellenbosch University Health Sciences Campus, South 
Africa. Analysis of the imaging data was conducted in the Department of Psychiatry and 
Mental Health at UCT. Briefly, for 50 of the subjects, images were acquired using a 
transaxial T1-weighted acquisition, and 66 were acquired with the sagittal T1 protocol. MRIs 
in 28 subjects were acquired using both protocols. Manual reorientation and realignment of 
the cross-hair on the anterior and posterior commissure plane in all the nifti-converted 
DICOM T1 images were performed. Using the voxel-based morphometry (VBM) unified 
segmentation approach [Ashburner and Friston, 2005] in SPM8 [www.fil.ucl.acuk/spm8] 
initial quality control for signal artifacts, morphological changes were calculated in gray 
matter by segmenting from white matter and cerebrospinal fluid. Gray matter images, based 
on probability maps at each voxel, were spatially normalised using a pediatric template from 
the Cincinnati Children´s Hospital old children template 
[www.irc.cchmc.org/software/pedbrain.php] and then co-registered using the same 
segmented template [Brooks et al., 2014]. The following regions of interest (ROI) volumes 
were extracted using SPM8: Total matter, grey matter, white matter, cerebrospinal fluid 
(CSF), total intracranial, left caudate, right caudate, left amygdala, right amygdala, left 
superior temporal gyrus, right superior temporal gyrus, left dorsolateral prefrontal cortex 
(DLPFC), right DLPFC, left insula, right insula, left hippocampus, right hippocampus, left 




pallidus, left posterior cingulate, right posterior cingulate, left occipital lobe, right occipital 
lobe, left precuneus, and right precuneus.  
3.2.5 Statistical Analysis 
3.2.5.1 Demographic and Clinical measures 
Using SPSS [IBM, 2012], the Shapiro-Wilk test was used to determine whether the 
continuous variables, age, years of education, lifetime alcohol dose units, and CTQ measures, 
were normally distributed. The non-parametric Mann Whitney U-test was performed to 
determine whether there were differences in these variables between the genders and the 
groups (HC and AUD).  
3.2.5.2 IBS Clustering 
For case-control association studies, false positive results may be observed due to the 
presence of population stratification. Population stratification is when there are differences in 
the frequencies of ethnic groups in cases and controls and thus a difference in allele 
frequencies not due to the disease/phenotype of interest. This may also occur in admixed 
population groups, whereby ―different fractions of ancestry from each ancestral sub-
population are observed‖. Historically this has been overcome by the careful matching of 
cases and controls and the use of family-based association studies [Enoch et al., 2006].  
In this study, cases and controls were matched but in addition to this, IBS clustering was 
performed using the whole genome association analysis toolset, Plink (version 1.07) 
[http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007], in order to account for 
possible population stratification within the mixed ancestry group. Using pairwise identity by 
state (IBS) distance, this process uses a linkage agglomerative clustering method to determine 
whether two individuals belong to the same or different population groups. For this type of 
analysis, genome-wide SNP data is required, however, only the genotyped SNPs were 
available. This test was run without any constraints.  
3.2.5.3 Association Analysis 
a) Single-SNP 
Using the program Plink (version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] 
[Purcell et al., 2007], it was determined that all samples had a call rate of greater than 0.99. 
Before genotyping and frequency pruning there were 4656 SNPs. A total of 9 SNPs failed the 




583 SNPs were excluded because of a MAF of less than 5%. A total of 4 SNPs were 
excluded as these were not in Hardy-Weinberg equilibrium (HWE) (p-value less than 
0.00001). Therefore, after genotyping and frequency pruning there were 4065 SNPs used for 
downstream analysis.   
Logistic regression was used to test whether any of the SNPs had an association with AUD.  
IBS cluster ID was included as a covariate, an additive genetic test was used, and all tests 
were adjusted for multiple testing using the Bonferroni test [Dunn, 1961]. To visualise the 
chromosomal location of the significant SNPs from the Plink output, the program Haploview 
4.2 [Barrett et al., 2005] was used.  
b) Gene-Based 
Both SNP-based and gene-based tests have their respective advantages and disadvantages. A 
recent study found that gene-based tests were more powerful than the SNP-based test in 
detecting susceptibility loci for the addiction phenotype [Guo et al., 2012]. Gene-based tests 
are thought to be a useful way of overcoming the limitations of GWAS and candidate gene-
based association studies [Fabbri et al., 2013].  
A gene-based test was performed in Plink (version 1.07) 
[http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007], whereby SNPs from the 
same gene were grouped together and tested for association to AUD. Intergenic and control 
SNPs were excluded from the analysis.  Gene-based tests were calculated in the following 
way: 1) determined which SNPs were in LD, above a specified r2 threshold; 2) single SNP 
association to phenotype was carried out; 3) ―independent‖ SNPs were selected (as defined 
by step 1) which were lower than the specified p-value. SNPs were selected in order of 
decreasing statistical significance, after removing SNPs in LD with previously selected SNPs, 
4) a set statistic was calculated as the mean of the single SNP statistics, 5) the dataset was 
permuted 10 000 times, 6) steps 2 to 4 were repeated for each permutation, 7) the empirical 
p-value was the number of times the permuted set statistic was higher than the original p-
value calculated for that set.  
A logistic regression gene-based test was run with cluster assignment as a covariate, SNPs 
with a MAF of less than 0.05 and a ‗missingness‘ rate of greater than 90%, excluded.  A total 
of 10 000 permutations were run, with the default values for r2 (0.5), p-value (0.05) and the 




3.2.5.4 Pathway Analysis 
In order to determine which biological processes were over-represented in the uncorrected 
significant SNPs, a ―pathway based analysis‖ was carried using the web-based program 
Webgestalt (WEB based GEne SeT AnaLysis Toolkit) 
[http://bioinfo.vanderbilt.edu/webgestalt/]. The function of this program is to ―translate gene 
lists into biological insights‖. A list of the significant SNPs (uncorrected p-value < 0.05) from 
the association analysis was used as input. The following enrichment tools were used: Kegg 
analysis, Pathway Commons analysis and Disease Association analysis. For each separate 
analysis, the homo sapiens genome was selected as the reference genome, and default values 
were kept for the other parameters (statistical method: hypergeometric, multiple adjustment 
method: Benjamini & Hochberg, significance level: top 10, minimum number of genes for a 
category: 2).  
3.2.5.5 Polygenic Profile Scoring 
GWASs have not had much success in identifying replicable markers which account for the 
phenotypic variance observed in psychiatric disorders. It is now believed that the unexplained 
heritability may be due to the host of genetic markers which do not obtain significant 
associations in GWASs [Dudbridge, 2013]. The polygenic scoring procedure was employed 
to determine whether there is overlap in common ―risk‖ variants of small effect (not 
obtaining the threshold p-values in GWASs), between AUD and other psychiatric disorders. 
The use of this method has had success in identifying variants for SCZ treatment outcomes 
[Frank et al., 2014].  This procedure was first proposed by Purcell et al. (2009) and the basis 
of the method followed, is described below.  
1) Firstly, data was obtained from a ―discovery‖ dataset. In this instance, genotyping data 
for BD, MDD and SCZ were obtained from the PGC website 
[https://pgc.unc.edu/Sharing.php#SharingOpp] (Date accessed: 19 October 2012).   
2) Secondly, SNPs were selected which overlapped between the Illumina bead chip and the 
three PGC datasets and were below a certain p-value threshold. Overlapping SNPs were 
determined by the use of the ―merge‖ function in the statistical environment R 
[http://www.r-project.org/]. The number of overlapping SNPs in each dataset at varying 
thresholds are listed in Table 11.  




Polygenic Profile Score= S1*W1 + S2*W2 +S3*W3 +... ni 
Si= no. of reference alleles the individual has at SNPi 
Wi=  log odds ratio of SNPi 
This score was calculated using the statistical programme Plink (version 1.07) 
[http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007] using the ―score‖ 
option.  
4) Logistic regression was used to test whether the polygenic score for each individual had 
an association with AUD, using the statistical environment R [http://www.r-project.org/]. 
 
Table 11: Number of overlapping SNPs for each threshold between the current genotype data and PGC datasets 
p-value threshold Bipolar disorder Major depressive disorder Schizophrenia 
 No. SNPs No. SNPs No. SNPs 
All 3528 2470 2479 
< 0.1 576 291 424 
< 0.2 940 557 693 
< 0.3 1319 796 941 
< 0.4 1670 1017 1156 
< 0.5 1993 1259 1374 
 
3.3.5.6 Gene x Environment Interaction Analysis 
To test whether any of the genotypes interacted with an adverse environment to result in a 
high lifetime alcohol dose, gene x environment calculations were carried out using Plink 
(version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007]. The 
(dichotomised) CTQ subscales which were significantly different between the AUD and HC 
groups were used as the environmental risk factors in this analysis.  
3.2.5.7 Gene-Imaging Analysis 
To test whether the variance in the ROI brain volumes could be explained by the SNPs on the 
bead chip, a SNP by brain volume association was conducted using Plink (version 1.07) 
[http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007] on a subset of the total 
cohort (58 AUD and 58 HC). A linear regression test was used and the following were 




and protocol (transaxial vs sagittal). All analyses were adjusted for multiple testing.  As with 
the association tests (with AUD diagnosis), SNPs with a MAF of less than 0.05, not in HWE 
(p-value < 0.00001) and a genotype ‗missingness‘ rate of greater than 10% were excluded. 
To verify the initial association findings, the main effects of group (AUD and HC) and of the 
identified significant SNP genotypes on brain volume data, 2 x 2 ANCOVA using VBM in 
the SPM8 package [www.fil.ucl.acuk/spm8] was implemented. AUD and HC subjects were 
matched in terms of age, gender, and protocol (transaxial vs sagittal). Age, total matter 
volume and total CTQ score was were added as covariates of no interest to control for global 
differences in head size and emphasise local volume differences. All statistical analyses were 
corrected for multiple comparisons at the peak voxel level using the family-wise error 
(FWE). 
3.3 Results 
3.3.1 Research Group 
The research cohort consisted of 80 adolescents with AUD and 80 age- and gender- matched 
control subjects (Table 12). The total cohort consisted of 66 males and 94 females. In both 
the AUD and HC groups, there were 47 females and 33 males. The median ages of the AUD 
and HC groups were 14.94 and 14.92 years, respectively. In the AUD group, the median age 
of onset was 12 years. The majority of the participants were Afrikaans speaking and the 
median number of years of education was 8.0 years for both groups (AUD and HC). The 
same variables, as mentioned above, are reported for the imaging cohort (58 AUD and 58 
HC) in Table 12. The values for the reported variables do not differ greatly between the 
larger (n=160) and smaller (n=116) cohorts.  
3.3.2 Clinical Measures 
The median number of lifetime alcohol dose units for the AUD and HC groups in the total 
cohort was 1125.50 and 1.0, respectively, where a unit refers to one beer or wine cooler, one 
glass of wine, or one 43g shot of liquor (on its own, or in a mixed drink) (Table 12). In the 
total cohort, the median total CTQ score was 42.5 and 36.50 for the AUD and HC groups, 
respectively. The minimum CTQ total score was 25 and the maximum 83. The median values 
for each of the CTQ subscales are also reported in Table 12. Figure 14 represents the 
frequency of participants in the AUD and HC groups reporting clinically significant abuse 
and neglect. In the AUD group, the most prevalent CTQ subscale was PN, with 60.3% of the 




3.3.3 Statistical Analysis 
The quantitative variables (age, years of education, alcohol life dose units, and CTQ 
measures) were not normally distributed (Shapiro-Wilk Test p-value <0.05), therefore non-
parametric tests were used in subsequent analyses. As expected, adolescents with AUDs had 
significantly higher lifetime doses of alcohol than the HC group (Mann Whitney U-test p-
value<0.001; Table 13). The difference in median total CTQ scores was statistically 
significant (Mann Whitney U-test p-value= 0.023) (Table 13). There were significant 
differences (p-value < 0.05) in CTQ-SA, EA and PN between the AUD and HC groups, 
whereby these subscale scores were higher in the AUD compared to the HC group. In the 
AUD group, males reported higher physical and sexual abuse compared to females and this 
was statistically significant (p-value < 0.05). 
 
 


























Table 12: Median values and interquartile range for cohort characteristics and clinical measures 
Variable AUD HC 
Total cohort 
Imaging cohort1 
Females (n= 47) 
Females (n= 33) 
Males (n= 33) 
Males (n= 25) 
Total (n=80) 
Total (n=58) 
Females (n= 47) 
Females (n= 33) 
Males (n= 33) 


























































































































































1 Imaging cohort values indicated in italics 




Table 13: Comparison of cohort characteristics for HC and AUD groups- p-values from Mann Whitney U- test 
 AUD HC HC vs AUD 















































































































1Pearson chi-squared test (d.f. =1).  
2Imaging cohort values are indicated in italics. 
 
3.3.3.1 IBS Clustering 
The cohort was divided into four clusters, indicating population substructure within the 
mixed ancestry group. The cluster assignment for each individual was used as a covariate in 
subsequent association testing. The biggest and smallest clusters consisted of 65 and 14 
individuals, respectively.  
3.3.3.2 Association Analysis 
a) Single-SNP 
Logistic regression was used to test whether any of the SNPs had an association with AUD.  
A total of 192 SNPs obtained a p-value of less than 0.05. However, after correction for 




the 192 SNPs and the respective chromosomal locations of these SNPs. Table 14 lists the top 
ten SNPs with the lowest p-values for the single SNP association. The most significant SNP 
was rs7105258 (t-statistic= 3.12, OR= 3.091, uncorrected p-value=0.0018), located in the 
gene glutamate receptor, ionotropic kainate 4 (GRIK4) (chr11q22.3). These results indicate 
that the A-allele of this SNP increases the risk of having an AUD. Appendix 2 (Single-SNP 
Association Results) lists all the 192 SNPs and the corresponding test statistics and p-values.  
 
 




The gene which obtained the most significant association to AUD was nuclear receptor 
subfamily 1, group D, member 1 (NR1D1) (p-value=0.003), consisting of 5 SNPs in the set, 
with 1 SNP being significant (rs2071570). The second-most significant SNP (p-value=0.006) 
is located in the gene, basic helix-loop-helix family, member e41 (BHLHE41, also known as 
BHLHB3 and DEC2).  This set consisted of four SNPs, with rs3809140 being the only 
significant SNP in the set. Both of the above-mentioned genes form part of the circadian 
pathway and were in the top ten SNPs for the single SNP association (Table 14). Appendix 2 





Table 14: Top ten results from single SNP association to AUD 









11 rs7105258 GRIK4 A 3.091 3.12 0.0018 
17 rs2071570 NR1D1 A 0.3624 -3.077 0.0021 
11 rs11030119 BDNF A 0.4038 -3.034 0.0024 
5 rs10515806 ADRA1B A 0.1805 -2.971 0.0030 
5 rs10515805 ADRA1B A 0.1805 -2.971 0.0030 




A 3.356 2.896 0.0038 
12 rs3809140 BHLHE41 G 0.4546 -2.892 0.0038 
10 rs10509117 ANK3 A 2.771 2.886 0.0039 
11 rs528833 ARRB1 A 0.3552 -2.857 0.0043 
 
3.3.3.4 Pathway Analysis 
Pathway analysis was conducted using the 192 uncorrected significant SNPs (comprising 96 
genes). Using Kegg, the neuroactive ligand-receptor interaction was the most significant 
pathway comprising 24 genes and with an adjusted p-value of 5.69e-31. From the Pathway 
Commons analysis, the most significantly represented pathway, comprising 19 genes and 
with an adjusted p-value of 6.91e-20, was the g-protein coupled receptor ligand binding 
pathway. The mental disorders most significantly represented by the genes were depression 
and anxiety with an adjusted p-value of 7.59e-43 and comprising 28 and 27 genes, 
respectively. 
3.3.3.5 Polygenic Profile Scoring 
From the logistic regression analysis, none of the polygenic scores generated for each of the 
individuals in the cohort, had an association with AUD (p-value < 0.05).  
3.3.3.6 Gene x Environment Interaction Analysis 
Gene x environment interactions were calculated using a regression analysis. All of the SNPs 
(n=4065) were tested for interaction with the CTQ subscales SA, EA and PN. The outcome 
measure was lifetime alcohol dosage. None of the SNPs obtained a significant interaction 




rs1538974 (z-score = -3.98, p-value = 6.904e-005) located in the gene disrupted in 
schizophrenia 1 (DISC1). For EA, the top SNP was rs12010790 (z-score = -4.301, p-value = 
1.7e-005) upstream of the gene gamma-aminobutyric acid A receptor, theta (GABRQ) and 
PN, rs2298703 (z-score = -3.913, p-value = 9.128e-005) located in the gene neural cell 
adhesion molecule 1 (NCAM1). 
3.3.3.7 Gene-Imaging Analysis 
From the association analysis, only one SNP, rs219927, located in an intron of the gene 
glutamate receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B) (chr 12p12) was 
associated with ROI brain volume in the left posterior cingulate cortex (t-stat=-4.806, beta = -
0.03358, corrected p-value< 0.05). However, this SNP had a relatively small effect size. 
From this, four ―functional‖ variants (two exonic [rs1806201 and rs7301328] and two located 
in the 3‘UTR [rs890 and rs1805502]) within the GRIN2B gene were investigated to 
determine whether these variants were associated with variation in brain volume that was not 
detected in the earlier association tests due to the multiple testing burden. It was found that 
the 3‘UTR SNP, rs890, was associated with brain volume in the left and right DLPFC (t-
stat=-2.736, beta = -0.0178, corrected p-value< 0.05).   
ANCOVA and post-hoc t-tests for brain volume and genotype (rs219927 and rs890 in two 
separate ANCOVA analyses) were conducted using VBM. There were no FWE-corrected 
significant findings and no main effects for group (AUD and HC) were observed for any of 
the brain volumes. In terms of uncorrected findings, a main effect for rs219927 was found in 
the left orbitofrontal cortex (OFC) (x=-21, y=37, z=-16, uncorrected p-value< 0.05) (Table 
15). Post-hoc tests indicated that volume in the left OFC was smaller in individuals with 
AUD and a GG genotype, although this association was only nominally significant 
(uncorrected p-value= 0.05).  Furthermore, t-tests indicated that AUD individuals with the 
AG genotype had larger volume in the left-mid posterior cingulate (x=-1, y=-48, z=55, 
uncorrected p-value< 0.05) (Table 15). For the SNP, rs890, a main effect of genotype was 
observed in the left parahippocampal gyrus (x=-24, y=-30, z=-21, uncorrected p-value< 
0.001) (Table 16) from the ANCOVA analysis. However, this finding was not confirmed 




Table 15: 2 x 2 ANCOVA with intronic non-functional SNP rs219927 matched for age, gender, group and protocol (with total matter volume age,  gender and total CTQ as covariates 




Brain region x y z Brodmann Area Cluster Size 
(Voxels) 
Z-statistic P-value  
 
Ancova Analyses 
Main effect of group 
Right posterior cingulate/parietal lobe 19 -57 49 23 379 4.64 0.08 
Main effect of genotype 
Left orbitofrontal cortex -21 37 -16 11 891 5.12 0.01 
 
Post-Hoc t-tests 
Between-group genotype (AA): HC > AUD 
--- --- --- --- --- --- --- --- 
Between-group genotype (AA): AUD > HC 
Right posterior cingulate/parietal lobe 46 -34 41 40 712 3.96 0.05 
Between-group genotype (AG): HC > AUD 
--- --- --- --- --- --- --- --- 
Between-group genotype (AG): AUD > HC 
Left-mid posterior cingulate/parietal lobe -1 -48 55 5 2578 4.09 0.01 
Between-group genotype (GG):  HC >AUD 
Right posterior cingulate/parietal lobe 21 -51 50 7 572 4.37 0.05 




Between-group genotype (GG): AUD > HC 
--- --- --- --- --- --- --- --- 
MNI-Montreal Neurological Institute Coordinates, CTQ-Childhood Trauma Questionnaire 
 




Brain region x y z Brodmann Area Cluster Size 
(Voxels) 
Z-statistic P-value  
 
Ancova Analyses 
Main effect of group 
Right posterior cingulate/parietal lobe 19 -57 49 23/5 379 4.64 0.08 
Main effect of genotype 
Left parahippocampal gyrus -24 -30 -21 36 1073 2.91 <0.001 






This investigation sought to determine the complex biological interactions underlying 
adolescent AUD using genetic, brain imaging, and environmental data. From the analysis of 
the genetic data, no single SNP was found to be associated with adolescent AUDs, after 
correction for multiple testing. However, the circadian rhythm genes NR1D1 and BHLHE41 
were associated with AUD in a gene-based test. Childhood trauma was shown to be higher in 
adolescents with AUD, compared to matched controls. No significant gene x environment 
interaction was found for lifetime alcohol units. The gene-imaging analysis identified a SNP 
in the GRIN2B gene as being associated with brain volume in the left OFC and posterior 
cingulate.  
No single SNP was found to be statistically associated with AUD. This finding adds further 
evidence that the aetiology of AUD may be as a result of multiple genes of small effect 
[Johnson et al., 2006; Heath et al., 2011; Yang et al., 2014] that were not detectable in this 
relatively small sample size. Although no single SNP reached statistical significance, it is 
worth noting that the most significant SNP was the rs7105258 intronic SNP, located in the 
glutamate ionotropic receptor gene, GRIK4 (11q22.3). Variation within GRIK4 has 
previously been associated with BD and SCZ [Pickard et al., 2006; Pickard et al., 2008]. 
While this is the first time that this particular SNP and gene have been implicated in AUD, 
previous studies have highlighted the role of the glutamate system in AUDs, with variation in 
the glutamate receptor, ionotropic, kainite 1 (GRIK1) gene associated with AD [Kranzler et 
al., 2009] and variants in the glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
(GRIN2A) gene shown to have an association with AD, positive family history, an earlier age 
of onset, risky drinking patterns in adolescents and maximum number of drinks for adults 
[Schumann et al., 2008]. Further work with larger samples is needed to explore the role of 
GRIK4 in particular. 
From the gene-based analysis, NR1D1 and BHLHE41 were identified as being significantly 
associated with AUD. Both NRID1 (also known as REV-ERBα) and BHLHE41 play essential 
roles in the circadian pathway (the protein encoded by the BHLHE41 gene is a transcriptional 
repressor) [Fujimoto et al., 2007]. This is consistent with animal and human evidence that 
circadian disturbances may be relevant to AUDs [Chen et al., 2004; Hatonen et al., 2008]. 
NR1D1 is an orphan nuclear hormone receptor gene which is a ―gatekeeper‖ for appropriate 
co-ordination of the circadian response [Duez and Staels, 2009] by regulating the 




[Preitner et al., 2002]. This is the first time this particular gene variant has been associated 
with AUD but it has been associated with BD [Kripke et al., 2009] and it may well play a role 
in a range of neuropsychiatric disorders given the importance of circadian rhythms in a 
variety of psychobiological processes [Merrow et al., 2005]. Similarly, BHLHE41 which is 
rhythmically expressed in the suprachiasmatic nucleus, is involved in the repression of the 
clock circadian regulator, (CLOCK)/ARNTL heterodimer dependent transcription of the 
period circadian clock 1 (PER1) gene [Honma et al., 2002]. As with NR1D1, this gene and 
variant has also not previously been implicated in AUD. 
Even though AUD has proven to have a considerable genetic heritability [Prescott and 
Kendler, 1999; Epps and Holt, 2011], it is clear that environment plays a substantial role in 
whether an individual will abuse illicit substances or not. In this study, childhood trauma was 
more prevalent in adolescents with AUD compared to control individuals. In particular, 
sexual and emotional abuse, and physical neglect were higher in the alcohol using group. 
This has been found in previous studies whereby an adverse childhood environment predicted 
substance use later in life [Duncan et al., 1996; Felitti et al., 1998; Dube et al., 2006; Khoury 
et al., 2010; Nelson et al., 2010; Copeland et al., 2011; Sartor et al., 2013]. Childhood 
maltreatment is also associated with a higher occurrence of comorbid personality disorders in 
individuals who abuse substances [Bernstein et al., 1998]. These findings clearly illustrate the 
long-term effects that adverse events during childhood have on psychopathology during 
adolescence and eventually adulthood.   
From the gene-imaging analysis, it was noted that a SNP within the GRIN2B gene was 
associated with differential brain volume. GRIN2B (12p12) encodes the 2B subunit of the 
ionotropic N-methyl-D-aspartate (NMDA) glutamate receptor [Collingridge et al., 2009] and 
in brain tissue is primarily expressed in the fronto-parieto-temporal cortex and the 
hippocampal pyramidal cells [Schito et al., 1997]. The NMDA receptor is an ion gated-
channel which plays a role in the process of long term potentiation (LTP) and is thought to be 
involved in learning and memory [Ishii et al., 1993]. In this investigation we found a nominal 
association between the intronic SNP, rs219927, and smaller volume in the left OFC and 
larger volume in the left posterior cingulate. The OFC has been implicated in the neural 
process of decision-making [Bechara et al., 2000] and reward-related behaviour in response 
to taste, smell and visual cues [Rolls, 2000; Kringelbach, 2005] and the posterior cingulate is 
involved in memory retrieval [Maddock et al., 2001]. Both the posterior cingulate and 




addictive behaviour [Volkow and Fowler, 2000; Tapert et al., 2003; Hill et al., 2009; 
Acheson et al., 2014; Camchong et al., 2014]. Genetic polymorphisms within GRIN2B have 
previously been associated with variation in brain volume. In particular the SNP, rs890 in 
GRIN2B was shown to have an association with reduced fractional anisotropy (FA) in several 
brain areas, including the bilateral frontal region and left cingulate gyrus, in individuals with 
BD [Kuswanto et al., 2013]. Similar to our findings, a previous study reported that the 
rs1805476 GRIN2B SNP was associated with smaller OFC volume in individuals with 
obsessive compulsive disorder [Arnold et al., 2009a]. Another study reported that the 
rs1019385 GRIN2B SNP was associated with smaller anterior cingulate glutamatergic 
concentration [Arnold et al., 2009b]. Also, the 3‘UTR GRIN2B SNP, rs1805476, was 
associated with smaller anterior cingulate cortical volume [Arnold et al., 2009a]. Another 
study showed increased glutamate receptor, ionotropic, N-methyl-D-aspartate 3A (GRIN3A) 
mRNA, an NMDA receptor subunit, levels in the OFC of alcoholics [Jin et al., 2014]. The 
intronic GRIN2B SNP, rs219927, has not previously been associated with any brain volume 
or psychiatric phenotype. As mentioned, GRIN2B is involved in glutamatergic signalling 
suggesting that this pathway may possibly be associated with differential brain volumes 
particularly in individuals with AUD. These preliminary findings implicating GRIN2B should 
be investigated further in larger cohorts.  
One of the main limitations of this study is the small sample size. With a bigger sample, 
SNPs which were nominally significant may prove to actually be associated with AUD. A 
post-hoc power calculation demonstrated that in order to obtain 80% power to detect an 
association between AUD and the 4065 SNPs, a sample size of 409 would be required. 
Nevertheless, even a small sample may be useful in providing signals for further 
investigation, and the value of this sample lies in the early onset of the phenotype, and in the 
lack of comorbidity. Another limitation is the fact that the MRIs were acquired using two 
different protocols. However, an attempt to overcome this was made by matching imaging 
scans based on protocol and have shown previously that images obtained from two different 
protocols could be combined for analysis [Fein et al., 2013]. 
The findings from this study imply that the onset of AUD in adolescents may be as a result of 
dysfunction in the circadian and glutamatergic pathways. Both of these pathways have 
previously been implicated in BD and suggest that a common pathophysiology between AUD 




appears that childhood trauma may predict AUD in adolescence. The next chapter of this 





















Chapter 4: An Investigation of Alcohol Use in a Group of 
Adolescents from the ALSPAC Cohort 
Abstract  
There is evidence that specific genetic variants within components of the HPA-axis and 
exposure to childhood adversity are associated with AUD. There is also evidence that 
internalising behaviour may be a risk factor for AUD. The aim of this study was to determine 
whether variants within genes involved in the HPA-axis play a role in predisposing 
individuals to AUDs and whether these variants interact with childhood adversity to predict 
AUDs in adolescence. This study also set out to determine whether the internalising 
behaviour observed during early childhood has an association with adolescent alcohol use.  
The experimental group consisted of 8123 individuals from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) birth cohort. Alcohol use was measured with the Alcohol 
Use Disorders Identification Test (AUDIT) questionnaire, childhood life events were 
measured at 42 months and the emotional scores from the Strength and Difficulties 
Questionnaire (SDQ), part of which measures internalising behaviour, were obtained. 
Genotype data was acquired for six HPA-axis genes. None of the genetic variants were 
associated with AUDIT score. However, from the gene-based analysis, UCN3 for the SNP 
rs12783734 was associated with AUDIT score. No significant gene x environment 
interactions were detected and SDQ was not associated with AUDIT score. These results 
suggest that the HPA-axis genetic variants may not interact with childhood life events to 
predict adolescent alcohol use. Also, it appears that childhood internalising behaviour is not 
associated with alcohol consumption in adolescence.  
4.1 Introduction 
There is evidence from previous studies that both particular genes and particular 
environments contribute to vulnerability to AUD. However, there is relatively little data on 
gene x environment interactions in the aetiology of AUDs [Van Der Zwaluw and Engels, 
2009]. The results from Chapter 3 showed that childhood trauma may predict AUD in 
adolescence, possibly indicating that early life stress may have an effect on drinking patterns 
later in life. However, no statistically significant gene x environment interaction was detected 
in the relatively small sample size. Genetic variants within the HPA-axis, which mediates the 
stress response, have previously been associated with alcohol use. In this chapter we 




large European birth cohort. Further, little is known about the role of internalising behaviour 
in the development AUD. In this chapter we also investigated whether internalising 
behaviour has an association with alcohol use in adolescence.   
4.1.1 Hypothalamic-Pituitary-Adrenal Axis 
Homeostasis is the maintenance of a constant internal environment. ―Normal‖ physiological 
processes aim to maintain this equilibrium when the body is confronted by internal or 
external forces, known as stressors. During a stressful situation, brain function is heightened 
and focussed on the stressor [Tsigos and Chrousos, 2002]. The stress response is mediated by 
the stress system which forms part of the central and peripheral nervous systems. Stimulation 
of the stress system gives rise to a host of physical and behavioural alterations in a time-
limited manner which ultimately promotes the survival of the individual [Chrousos, 1998].  
The HPA axis is the main centre involved in the physiological response to stress through its 
interactions with stress-sensitive regions in the brain and neuroendocrine systems in the 
hypothalamic paraventricular nucleus (PVN). This complex process is outlined in a simple 
diagram in Figure 16. After the stimulation by stress or circadian signals from the 
suprachiasmatic nucleus (SCN), neurons in the PVN secrete CRH and arginine vasopressin 
(AVP) into the portal vein which stimulates the secretion of the adrenocorticotrophin 
hormone (ACTH) (also known as corticotrophin) from the corticotroph cells in the pituitary 
gland. An increase in circulating levels of ACTH results in the synthesis and secretion of 
glucocorticoids, such as corticosterone and cortisol, by the adrenal cortex [Herman and 
Cullinan, 1997]. In humans, cortisol is the primary glucocorticoid which initiates a wide 
range of physiological responses in the body. For example, cortisol plays a major role in 
metabolism in order to supply the body with sufficient energy during a stress response. It is 
also involved in the immune and cardiovascular systems and plays a role in cognitive 
processes [Kudielka and Kirschbaum, 2005].  Also involved in the stress system is the locus 
ceruleus and noradrenergic neurons in the medulla and pons [Chrousos, 1998]. The HPA-axis 
also has an auto-regulatory feedback mechanism whereby cortisol binds to glucocorticoid 
receptors in the HPA-axis and hippocampus. This auto-regulation is important for the 
maintenance of homeostasis in the HPA-axis [Watson and Mackin, 2006]. Continued or over-
secretion of glucocorticoids from the adrenal glands, as a result of stress, can be 






Figure 16: A representation of the HPA axis. The hypothalamus receives input from the central nervous system (CNS) 
and suprachiasmatic nucleus (SCN) and stimulates the appropriate response, which results in the release of glucocorticoids 
from the adrenal cortex [Lightman and Conway-Campbell, 2010]. 
 
4.1.2 Stress and Alcohol Use 
Heavy alcohol use is positively associated with the experience of environmental stressors 
such as job, health-related, social and legal stress [Dawson et al., 2005; Enoch, 2012]. A 
study conducted in 1991 showed that peer-reared rhesus macaques had higher levels of 
alcohol consumption, higher levels of plasma cortisol and corticotrophin compared to those 
who were maternally reared. In addition, when the maternally-reared monkeys were 
separated from their mothers, their alcohol consumption increased to a level nearly as high as 
the peer-reared monkeys. These results suggested that rearing experiences and early stressful 
life situations can lead to an increase in alcohol consumption [Higley et al., 1991]. Similar 
results were found in a subsequent study conducted on rhesus macaques which concluded 
that early rearing experiences and elevated plasma cortisol levels after stressful experiences 




involving rats, alcohol consumption increased with exposure to the stress hormone, 
corticosterone [Besheer et al., 2013]. University students suffering from examination stress, 
with low social support, increased their alcohol consumption by an average of 18.5% 
compared to students in the same group with high social support, who on the other hand, 
decreased their consumption by an average of 17.5% [Steptoe et al., 1996]. Upon alcohol 
withdrawal, activation of the HPA stress response system is observed [Adinoff et al., 1991]. 
These studies indicate a close relationship between the experience of stress and alcohol 
consumption. 
4.1.2.1 HPA-Axis Genetics and Alcohol Use  
The HPA-axis involves the following genes: CRH (also known as corticotropin releasing 
factor (CRF)), CRHR1, corticotropin releasing hormone receptor 2 (CRHR2), urocortin 
(UCN), urocortin 2 (UCN2), urocortin 3 (UCN3), and proopiomelanocortin (POMC), 
amongst others. The interactions of these gene products (blue ovals) within the context of the 
HPA-axis are illustrated in Figure 17 [Whirl‐Carrillo et al., 2012]. These genes are relatively 
unexplored in terms of vulnerability to AD; however, it is thought that the products of these 
genes interact with each other in specific brain regions to regulate alcohol consumptive 
behaviours [Ryabinin et al., 2012]. Below are descriptions of each of these HPA-axis genes 
and their possible involvement with alcohol use:  
4.1.2.1.1 CRH  
The CRH gene, located on chromosome 8q13, encodes the 41 amino acid corticotropin-
releasing hormone which is released from the PVN. Upon release from the PVN, CRH binds 
to its receptors located on the anterior pituitary corticotroph cells to stimulate the release of 
ACTH. The CRH protein, first characterised by [Vale et al., 1981], is hypothesised to be the 
key regulator in the HPA-axis. This protein is purported to play roles in learning, memory, 
depression, and anxiety disorders [Raadsheer et al., 1994; Raadsheer et al., 1995; Radulovic 
et al., 1999; Blank et al., 2002; Roozendaal et al., 2002].  
In rats characterised as ―ethanol-preferring‖, an increase in basal levels of CRH was observed 
in the amygdala [Richter et al., 2000] and in a separate study, increased levels of ACTH was 
detected in the plasma of rats after alcohol consumption. This effect was attenuated when 
CRH receptors were blocked suggesting that the mechanism of ACTH increase is mediated 
by CRH [Rivier and Lee, 1996]. Crh-knockout (KO) mice consumed less alcohol and had 




A cell culture model has shown that alcohol administration increases the expression of the 
CRH gene [Li et al., 2005]. 
Variations within the CRH gene have previously been reported to be associated with alcohol-
use behaviour [Barr et al., 2008; Barr et al., 2009]. A CRH SNP (-2232 C>G) was shown to 
be associated with decreased levels of CRH in CSF, increased levels of ACTH in CSF and 
increased alcohol consumption in rhesus macaques [Barr et al., 2008].  Another CRH 
polymorphism (-248C>T), located in the promoter of the gene, was shown to be associated 
with greater alcohol consumption after early life adversity in rhesus macaques [Barr et al., 
2009]. Two receptors which bind CRH, CRHR1 and CRHR2, have been identified and are 
described in greater detail below.   
4.1.2.1.2 CRHR1 
The 415 amino acid receptor protein, CRHR1, was first cloned in 1993. This protein is a G-
protein coupled receptor consisting of seven membrane spanning domains [Chen et al., 1993] 
and is expressed in the CNS, particularly the cortex, cerebellum, and sensory relay structures 
[Chalmers et al., 1995; Van Pett et al., 2000].  It has been suggested that CRH receptor 
antagonists may be good treatment options for alcoholism [Lowery and Thiele, 2010; Zorrilla 
et al., 2013], suggesting a role for this protein in the pathophysiology of AUD. The gene 
encoding this receptor is located on chromosome 17q12-q22. A few studies have shown the 
effects of this gene on alcohol use in animal models [Sillaber et al., 2002; Kaur et al., 2012; 
Molander et al., 2012]. One such study showed that Crhr1-KO mice consumed less alcohol 
than WT mice [Kaur et al., 2012]. In contrast, others have found that mice without a 
functional Crhr1 consume more alcohol after being exposed to stress [Sillaber et al., 2002; 
Molander et al., 2012]. Several studies have looked at CRHR1 polymorphisms in human 
subjects and, similar to the findings of the animal studies, results have been conflicting. One 
such study found that two haplotype-tagging SNPs (rs242938 and rs1876831) within CRHR1 
had been associated with higher alcohol consumption and binge drinking in adult and 
adolescent groups [Treutlein et al., 2006]. Similarly, [Chen et al., 2010] found that several 
SNPs in CRHR1 had an association with AD. In contrast, another study did not find any 
association between the following CRHR1 SNPs: hCV449763, rs7209436, rs242924, 





The CRHR2 receptor consists of 431 amino acids and shares 68% similarity with the CRHR1 
protein [Perrin et al., 1995]. This receptor has a distinct expression profile in the brain 
compared to the Type 1 receptor, and is primarily expressed in the lateral septal nucleus, 
ventromedial hypothalamic nucleus, hippocampus and the choroid plexus [Chalmers et al., 
1995; Van Pett et al., 2000]. CRH preferentially binds CRHR1 with high affinity, suggesting 
the 2 receptors have different functions [Lovenberg et al., 1995]. Furthermore, there are two 
splice variants of CRHR2, namely CRHR2α and CRHR2β [Lovenberg et al., 1995]. The 
CRHR2 gene is located on chromosome 7p14.3. Of the few studies investigating the effects 
of CRHR2 in terms of alcohol consumption, one reported that ―alcohol-preferring‖ rats 
showed decreased CRHR2 mRNA levels compared to ―non-preferring‖ rats [Yong et al., 
2014].  
4.1.2.1.4 UCN 
Urocortins are members of the CRH family of peptides which illicit similar physiological 
responses to CRH by binding to the CRH receptors. UCN binds with high affinity to CRHR1 
and CRHR2 [Suda et al., 2004] and administration of UCN results in ACTH and 
corticosterone secretion [Vaughan et al., 1995; Asaba et al., 1998]. UCN is primarily 
expressed in the region known as the Edinger-Westphal nuclei in the brain [Bittencourt et al., 
1999]. The gene encoding the 40 amino acid protein, urocortin, is located on chromosome 
2p23 [Donaldson et al., 1996]. In terms of alcohol consumption, ―ethanol-preferring‖ mice 
had higher levels of Ucn1 (UCN ortholog) positive cells than ―ethanol-avoiding mice‖, after 
consumption of alcohol, suggesting a possible role of UCN in alcohol-use behaviour 
[Bachtell et al., 2003; Weitemier and Ryabinin, 2005]. Similar results were also shown in 
studies on rats [Turek et al., 2005; Fonareva et al., 2009]. No studies have been reported 
regarding the association of variants within UCN and AUD in humans.  
4.1.2.1.5 UCN2 
The mature UCN2 protein (also known as stresscopin-related peptide) consists of 38 amino 
acids and selectively binds to the receptor CRHR2 [Reyes et al., 2001]. The gene encoding 
this protein is located on chromosome 3p21.3. To the best of the knowledge of the author, 
neither the UCN2 protein nor its encoding gene has been investigated in terms of alcohol-





UCN3 (also known as stresscopin) also encodes a 38 amino acid protein, which has a 90% 
homology to mouse UCN protein, and selectively binds to the type 2 CRH receptor [Lewis et 
al., 2001]. UCN3 is also thought to play a role in alcohol-use behaviour as central 
administration of Ucn3, in a saline solution, to non-dependent mice reduced alcohol intake 
but not the self-administration of water [Sharpe and Phillips, 2009]. Also, Ucn3-KO mice 
consumed more alcohol compared to WT mice [Smith et al., 2014].  
4.1.2.1.7 POMC 
POMC is a hormone precursor protein which is mainly expressed in the pituitary gland where 
it undergoes differential post-translational processing to produce hormones such as ACTH 
and β-LPH. The gene for POMC is located on chromosome 2p23.3 and encodes for a protein 
of 267 amino acids [Chang et al., 1980; Whitfeld et al., 1982]. Animal studies have shown 
that alcohol consumption decreases POMC transcriptional activity [Gangisetty et al., 2014; 
Zhou and Lapingo, 2014].  Also, rat pups who consumed alcohol displayed an increase in 
POMC methylation [Gangisetty et al., 2014]. Similarly, in humans, differential methylation 
patterns in the 5‘ promoter region of the POMC gene were observed in individuals with an 
AD diagnosis compared to controls. The authors of this study suggested that alcohol 
consumption may have resulted in epigenetic changes associated with alcohol craving 
[Muschler et al., 2010]. The results from all of these studies suggest that POMC may be an 
important candidate in terms of the aetiology of AD. However, no association was found 
between seven SNPs, namely rs1042571, rs2071345, rs6713532, rs12473543, rs8192605, 
rs934778, and rs1009388, located in this gene, and an AD phenotype [Xuei et al., 2007].  
4.1.3 HPA-Axis Gene x Environment Interactions 
Studies involving animal models have shown that polymorphisms within the CRHR1, 
together with the experience of environmental stress factors, result in greater alcohol 
consumption [Sillaber et al., 2002; Hansson et al., 2006]. Similarly, in humans, 
polymorphisms in the CRHR1 gene (and adjacent chromosomal regions) interact with 
negative life events to predict heavy alcohol use [Blomeyer et al., 2008; Nelson et al., 2010; 
Ray et al., 2013] and earlier age of first drink [Schmid et al., 2010]. In fact, it has been shown 
that CRHR1 polymorphisms interact with measures of childhood abuse to predict depressive 
symptoms in adults [Bradley et al., 2008] and have an effect on cortisol response in the 




These findings suggest a possible relationship between variants in HPA-axis genes and 
environmental stressors in AUD.  
 
 
Figure 17: Simplified illustration of glucocorticoid release via the hypothalamic-pituitary-adrenal (HPA) axis [Whirl‐
Carrillo et al., 2012]. 
 
4.1.4 Internalising Behaviour and Alcohol Use  
It is often argued that AUD is characterised by externalising behaviour [Kumpulainen, 2000; 
Englund et al., 2008]. Externalising symptoms or behavioural disinhibition is the ―inability to 
constrain impulses to behave in socially undesirable ways‖ [Iacono et al., 2008]. It has been 




disinhibition together with an environmental risk factor, such as poor family management 
[Hill et al., 2010].   
Findings regarding the link between behavioural inhibition/internalizing symptoms and AUD 
are less emphasised in the literature, although a few studies have shown that internalising 
symptoms, such as anxiety and depression, are associated with alcohol and substance use 
[Loeber et al., 1999; Sood et al., 2001; Fite et al., 2006; Saraceno et al., 2009; Edwards et al., 
2014]. Behavioural disinhibition is further defined as ―consistent tendency of some children 
to demonstrate fear and withdrawal in novel situations‖ [Svihra and Katzman, 2004]. A study 
has shown an association between AUD and anxiety disorders [Merikangas et al., 1998c]. 
However, it appears that this association is greater in females than in males. This could 
possibly be due to the low rate of anxiety disorders in males [Merikangas et al., 1998c]. 
Results from the International Consortium in Psychiatric Epidemiology, which combined 
previous epidemiological data from Canada, Germany, Mexico, the Netherlands, and the 
United States, found that 32% of individuals affected with an AUD met the diagnosis for an 
anxiety disorder [Merikangas et al., 1998b]. A separate study, involving German participants, 
found that anxiety disorders had the highest rate of comorbidity amongst AD subjects who 
were undergoing treatment [Schneider et al., 2001].  
There are three possible causal mechanisms of comorbidity between AUD and anxiety 
disorders: i) the anxiety disorder encourages the use of alcohol and thus the onset of AUDs. 
This has been shown in previous studies where anxiety disorders commonly preceded AUDs 
[Chambless et al., 1987; Merikangas et al., 1998c; Zimmermann et al., 2003; Schneier et al., 
2010], ii) Alcohol use promotes anxiety disorders, and  iii) the presence of a common causal 
factor for both disorders which may be genetic or environmental [Kushner et al., 2000].   
4.1.5 HPA-Axis Genes and Internalising Behaviour 
The HPA-axis has previously been associated with emotional dysregulation, whereby 
adolescents with internalising behaviour had lower evening cortisol levels, a measure of 
HPA-axis activity, than those with externalising behaviour [Marsman et al., 2008]. Another 
study found that dysregulation of cortisol levels predicted internalising symptoms in young 
children [Saridjan et al., 2014]. Evidence of a genetic basis to developing internalising 
symptoms is provided by a meta-analysis which found that generalised anxiety disorders have 
a heritability of 32% and that it exhibits familial clustering [Hettema et al., 2001]. The 




shown to have a heritability of 45% [Stein et al., 1999]. Relatives of an individual with an 
anxiety disorder are twice more likely to have an anxiety disorder than control individuals 
[Merikangas et al., 1998c].  
Variations within HPA-axis genes have previously been associated with internalising 
behaviour. Polymorphisms within CRHR1 have been shown to have a significant association 
with anxious temperament and to have an influence on the metabolic activity of local brain 
regions in rhesus macaques [Rogers et al., 2013]. Mice lacking a functional Crhr1 gene have 
reduced ACTH and corticosterone secretion in response to stress, and display less anxiety-
like behaviour at baseline and during alcohol withdrawal [Timpl et al., 1998]. In contrast, 
mice with deficient Crhr2 have an increased sensitivity to stress and exhibit increased 
anxiety-like behaviour [Bale et al., 2000; Kishimoto et al., 2000]. Mice with deficient Ucn 
have no changes in the stress response but increased anxiety-like behaviour in maze and 
open-field tests [Vetter et al., 2002]. Ucn2 KO mice exhibited less depressive-like behaviour 
compared to WT mice [Chen et al., 2006]. These findings indicate an important role for CRH 
receptors and their ligands in the regulation of the stress response and anxious behaviour. A 
study conducted in humans found that an intronic variant within the CRHR1 gene, rs110402, 
had an effect on alcohol consumption in adolescents which was mediated by internalising 
behaviour [Glaser et al., 2014]. Another study found that genetic variants within CRHR1 and 
5-HTTLPR interact with childhood trauma to predict higher internalising behaviour [Cicchetti 
et al., 2011]. It has also been suggested, as with the treatment of AUD, that there is a 
potential role for CRHR1 antagonists in the treatment of anxiety disorders  [Holsboer and 
Ising, 2008]. 
4.1.6 The ALSPAC Study: “Children of the 90s” 
The Avon Longitudinal Study of Parents and Children (ALSPAC) initiative was first initiated 
at a WHO meeting in Moscow in 1985 and forms part of a series of longitudinal studies in 
Europe [Boyd et al., 2013]. The main aim of this prospective, trans-generational, 
observational project was to measure how genotype interacts with environmental factors to 
affect health and development in children. The study is defined by the following criteria 
[ALSPAC Study Team, 2001]: 
 
1) Has to include all pregnant mothers from a defined geographical region with an 




2) The study data is collected from mothers and partners from self-completed 
questionnaires and is linked to health records. 
3) All participant data is anonymised and unable to be linked to a particular individual 
from statistical data. 
4) The study is observational and intervention should be kept to a minimum. 
5) The same questions should be asked, in the same way, by all participating study 
centres except for a few culturally modified questions. 
6) As much detail should be added as possible, but core variables should all be obtained. 
7) A copy of the data should be cleaned and sent to the Bristol (UK) study co-ordinating 
office for analyses. 
 
Enrolment to the study first began in September 1990 [ALSPAC Study Team, 2001]. 
Individuals were considered eligible for the study if they resided in one of the three health 
districts of the county of Avon (Bristol & Weston, Frenchay and Southmead) in the UK, and 
gave birth between 1 April 1991 and 31 December 1992. Initially, the study had recruited the 
children of 14 541 pregnancies. Each participant has been assessed 68 times between birth 
and 18 years of age. A total of 59 of those assessments were questionnaires (34 child-
completed and 25 child-based completed by the mother or main caregiver) and the remaining 
9 assessments were clinical visits. The ALSPAC study is unique in the wealth and range of 
data that has been collected for the participants over the course of the study, at key 
developmental time points. This includes detailed biological, phenotypic and environmental 
variables [Boyd et al., 2013].    
 
It is clear that the ALSPAC study is an excellent resource and provides a unique opportunity 
to try and determine the relationship between genes and environment in the complex AUD 
phenotype, as this dataset includes information on genetic variants and on adverse 
environments (e.g. stressful life events). The examination of this cohort could also aid in the 
determination of whether AUD is as a result of internalising behaviours such as anxiety or 
depressive disorders experienced during early childhood, as this dataset includes 
comprehensive information on internalising behaviour experienced during childhood. 
 4.1.7 Aims and Objectives 
The first aim of this study was to determine whether variants within genes involved in the 




with adverse childhood events to predict AUDs in adolescence. The second aim was to 
determine whether internalising behaviour observed during early childhood is a risk factor for 
adolescent alcohol use behaviour.    
4.1.7.1 Objectives  
The objectives of this investigation were as follows: 
1) To determine whether variants in the seven HPA-axis genes have an association with 
the Alcohol Use Disorders Identification Test (AUDIT) score at 198 months (16.5 
years).  
2) To determine whether adverse childhood events occurring before 42 months of age 
(3.5 years) predicts a high AUDIT score at 198 months of age. 
3) To determine whether the HPA-axis variants interact with adverse childhood events 
occurring before 42 months of age (3.5 years) to predict a high AUDIT score at 198 
months of age.  
4) To determine if there is an association between HPA-axis variants and the emotional 
subscale of the Strength and Difficulties Questionnaire (SDQ) at 81 months (6.8 
years). 
5) To determine if the emotional subscale of the SDQ, which correlates with 
internalising behaviour, has an association with AUDIT score.  
4.2 Materials and Methods 
4.2.1 ALSPAC Variables of Interest and Cohort Details 
Access was granted from the ALSPAC Executive Committee for the genotype data of the 
selected HPA-axis genes and the following ALSPAC data variables:  AUDIT scores, 
weighted life events score and the emotional subscale of the SDQ. These variables are 
described below.  
4.2.1.1 Cohort Details 
The initial ALSPAC dataset contained information for 15 455 individuals. A total of 406 of 
these individuals were twins and were excluded from the analyses to ensure that there were 
no related individuals in the cohort. To avoid population stratification, 595 individuals were 
excluded as they were not of Caucasian ethnicity. The cohort was further filtered to include 




4.2.1.2 Genotype Data 
All the SNPs from the 7 selected genes (CRH, CRHR1, CRHR2, UCN, UCN2, UCN3, and 
POMC) involved in the HPA-axis were extracted from the NCBI dbSNP (short genetic 
variations database) website [http://www.ncbi.nlm.nih.gov/SNP]. Of those variants, 82 SNPs 
(corresponding to six genes) had genotype information available from the ALSPAC cohort 
and were utilised for downstream analysis. Observed genotypes were obtained using the 
Illumina HumanHap550 quad genome-wide SNP genotyping platform (Illumina Inc., San 
Diego, California, USA) by 23 and Me (California, USA), sub-contracted by the Wellcome 
Trust Sanger Institute, (Cambridge, UK) and the Laboratory Corporation of America, 
(Burlington, NC, USA). Imputed genotypes were obtained using the MACH 1.0.16 Markov 
Chain Haplotyping software, using CEPH individuals from phase 2 of the HapMap project as 
a reference (release 22) [Paternoster et al., 2011]. A total of 19 SNP genotypes were observed 
in addition to being imputed. The imputed SNPs had an average quality score (average 
posterior probability for the most likely genotype) of 0.986 and an average Rsq score 
(estimate of the squared correlation between imputed and observed genotypes) of 0.966 (most 
imputation programs recommend a cut-off of less than 0.3).  A full list of the SNPs and genes 
investigated in this study are listed in Appendix 3 (Genes and SNPs).  
4.2.1.3 AUDIT Scores 
The aim of the AUDIT, developed by the WHO, is to assess drinking patterns, identify 
excessive drinking and AD. It aids in reducing alcohol consumption by identifying risky 
drinking behaviour. The AUDIT has been validated and shown to be applicable across 
gender, individuals of all ages and cultural backgrounds [Babor et al., 2001] and has also 
been shown to have a high specificity and sensitivity [Moussas et al., 2009]. AUDIT scores 
were calculated by adding the scores of each of the 10 questions which comprise this 
questionnaire (see Appendix 3-AUDIT Questionnaire). Participants were assigned a score of 
zero if they answered ―no‖ to the stem question or if they ever had an alcoholic drink. 
Similarly, if the participant scored zero (―never‖) for the first question of the AUDIT 
questionnaire, the rest of the questions were skipped until question 9 and 10. Also, if the 
participant scored zero for both questions 2 and 3, the rest of the questions were skipped until 
questions 9 and 10. An AUDIT categorical variable was created by classifying individuals 
with an AUDIT score of less than 8 as ―non-hazardous‖, equal to or greater than 8 and less 
than or equal to 15 as ―hazardous‖ and those with a score of equal to or greater than 16 but 




characterised by ―alcohol consumption that increases the risk of harmful consequences for the 
user or others‖. A harmful pattern is one in which the ―alcohol consumption results in 
consequences to physical and mental health‖ [Babor et al., 2001].  A binary AUDIT variable 
was created by combining the ―harmful‖ and ―hazardous‖ groups (score of greater than or 
equal to 8 but less than 42) and a score of less than 8 was deemed ―non-hazardous‖.  
4.2.1.4 Adverse Childhood Events 
To determine whether any of the study participants experienced any traumatic events during 
childhood, the weighted life events score was derived from Section D (―upsetting events‖) of 
the parent-rated ALSPAC questionnaire ―My Son‘s/Daughter‘s Health and Behaviour-42 
months‖ was used. This section of the questionnaire (which can be found in Appendix 3-
Adverse Childhood Events) is based on life-events scales developed by [Barnett et al., 1983]. 
This section of the questionnaire consists of several questions dealing with events occurring 
in the child‘s life. Each question consists of five possible responses ranging from whether the 
event occurred or not, to the effect the event had on the child‘s life. A score of zero was 
assigned if a particular life event had not occurred and if it had occurred, a score of one to 
four was given dependent on the severity of the event (ranging from ―not affected at all‖ to 
―severely affected‖) [Dorrington et al., 2014]. The weighted life events score is the 
summation of the scores for each of the questions. In this study, a binary life events score was 
derived whereby any individual with a life event was given a score of one and an individual 
without any life events given a score of zero.  
4.2.1.5 SDQ 
Internalising behaviour was measured by the parent-rated, emotional subscale of the SDQ 
[Goodman, 1997], administered at 81 months of age (~7 years). This brief behavioural 
screening questionnaire, found in Appendix 3 (SDQ), is a widely used tool for assessing 
mental health in children [Goodman et al., 2010]. It contains 25 questions consisting of five 
hypothesised subscales measuring emotional symptoms, conduct problems, hyperactivity, 
peer relationship problems, and prosocial behaviour. Each subscale is scored from zero to ten, 
with a higher score indicating more emotional problems [Peacock et al., 2011]. The SDQ 
emotional symptoms subscale has shown to correlate with internalising symptoms [Stone et 
al., 2010].   
The emotional scores were categorised into 3 groups:, namely ―normal‖ for scores less than 




equal to five and less than or equal to ten [Goodman, 1997]. A binary emotional score 
variable was created by combining the ―borderline‖ and ―abnormal‖ groups (scores equal to 
and greater than four and less than ten) and the ―normal‖ group (scores less than or equal to 
three).  
4.2.2 Statistical Analysis 
Using the statistical program Stata 11 (StataCorp. 2009. Stata Statistical Software: Release 
11. College Station, TX: StataCorp LP), t-tests (with unequal variances), chi-squared and 
linear regression were performed to determine if there were associations between the AUDIT, 
SDQ-emotional subscale and life events variables and whether there were any differences for 
these variables across gender.  
Before genotyping and frequency pruning there were 82 SNPs. Using the program Plink 
(version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007], none of the 
SNPs failed the missingness test (i.e. only SNPs with a genotyping rate of 90% or more were 
included) and 5 SNPs were excluded because of a MAF of less than 5%. One SNP was 
excluded as this SNP was not in HWE (p-value less than 0.0006). Therefore, after genotyping 
and frequency pruning there were 76 SNPs used for downstream analysis.   
4.2.2.1 Association Analysis of Genetic Variants and Alcohol Use Measures 
Using Plink (version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 
2007], linear and logistic regression was used to test whether any of the SNPs had an 
association with the continuous variable, total AUDIT score and the binary AUDIT variable, 
respectively.  Gender was included as a covariate, an additive genetic test was used, and all 
tests were adjusted for multiple testing using the Bonferroni Correction [Dunn, 1961]. A 
gene-based analysis, using linear regression, was performed to determine whether any of the 
genes have an association with the total AUDIT score. A total of 10 000 permutations were 
run, gender was included as a covariate, with the default values for r2 (0.5), p-value (0.05) and 
the maximum number of SNPs (5).  
4.2.2.2 Gene x Environment Interactions for Total AUDIT Score 
A gene x environment interaction, using regression analysis, was performed using Plink 
(version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007]. Total 
AUDIT score was used as the outcome measure and the environmental measure was the 
binary life events variable. All 76 variants were analysed and the Bonferroni Correction 




4.2.2.3 Association Analysis of Genetic Variants and SDQ 
Chi-squared tests implemented in Stata 11 (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP) were used to determine if there were any 
significant associations between the genotypes for each of the variants and the categorical 
SDQ-emotional subscale variable. Logistic regression, using Plink (version 1.07) 
[http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007], was performed to test 
whether any of the SNPs had an association with the binary SDQ-emotional subscale 
variable.  An additive genetic test was used, and all tests were adjusted for multiple testing 
using the Bonferroni Correction [Dunn, 1961]. 
4.3 Results 
4.3.1 ALSPAC Variables of Interest and Cohort Details 
4.3.1.1 Cohort Details  
The final cohort consisted of 8123 individuals. Of this, 4159 were male and 3964 females. 
All of these individuals were of the same age and of Caucasian ethnicity. Not all of the 8123 
individuals had data available for all of the variables under investigation. Figure 18 illustrates 
a breakdown of the number of individuals with available data for each of the variables.  
 
 




4.3.1.2 Genotype Data 
There were 8123 individuals with genotype data for each of the 82 SNPs. All SNPs had 
imputed genotype calls and a total of 19 SNPs had observed calls. For SNPs with both 
observed and imputed genotype calls, only the observed genotypes were used in downstream 
analyses.  The SNPs rs9839959 (UCN2), rs13319651 (UCN2), rs3769671 (POMC), 
rs7812133 (CRHR2) and rs6982394 (CRH) had a MAF of less than 5% and the SNP 
rs255102 (CRHR2) was out of HWE. These six SNPs were excluded from the downstream 
analyses. 
4.3.1.3 AUDIT Scores 
In total, there were 3389 participants with an AUDIT score. The mean score was 6.71 (SD= 
5.20) and the minimum and maximum scores were 0 and 33, respectively. The distribution of 
total AUDIT scores is represented in Figure 19. Figure 20 is a box plot of the total AUDIT 
score for males and females. The numbers of participants belonging to each AUDIT category 
by gender are listed in Table 17. There were 1258 individuals in the ―harmful/hazardous‖ 
group and 2131 individuals in the ―non-hazardous‖ group.  
 
 










Table 17: Number of individuals in each AUDIT category by gender 
AUDIT category Score Number of males Number of females Total 
Non-hazardous < 8 918 1213 2131 
Hazardous 8 ≥ and ≤ 15 413 642 1055 
Harmful 16 ≥ and ≤ 42 69 134 203 
Total  1400 1989 3389 
 
4.3.1.4 Adverse Childhood Events 
There were 6354 individuals with a weighted life events score. The mean score was 2.74 
(SD= 2.57), the minimum and maximum scores were zero and 21, respectively. For the 
binary life events variable, there were 1118 individuals with no adverse life event and 5236 
individuals with at least one adverse life event.  
4.3.1.5 SDQ 
There were 5675 individuals with an emotional score. The mean score was 1.50 (SD= 1.66) 
and the minimum and maximum scores were zero and ten, respectively. The number of 



















There were 715 individuals in the SDQ binary category ―Abnormal/Borderline‖ and 4960 
individuals in the 4960 ―Normal‖ category.  
 
Table 18: Number of individuals in each emotional score category by gender 
Emotional Score  category Score Number of males Number of females Total 
Normal ≤3 2546 2414 4960 
Borderline 4 169 188 357 
Abnormal 5 ≥ and ≤ 10 179 179 358 
Total  2894 2781 5675 
 
4.3.2 Statistical Analysis 
Total AUDIT score was significantly different between males and females (t=3.1, df= 
3124.75, two-tailed p-value = 0.001) whereby females had a higher mean total AUDIT score 
than males. There was no difference in the SDQ-emotional subscale categorical variable 
between males and females (Pearson chi-squared = 2.2750, df =2, p-value = 0.321). 
Similarly, for the life events score there was no difference across gender (t=0.4360, df= 
6311.91, two-tailed p-value = 0.3314). There was no difference in mean total AUDIT score 
between the borderline/abnormal and normal SDQ-emotional subscale groups (t= -1.1214, 
df= 436.038, two-tailed p-value = 0.8686). There was no association between life events and 
total AUDIT score (t-stat= 0.83, co-efficient= .0319214, p-value= 0.405). 
4.3.2.1 Association Analysis of Genetic Variants and Alcohol Use Measures 
From the linear and logistic regressions, none of the SNPs obtained a significant association 
with the total AUDIT score or the binary AUDIT category after correction for multiple 
testing. However, the top SNPs with uncorrected p-values of less than 0.05 are listed in Table 
19. Three of these SNPs are located in the gene UCN3 and the other two in POMC.  The 




Only five genes were included in the gene-based analysis as both UCN2 SNPs had a MAF of 
less than 5%. From the gene-based analysis only one SNP, rs12783734, located upstream of 
the gene UCN3 obtained a p-value less than 0.05 (p-value = 0.0384). 
4.3.2.2 Gene x Environment Interactions for Total AUDIT Score 
There were no statistically significant interactions between any of the variants and the binary 
life events variable, after correction for multiple testing. Interactions which obtained 
uncorrected p-values of less than 0.05 are listed in Table 20. All of these CRHR2 SNPs are 
intronic. All the results from this analysis can be found in Appendix 3 (Gene x Environment 
Interaction Results).  
4.3.2.3 Association Analysis of Genetic Variants and SDQ 
There were no significant differences in the genotypic distributions of the 76 variants 
between the three SDQ-emotional subscale categories. From the logistic regression analysis, 
none of the SNPs obtained a significant association with the binary SDQ-emotional subscale 
variable, after correction for multiple testing. Three SNPs obtained uncorrected p-values less 
than 0.05, listed in Table 21. Two of these SNPs are located in POMC and the other in CRH. 
 
Table 19: Linear and logistic regression results for total AUDIT score and binary AUDIT score 












10 rs12783734 UCN3 A 0.3581 2.397 0.01657 
AUDIT 
score 
10 rs12768198 UCN3 A 0.3555 2.382 0.01729 
AUDIT 
score 





rs6545975 POMC C 
0.2817 2.201 0.0278 
AUDIT 
score 
1.115 2.133 0.03295 
Binary 
AUDIT 







Table 20: Top results from gene x environment interaction analysis 
Chromosome SNP Gene Z score Uncorrected p-value 
7 rs2284217 CRHR2 2.253 0.02429 
7 rs255100 CRHR2 2.159 0.03087 
7 rs1076292 CRHR2 2.017 0.04365 
7 rs2251002 CRHR2 2.017 0.04365 
 
Table 21: Logistic regression results for binary SDQ variable 
Chromosome SNP Gene Minor allele Odds ratio t-statistic Uncorrected p-value 
2 rs6713532 POMC C 1.222 3.065 0.002176 
8 rs12721510 CRH T 1.312 2.547 0.01087 
2 rs6545975 POMC C 0.8789 -2.206 0.0274 
 
 4.4 Discussion 
In this chapter, the aim was to determine whether variants within HPA-axis genes play a role 
in predisposing individuals to AUD and whether these variants interact with childhood 
adversity to predict AUD in adolescence. The second aim was to determine whether 
internalising symptoms during childhood, as measured by the emotional subscale of the SDQ, 
had an association with adolescent alcohol use. No main effects or gene x environment 
interactions were detected for the for the AUDIT variables. However, from the gene-based 
analysis, UCN) was associated with the total AUDIT score. Specifically, the minor allele of 
the UCN3 SNP rs12783734 decreases the risk of having an AUD. Also, internalising 
behaviour did not have an association with the total AUDIT score.  
In this study no significant association was found between any of the genetic variants and the 
total AUDIT score or the binary AUDIT variable, after correction for multiple testing. This is 
in agreement with previous studies which did not find an association between HPA-axis 
genes and alcohol use behaviours [Dahl et al., 2005; Xuei et al., 2007]. Even though there 
were no statistically significant associations, it is still worth discussing the top SNPs from 
this analysis. SNPs in the genes UCN3 (rs12783734, rs12768198, and rs11591351) and 
POMC (rs6545975 and rs7565877) obtained uncorrected p-values of less than 0.05.  None of 
these SNPs have previously been shown to be associated with an alcohol-related phenotype. 
The gene-based analysis also identified UCN3 as having an association with the total AUDIT 




alcohol use behaviour as administration of Ucn3 to mice reduced alcohol intake but not the 
self-administration of water [Sharpe and Phillips, 2009]. Also, Ucn3-KO mice have been 
shown to consume more alcohol compared to WT mice [Smith et al., 2014]. Animal studies 
have also shown a role for POMC in alcohol use [Chen et al., 2004; Gangisetty et al., 2014; 
Zhou and Lapingo, 2014]. After alcohol consumption, the circadian rhythm of POMC 
expression in the hypothalamus of rats was dysregulated [Chen et al., 2004]. Studies 
conducted on humans have shown differential methylation patterns in the 5‘ promoter region 
of the POMC gene in individuals with an AD diagnosis compared to controls [Muschler et 
al., 2010]. These findings suggest a role for UCN and POMC in alcohol use behaviour which 
warrants further exploration.   
No association was found between the life events score and the AUDIT score. This suggests 
that childhood adverse events do not affect alcohol usage later in life. This is in contrast to 
what was found in Chapter 3, where childhood trauma was found to be significantly 
associated with adolescent AUD. However, for each of these chapters, different measures of 
childhood trauma and alcohol use were used. The life events measure used in this chapter 
included a wide range of childhood traumatic events whereas the CTQ (used in Chapter 3) 
specifically measures abuse (physical, sexual and emotional) and neglect (physical and 
emotional). It could be that environmental factors need to be of a certain severity to influence 
alcohol consumption. Also, the life events assessed in this chapter (by the parent or care-
giver) was at an early time-point in the life of the child (before the age of 3.5 years). The 
CTQ is usually administered to adolescents over the age of 12 years or as adults, and assesses 
abuse and neglect which could have occurred throughout childhood. Also, the CTQ may be a 
more reliable measure of childhood maltreatment compared to other methods such as parental 
observation [Polanczyk et al., 2009]. Another difference between the two chapters was that 
the alcohol outcome measure (AUDIT score vs DSM-IV AUD) was different for the two 
analyses. This was because these studies were conducted separately and under completely 
different conditions.  
No significant gene x environment interaction was found in this study. Similarly, another 
study did not find a significant interaction between the 5-HTTLPR polymorphism and 
stressful life events for AD [Dick et al., 2007]. However, a gene x environment interaction 
should not be ruled out as a possible mechanism for the development of AUD as many 
previous studies have found significant interactions with different genes and different 




al., 2007; Kaufman et al., 2007; Ducci et al., 2007; Nilsson et al., 2007; Nelson et al., 2010; 
Blomeyer et al., 2013; Miranda et al., 2013; Sartor et al., 2014; Kim et al., 2015].  
No association was found between the SDQ variable and the AUDIT score. This suggests 
that childhood internalising behaviour may not have an association with adolescent alcohol 
use. This is in agreement with previous studies which have also not found strong associations 
between internalising symptoms and alcohol use [King et al., 2004; Kivimäki et al., 2014]. 
Some studies report that alcohol use is characterised by externalising behaviour 
[Kumpulainen, 2000; Englund et al., 2008]. None of the genetic variants were associated with 
the SDQ-emotional subscale. A previous study did not find an association between variants 
within CRHR1 and internalising behaviour [Cicchetti et al., 2011]. Although different 
measures of internalising behaviour were used across these studies, these findings suggest 
that internalising behaviour may not be predicted by HPA-axis genes alone.  
There were several limitations of this study. Not all of the genes and variants involved in the 
HPA-axis were investigated in this study, as only the previously genotyped variants were 
available for analysis. Other variants within the genes of interest, not analysed in this study, 
could play a role in the development of alcohol use during adolescence. Therefore, the HPA-
axis still remains a viable candidate pathway for AUD. Another limitation of this study was 
that possible population stratification was not controlled for. However, genotype data was 
only available for a limited number of SNPs, insufficient to do an IBS cluster analysis. Also, 
a substantial proportion of the data variables were missing. In particular, close to half of the 
cohort had missing AUDIT scores, the main outcome measure in this study.  More statistical 
power could be achieved with a more complete dataset.   
The results from this study indicate that single variants in HPA-axis genes may not have an 
association with AUD and internalising behaviour. However, the gene UCN3 showed some 
preliminary evidence of association to AUD and should be investigated further.  Adverse life 
events do not seem to impact on alcohol usage, however this is in contrast to the results from 
Chapter 3 regarding the link between childhood trauma and adolescent alcoholism. Also, 
HPA-axis variants may not interact with adverse childhood events to predict alcohol 
consumption during adolescence. However, the HPA-axis still represents an important 
candidate pathway in psychiatric disorders. In Chapter 5, BD-AUD comorbidity is 




Chapter 5: An Investigation of the Glutamate Pathway and HPA-
Axis in BD-AUD Comorbidity  
Abstract  
Glutamatergic and HPA-axis pathways have been shown to be dysregulated in both BD and 
AUD. BD is often comorbid with AUD. The effects of the glutamatergic and HPA systems 
have not been extensively examined in individuals with BD-AUD comorbidity. The main aim 
of this investigation was to determine whether variants in the glutamatergic and HPA-axis 
pathways are associated with BD-AUD comorbidity. The cohort consisted of 498 individuals 
with BDI from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-
BD). A subset of the cohort had comorbid current AUD (n=233). A total of 1935 SNPs from 
both the glutamatergic and HPA-axis pathways were selected from the STEP-BD genome-
wide dataset. Using the program Plink, IBS clustering to identify population stratification, 
single SNP association with logistic regression, and gene-based association testing were 
performed. No single SNP was associated with BD-AUD comorbidity after correction for 
multiple testing. However, from the gene-based analysis, the gene protein kinase C, iota 
(PRKCI) was significantly associated with current AUD. Although the glutamatergic 
pathway and HPA axis may not have a major impact on BD-AUD comorbidity, the gene 
PRKCI deserves further investigation. 
5.1 Introduction 
Most research into the pathophysiology of BD and AUD has primarily focussed on the 
monoaminergic systems in the brain. Less attention has been focussed on the major excitatory 
neurotransmitter, glutamate, and its pathways which are now considered to be a therapeutic 
target for mood disorders. Disruption of the HPA-axis in psychiatric disorders has been 
researched extensively. In chapter 4 of this thesis, the role of the HPA-axis in AUD was 
investigated and discussed. In the current chapter, the glutamatergic and the HPA-axis 
pathways are examined in BD-AUD comorbidity.   
5.1.1 The Glutamate Pathway 
It is known that excitatory amino acids, acting as neurotransmitters, are responsible for most 
of the synapses in the CNS [Monaghan et al., 1989]. An estimated 75% of all excitatory 
neurotransmission in the brain is due to the amino acid, glutamate [Ganong, 1995]. Glutamate 




normal neuronal functioning; the regulation of this neurotransmitter is tightly controlled 
[Sanacora et al., 2008]. Glutamate is synthesised in the presynaptic neuronal terminal from 
glucose and glutamine, via the enzyme, glutaminase. Thereafter it is packaged, at a high 
concentration into synaptic vesicles, by vesicular glutamate transporters. Glutamatergic 
neurotransmission is accomplished by the release of glutamate into the synaptic terminals and 
binding of this substrate to the receptors. Upon binding to the various receptors, excitation of 
the post-synaptic cell is elicited by the entry of positively charged cations into these cells, 
which in turn, convey the message to the appropriate target cells [Nakanishi, 1992; Gonzales 
and Jaworski, 1997; Belsham, 2001] (Figure 21). 
There are two types of glutamatergic receptors found on neuronal and glial cells: the 
ionotropic (gated ion channels) and metabotropic G-protein coupled receptors (mGluRs).  
The ionotropic receptors (responsible for the passage of calcium, sodium and potassium ions) 
are further subdivided into the α-amino-3-hydroxy-5-methyl-ioxyzole-4-propionic acid 
(AMPA), kainate receptors and the voltage-dependent N-methyl-D-aspartate (NMDA) 
receptors, so named due to the compounds which bind to these receptors [Nakanishi, 1992; 
Tsai and Coyle, 2002]. The metabotropic receptors consist of eight subtypes which are sub-
classified into three groups (Group I, II and III) based on the amino acid sequence of the 
receptor protein and signal transduction mechanism [Pin and Duvoisin, 1995; Conn and Pin, 
1997].  Group I receptors (mGluR1 and mGluR5) stimulate phospholipase C and 
phosphoinositide (PI) hydrolysis and activate protein kinase C (PKC), Group II receptors 
(mGluR2 and mGluR3) are responsible for inhibiting the generation of cyclic AMP, and 
Group III (mGluR4, mGluR6, mGluR7, and mGluR8) inhibit adenyl cyclase (AC) [Pin and 
Duvoisin, 1995; Conn and Pin, 1997].  
Glutamate is reported to have essential roles in neural plasticity, learning and memory 
[Hollmann and Heinemann, 1994]. In particular, the ionotropic receptors allow the entry of 
calcium into the cell; thereafter the activation of intracellular signalling pathways and the 
appropriate gene expression, result in LTP [Bliss and Collingridge, 1993; Ménard and 
Quirion, 2012]. LTP is a process of long lasting signal transduction whereby there is a high 
frequency stimulation of excitatory neurotransmission within the hippocampus and other 
regions in the brain [Bliss and Collingridge, 1993].  LTP is thought to underlie learning and 




Glutamatergic signalling has multiple downstream physiological effects and has increasingly 
been implicated in the pathophysiology of mental disorders [Belsham, 2001]. For example, 
glutamate receptor and transporter expression has been reported to be dysregulated in SCZ 
and MDD [McCullumsmith and Meador-Woodruff, 2002; Gupta et al., 2005; Beneyto et al., 
2007]. Also, it has been suggested that the glutamate pathway is a viable target for 
psychiatric therapeutics [Krystal et al., 2002; Javitt, 2004]. These studies emphasise the 
important role that glutamate signalling has in psychiatric disorders, thereby highlighting the 
need for further investigation of this pathway. 
 
 
Figure 21: Glutamatergic neurotransmission in the normal state (adapted from [Clapp et al., 2008]). Glutamate is 
released from the presynaptic neuron where it binds to ionotropic (NMDAR, AMPAR, and Kainate receptors) and 
metabotropic receptors (mGlur) on the postsynaptic neuron. The appropriate responses are then initiated. 
 
5.1.1.1 The Glutamate Pathway in BD  
Several lines of evidence point to glutamatergic neurotransmission being disrupted in patients 
with BD suggesting that glutamate plays an important role in the aetiology of this disorder 
[McCullumsmith and Meador-Woodruff, 2002; Hashimoto et al., 2007; McCullumsmith et 
al., 2007]. Post-mortem studies have found increased glutamate levels in the frontal cortex of 
individuals with BD [Hashimoto et al., 2007]. Also, the NMDA-signalling complex has been 




expression of glutamate transporters have been shown in the striatum of individuals with BD 
[McCullumsmith and Meador-Woodruff, 2002].  
Numerous studies have investigated the genetic basis of BD with a focus on glutamatergic 
genes. CNV in the glutamatergic genes mGluR7, calcium channel, voltage-dependent, 
gamma subunit 2 (CACNG2) and A kinase anchor protein 5 (AKAP5) have shown these to be 
prevalent in post-mortem brains of BD patients, compared to controls [Wilson et al., 2006]. 
Variation (SNPs and CNVs) within the ionotropic and metabotropic glutamate receptor 
genes, N-methyl-D-aspartate subunit 1 (GRIN1) [Mundo et al., 2003], GRIN2A [Itokawa et 
al., 2003], GRIN2B [Martucci et al., 2006; Dalvie et al., 2010], glutamate receptor, 
metabotropic 3 (GRM3/mGluR3) [Kandaswamy et al., 2013], glutamate receptor, 
metabotropic 7 (GRM7/mGluR7) [Kandaswamy et al., 2014], and GRIK4 [Pickard et al., 
2006; Pickard et al., 2008] have shown an association with BD and BD phenotype severity. A 
recent GWAS study found that glutamate receptor signalling was one of the most enriched 
pathways in BD [Xu et al., 2014]. Similarly, a recent BD GWAS meta-analysis identified the 
glutamatergic pathway as one of the most significantly overrepresented pathways associated 
with BD [Nurnberger et al., 2014].  
It has also been shown that several BD treatments affect glutamate signalling [de Bartolomeis 
et al., 2014]. A study involving rats showed that treatment with anti-depressants increased the 
expression of the AMPA receptors whereas anti-manic treatments greatly decreased the 
expression of these receptors in the hippocampus [Du et al., 2007]. Another study examining 
the effect of lithium, (which is a mood-stabilising treatment for BD) on glutamate signalling, 
found that administration of the drug reduced the phosphorylation of the GRIN2B receptor 
subunit, suggesting that this drug may play a role in the inactivation of NMDA receptors 
[Hashimoto et al., 2002]. Also, the drug riluzole (sometimes used as an anti-depressant) 
increases the glutamine/glutamate ratio in the anterior cingulate cortex of individuals with 
BD, suggesting that this drug increases synaptic glutamate signalling [Brennan et al., 2010].  
These studies illustrate that certain BD treatment strategies affect glutamatergic signalling, 
suggesting a possible role of glutamate in the aetiology of BD.  
5.1.1.2 The Glutamate Pathway in AUD 
The consumption of alcohol appears to have an effect on the glutamatergic pathway. In this 
regard, the glutamate-signalling pathway has been implicated in a study investigating an 




After acute alcohol withdrawal, an increase in glutamate neurotransmission and a rise in 
oxidative stress are observed, which may explain the symptoms of neurotoxicity observed in 
alcohol-dependent individuals after withdrawal [Tsai et al., 1998].  
As previously mentioned (in Chapter 3), alcohol inhibits glutamate signalling, particularly by 
preventing the flow of ions through the NMDA receptors [Hoffman et al., 1989; Lovinger et 
al., 1989] (Figure 22). This inhibition has also been shown for the AMPA and kainate 
receptors although the effects seem to differ amongst the three ionotropic subtypes 
[Valenzuela et al., 1998; Carta et al., 2003]. After long-term alcohol exposure, as 
compensation for the inhibition of the NMDA receptors, up-regulation of NMDA receptor 
subunits is observed in the hippocampus and cerebral cortex of rats [Kalluri et al., 1998]. 
Likewise, the expression of the glutamate AMPA receptor subtypes GluR2 and GluR3 
(products of the genes glutamate receptor, ionotropic, AMPA 2 (GRIA2) and glutamate 
receptor, ionotropic, AMPA 3 (GRIA3), respectively) were significantly increased in the post-
mortem hippocampi of individuals who abused alcohol [Breese et al., 1995]. It has also been 
shown that disruption of NMDA receptor function alters the subjective response to alcohol 
which may increase the odds of becoming an alcoholic [Petrakis et al., 2004]. There is not 
much information regarding the effect of alcohol on the metabotropic glutamate receptors. 
However, animal studies have shown that microinjection of the mGlur5 antagonist resulted in 
decreased alcohol self-administration, suggesting that the metabotropic receptors may play a 
role in the regulation of alcohol intake [Schroeder et al., 2005; Hodge et al., 2006; Besheer et 
al., 2010].  
As with genetic studies conducted on BD, associations between glutamatergic variants and 
alcohol use have been reported. Variants in the gene GRIN2A, which encodes a subunit of an 
NMDA receptor, has been associated with AD, positive family history, an earlier age of 
onset, risky drinking patterns in adolescents and maximum number of drinks for adults 
[Schumann et al., 2008; Domart et al., 2012]. The GRIN1 and GRIN2B genes have also been 
associated with AD in European and Korean population groups [Wernicke et al., 2003; Kim 
et al., 2006]. In addition to the ionotropic receptors, variation within the metabotropic 
glutamate receptor gene, GRM8, has shown an association with AD [Chen et al., 2009]. The 
results of these findings suggest that alterations in glutamatergic neurotransmission may be 






Figure 22: Glutamatergic neurotransmission after alcohol use (adapted from [Clapp et al., 2008]). The inotropic 
receptors are inhibited after alcohol binds (purple circles). This results in the disruption of cation flow into the post-synaptic 
cell. 
5.1.2 The HPA-Axis in BD  
In chapter 4, the role of the HPA-axis in AUD was examined. In the current chapter the HPA-
axis is explored in terms of BD-AUD comorbidity.  
Glucocorticoids, which are used as treatment for several ailments, produce a range of 
neuropsychiatric side-effects [Dubovsky et al., 2012]. This suggests a link between the HPA-
axis and mental illness. Indeed, dysfunction of the HPA has been shown to be associated with 
BD, whereby individuals with BD had an elevated cortisol response to the 
dexamethasone/CRH test [Watson et al., 2004]. As mentioned in Chapter 4, there is a close 
relationship between the HPA-axis and the circadian pathway. One of the core features of BD 
is a disrupted circadian rhythm whereby sleep wake-cycles have an effect on the development 
of a manic or depressive episode [Leibenluft et al., 1996; Perlman et al., 2006].  
There are various hypotheses as to how disruption in the HPA-axis may result in mood 
disorders. One of those hypotheses is that there is hypersensitivity of the HPA-axis as a result 
of over-secretion of CRH in individuals with mood disorders [Watson and Mackin, 2006]. 
This was shown in a study where elevated levels of CRH were observed in the CSF of 
patients with depression [Nemeroff et al., 1984]. Another hypothesis is that the 
hypersensitivity of the HPA-axis and over-secretion of CRH may occur as a result of 




involving mice with dysregulated forebrain GR function noted hypersensitivity of the HPA-
axis and symptoms similar to that shown in humans with MDD [Boyle et al., 2005]. Other 
lines of evidence showing a relationship between HPA-axis and BD exist, for example, hair 
cortisol levels were associated with a more severe BD phenotype characterised by an earlier 
age of onset and psychiatric comorbidity [Manenschijn et al., 2012]. A study has shown that 
polymorphisms within the HPA-axis gene, CRHR1, have an association with psychotic 
dimensions in BD [Leszczyńska-Rodziewicz et al., 2013a]. From a BD GWAS meta-
analysis, the CRH pathway has been identified to be the most significantly overrepresented 
pathway in BD [Nurnberger et al., 2014]. The results of these studies strongly suggest a 
relationship between the HPA-axis and BD. However, the direction of the relationship is still 
unknown i.e. is disruption of the HPA-axis causative of BD or is the axis disrupted as a result 
of BD.  
5.1.3 Interactions Between Glutamate Pathway and HPA-Axis 
The glutamatergic and HPA-axis pathways do not function completely in isolation, but rather, 
have been shown to have an interacting role with each other via the CRH neurons in the PVN 
[Herman et al., 2004]. In particular, it has been shown that glutamate regulates the HPA-axis 
by increasing the secretion of ACTH and corticosterone serum levels [Feldman and 
Weidenfeld, 1997]. In rats, CRH neurons in the PVN have been shown to express the 
glutamate ionotropic receptor subunits providing further evidence that glutamate has an effect 
on the HPA-axis [Aubry et al., 1996]. Furthermore, mGLuR7 KO mice have increased levels 
of GRs in the brain, reflecting dysregulation of the stress response system [Mitsukawa et al., 
2006].  
5.1.4 BD-AUD Comorbidity 
As stated before, BD and AUD are often found to be comorbid [Hsieh et al., 2012; Schoepf 
and Heun, 2014], however, the nature of the relationship between these two disorders is not 
well understood. Approximately 70% of patients with BD abuse alcohol. The presence of 
alcohol use in BD has a negative effect on the course of the disorder and results in poorer 
cognitive abilities compared to patients with BD-only and controls [van Gorp et al., 1998]. 
An MRI study found that BD patients with AUD comorbidity had lower glutamate 
concentrations in their left DLPFC compared to non-alcoholic BD individuals, suggesting 
that BD-AUD comorbidity could be as a result of neurochemical imbalance in the 
glutamatergic pathway [Nery et al., 2010]. Similarly, a study involving MMN (mismatch 




dysregulation in BD could be modulated by the effects of alcohol [Chitty et al., 2014]. A 
specific SNP (rs148754219) within the glutamate receptor gene GRM3 is thought to increase 
the risk of developing BD and AUD [Kandaswamy et al., 2013; O'Brien et al., 2014]. There 
has not been much research in terms of disruption in the HPA-axis and BD-AUD 
comorbidity. However, as the HPA-axis and the glutamate pathways have been implicated in 
both AUD and BD, it is plausible that these biological systems may play a role in the 
comorbid phenotype.  
5.1.5 Aims and Objectives  
The aim of this investigation was to determine whether genetic variants in the glutamatergic 
pathway and HPA-axis are associated with BD-AUD comorbidity. Also, to determine 
whether there is an association between the glutamatergic and HPA-axis variants and BD. 
5.1.5.1 Objectives  
The objectives of this investigation were as follows: 
1) Using publically available genotype data, determine whether there is a significant 
difference in the genotype distributions for the selected SNPs, in a group of 
individuals with BD-AUD comorbidity and BD only. 
2) Determine whether there is a difference in the genotype distributions for the selected 
SNPs in the BD-only and control groups. 
 
5.2 Materials and Methods 
5.2.1 Overview of STEP-BD 
For the current study, the Systematic Treatment Enhancement Program for Bipolar Disorder 
(STEP-BD) cohort was used to investigate the hypothesis that BD comorbid with an AUD 
has a distinct genetic aetiology from BD on its own. The STEP-BD cohort is a long-term 
health study, which recruited 4360 participants, and is the largest government-funded project 
for BD treatment in the USA. The aim of this project was to determine which medications 
and combinations thereof resulted in the best treatment for manic and depressive episodes 
and which of these might have prevented the recurrence of these episodes. This project was 
different to classical clinical trials in that participants were offered long term care and 
treatment. All study participants had a diagnosis for BDI, BDII, BDNOS and cyclothymia 




psychiatrists using the DSM-IV based MINI-International Neuropsychiatric Interview (MINI) 
[Lecrubier et al., 1997] and a standardised affective disorder evaluation (ADE), respectively.  
Subjects had to have a consensus diagnosis from both instruments to be enrolled in the study.  
Individuals with a comorbid psychiatric diagnosis were also included in the study [Sachs et 
al., 2003].   
Of the 4360 STEP-BD participants, 2089 individuals over the age of 18 years consented for 
DNA collection. Of this group, 62% had a BDI diagnosis and were of Caucasian ethnicity. A 
subset of these individuals was genotyped by [Sklar et al., 2008] using the Affymetrix 
GeneChip Human 500K Mapping Array set at the Center for Genotyping and Analysis at the 
Broad Institute (Massachusetts Institute of Technology, Boston, USA). Individual samples 
were excluded based on the following criteria: i) had a genotyping call rate of less than 95%, 
ii) had increased heterozygosity or homozygosity, iii) after IBS calculations and clustering 
were found to be sample duplications, close relatives or non-Caucasian. Markers were 
excluded based on the following criteria: i) a call rate of less than 95%, ii) MAF of less than 
1%, iii) not in HWE in control samples (p <1x10-6), iv) difference in missing genotype rates 
in case and control samples, v) genotyping failure based on haplotype tests, and vi) SNPs on 
plates with remarkable differences in allele frequencies with SNPs on other plates [Sklar et 
al., 2008].  The total sample for the [Sklar et al., 2008] study consisted of 955 BDI 
individuals and 1498 controls, of Caucasian ethnicity, genotyped for 372 193 SNPs. Of this 
group 1218 were males and 1235 were females [Sklar et al., 2008].  
5.2.2 Candidate Gene and Variant Selection 
The aim of this study was to examine whether genetic variants within the glutamatergic 
pathways and HPA-axis pathways have an association with BD-AUD comorbidity. 
Therefore, 58 glutamatergic genes (and the respective variants) were selected based on those 
identified in a previous publication [Drago et al., 2011]. Of these glutamate pathway genes, 
21 encoded receptors or receptor-subunits, one encoded a receptor-associated protein, one a 
ribonuclease, 12 were AKAP genes, one encoded a DNA-binding protein, one a glutamate 
transporter gene, two encoded metabolic enzymes, and 19 encoded protein kinases.   
The following 11 HPA-axis genes were selected for analysis: POMC, UCN2, UCN3, CRHR1, 
CRHR2, FK506 binding protein 5 (FKBP5), nuclear receptor subfamily 3, group C, member 
1 (NR3C1), nuclear receptor subfamily 3, group C, member 2 (NR3C2), corticotropin 




peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 (SERPINA6). 
These genes were chosen based on a search done in PharmGkB [Whirl‐Carrillo et al., 2012] 
for the term ―HPA‖ (date accessed: 13 March 2013) and from the literature [Holliday et al., 
2010; Muráni et al., 2010; Schatzberg et al., 2013]. A list of variants (regulatory, intronic and 
exonic regions) for all of the above-mentioned HPA-axis genes was obtained from NCBI 
dbSNP [http://www.ncbi.nlm.nih.gov/SNP/] (date accessed: 13 March 2013).  
5.2.3 Research Group 
Phenotype and clinical information on the STEP-BD 16.01 group (Bipolar Disorder Data 
Distribution 7.0) was obtained from the National Institute of Mental Health (NIMH) Center 
for Collaborative Genomic Studies on Mental Disorders [https://www.nimhgenetics.org/]. A 
total of 498 individuals with BDI with data on current AUD (n= 233) comorbidity was 
selected. The main outcome variable, current AUD, was derived by combining data from 
current AD and current AA from the MINI questionnaire. The final list of variants analysed 
in this study consisted of the glutamatergic and HPA-axis variants which were genotyped in 
the GWAS study conducted by Sklar et al. (2008) on the STEP-BD 16.01 cohort. Genotype 
data from the STEP-BD 16.01 dataset was obtained from the above-mentioned NIMH 
website. All of the variants had a call rate of greater than 95% and a MAF of greater than 1% 
[Sklar et al., 2008].  For the current study, a total of 1935 SNPs comprising 69 genes were 
investigated. A list of all the genes and variants analysed are available in Appendix 4 (Genes 
and SNPs).  
Chi-squared and Mann-Whitney U tests were used to determine whether there were any 
significant differences between the two groups (BD and BD-AUD) for each of the clinical 
(age of onset, number of previous depressive and manic episodes) and demographic (age and 
gender) variables. This was performed using the statistical program SPSS [IBM, 2012].  
5.2.4 Power Calculation 
A power calculation was performed using G* Power 3.1.3 software [Faul et al., 2007] for 233 
cases and 265 controls.  Setting alpha level at 0.00003 (Bonferroni corrected p-value for 1935 
SNPs), the present study shows a power of 0.80 to detect genetic effects with an OR of 3.6 
(logistic regression model, binomial distribution).  
5.2.5 IBS Clustering 
To account for possible population stratification, IBS clustering was employed in Plink 




entire [Sklar et al., 2008] dataset (955 cases, 1498 controls, and 372193 SNPs). Clustering 
constraints included a pairwise population concordance of 0.0001 which is a significance test 
to determine whether two individuals are from the same randomly-mating population group. 
The cluster output was used as a covariate in the association analysis.  
5.2.6 Association Testing: SNP-Based and Gene-Based 
To test for association between each of the SNPs and current AUD, logistic regression was 
used in Plink (version 1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 
2007]. The covariates, age, gender and cluster were included in the analysis. The Bonferroni 
correction [Dunn, 1961] was used to adjust for multiple testing. As a secondary analysis, the 
same markers (with covariates) were tested in the larger cohort (955 cases and 1498 
controls), to determine whether these 1935 SNPs were associated with BD.  
Gene-based tests, as described in Chapter 3, consisting of 54 genes (genes with genotypic 
data for more than 2 SNPs), were used to test for association with BD-AUD comorbidity. 
Logistic regression was used, a total of 20 000 permutations were run and age, gender and 
cluster assignment were included as covariates. This test was also run using Plink (version 
1.07) [http://pngu.mgh.harvard.edu/~purcell/plink/] [Purcell et al., 2007]. The gene-based test 
was also run for the total BD cohort to determine whether any of the genes of interest are 
associated with BD. This test was run with the same parameters as that for the BD-AUD 
group.  
5.3 Results 
5.3.1 Research Group 
The final research group consisted of 233 individuals with BD-AUD comorbidity and 265 
individuals with BDI only. The number of individuals in each of the groups, together with 
clinical and demographic data, and results from the chi-squared and Mann-Whitney U tests 
are listed in Table 22. There was no difference for gender and age between the two groups 
(BD-AUD and BD-only). However, there were significant differences (p-value < 0.01) 
between the two groups for age at onset, number of previous depressive and manic episodes. 
The BD-AUD group had an earlier age of onset and more depressive and manic episodes 




5.3.2 IBS Clustering 
In total there were 24 clusters. The biggest cluster consisted of 235 individuals and the 
smallest, nine individuals. 
 













114:119 110:155 2.76 0.097 
Age 40.6±11.3 41.1±13.8 30798.5 0.963 
Age at onset 15.4±7.1 19.8±9.7 21131.0 < 0.01 
Number of previous depressive 
episodes 
5.4±1.8 4.7±2.2 24346.5 < 0.01 
Number of previous manic 
episodes 
5.2±2.0 4.3±2.2 23354.5 < 0.01 
 
5.3.3 Association Testing: SNP-Based and Gene-Based 
From the single-SNP association analysis, none of the investigated SNPs remained associated 
with BD-AUD comorbidity after correction for multiple testing. Table 23 lists the SNPs 
which obtained an unadjusted p-value of less than 0.01. The top SNP, rs2594491 (OR= 0.67, 
p-value = 0.002), is an intronic variant in the protein kinase C, epsilon (PRKCE) gene. 
Individuals with the C-allele of this SNP are at a decreased risk of having BD-AUD 
comorbidity. The other three variants are all intronic and are located within the glutamate 
receptors genes, GRIN2A and GRM8. Individuals with the T and C alleles for the GRIN2A 
rs3104704 and GRIN2A rs1875205 SNPs, respectively, are at a decreased risk for having 
AUD comorbidity with BD. For GRM8 rs2299556, a G-allele increases the risk for having 
AUD comorbidity. A total of 61 SNPs obtained an unadjusted p-value of less than 0.05 and 
are listed in Appendix 4 (Single-SNP Association (BD-AUD)). 
In the larger cohort no single-SNP obtained significance after correction for multiple testing. 
However, the top two SNPs (unadjusted p-value < 0.05) were (i) rs812389 (intronic) (OR= 




(intronic) (OR= 2.4, t-stat= 3.077, p-value = 0.002, allele= G) located in A kinase anchor 
protein 2 (AKAP2). Table 24 lists the SNPs which obtained an unadjusted p-value of less than 
0.01. A list of all the SNPs with an unadjusted p-value of less than 0.05 is listed in Appendix 
4 (Single-SNP Association (BD)). 
From the gene-based analysis, only one gene was significantly associated with BD-AUD. 
This gene was protein kinase C, iota (PRKCI) (p-value=0.028), significant for the SNP 
rs1392366 (a total of 5 PRKCI SNPs were included in the analysis). The gene GRIA2 was 
approaching significance with a p-value of 0.06 for the SNP rs17035959 (a total of 3 GRIA2 
SNPs were included in the analysis). The results from the gene-based analysis for all the 
genes investigated are presented in Appendix 4 (Gene-Based Results (BD-AUD)).  
In the larger BD cohort three genes obtained a p-value of less than 0.05 for the gene-based 
analysis. These genes were AKAP2 (p-value =0.0202) for the intronic SNPs rs10980210 and 
rs10816924 (40 SNPs were included in the analysis), POMC (p-value =0.0117) for the 
intronic SNP rs7565427 (4 SNPs were included in the analysis) and NR3C2 (p-value 
=0.0262) for the intronic SNP rs4027073 (51 SNPs were included in the analysis). All of 
these genes were in the top results from the single-SNP association (Table 24). The results 
from the gene-based analysis for all the genes investigated are presented in Appendix 4 
(Gene-Based Results (BD)). 
Table 23: Top SNPs (p-value < 0.01) from single SNP association for BD-AUD 











rs2594491 PRKCE 2 C -3.066 0.6677 0.0022 1 
rs3104704 GRIN2A 16 T -2.986 0.5604 0.0028 1 
rs1875205 GRIN2A 16 C -2.864 0.6155 0.0042 1 










Table 24: Top SNPs (p-value < 0.01) from single SNP association for BD 











rs812389 GRIA1 5 G 3.112 1.565 0.001858 1 
rs10980210 AKAP2 9 G 3.077 2.381 0.002093 1 
rs16909348 GRIN2B 12 A -3.003 0.3075 0.002672 1 
rs4027073 NR3C2 4 C 2.867 1.5 0.00414 1 
rs10816924 AKAP2 9 A 2.843 1.676 0.004462 1 
rs7565427 POMC 2 A -2.833 0.4937 0.004615 1 
rs10865208 PRKCE 2 G 2.742 1.45 0.006098 1 
rs2239340 PRKCB 16 A 2.738 1.501 0.006186 1 
rs16959593 PRKCA 17 T 2.716 1.823 0.006607 1 
rs9823996 GRM7 3 G 2.702 1.463 0.006895 1 
rs13142954 NR3C2 4 A 2.692 1.494 0.007092 1 
 
5.4 Discussion  
The aims of the previous chapters of this thesis were to determine the genetic basis of BD and 
AUD as separate diagnoses. In this chapter the aim was to determine whether BD comorbid 
with AUD was genetically distinct to BD without substance-use comorbidity, in terms of the 
glutamatergic and HPA-axis pathways. When analysing genes, PRKCI was found to be 
associated with BD-AUD comorbidity. After correction for multiple testing, no single SNP 
was associated with BD-AUD comorbidity or with BD. None of the selected HPA-axis genes 
were associated with the BD-AUD phenotype.  
From the gene-based analysis, PRKCI, located on chromosome 3q26.3 was shown to be 
associated with the BD-AUD phenotype. The SNP within this gene driving the association is 




neuronal cells [Tanaka and Nishizuka, 1994] and play an important role in cell signalling 
[Nishizuka, 1989]. PKC proteins regulate many intracellular processes and are activated by 
diacylglycerol as a result of the hydrolysis of inositol phospholipids. PKC proteins are 
thought to regulate the efficiency of synapses [Tanaka and Nishizuka, 1994] and to be 
involved in the pathophysiology of mood disorders [Hahn and Friedman, 1999]. These 
proteins are targets of lithium treatment [Manji and Lenox, 1999]. The PRKCI gene and the 
SNP rs1392366 have not previously been associated with AUD or BD-AUD comorbidity. 
However, another intronic SNP within PRKCI, rs2140825, has previously been associated 
with BD [Iwamoto et al., 2011]. Further investigation would be needed to verify whether this 
gene plays a role in determining whether a BD affected individual will go on to abuse and 
become dependent on alcohol.  
No single SNP was significantly associated with BD-AUD comorbidity. This is consistent 
with previous studies which have not found an association between BD, AUD and SNPs in 
the glutamatergic pathway or HPA axis [Feder et al., 1985; Martí et al., 2002; Dahl et al., 
2005; Tadic et al., 2005; Leszczyńska-Rodziewicz et al., 2013b]. Although no single SNP 
obtained a statistically significant association with BD-AUD comorbidity, it is worth 
discussing the genes which had SNPs with pre-corrected p-values approaching significance 
as these may have biological significance to the phenotype and could potentially be 
investigated in future studies. These genes were PRKCE, GRIN2A, and GRM8. PRKCE is 
also part of the PKC family of isozymes. Cytosolic levels of PRKCE have been shown to be 
reduced in the post-mortem brains of BD subjects [Wang and Friedman, 1996] as well as the 
brains of rats treated with lithium [Manji and Lenox, 1999]. In terms of AUD, the activity of 
PRKCE is inhibited by ethanol via an alcohol binding site present on the protein [Das et al., 
2009]. The GRIN2A gene located on chromosome 16p13.2 encodes a subunit of the 
glutamate ionotropic NMDA receptor. A variable number tandem repeat in the 5‘ region of 
this gene has previously been implicated in the aetiology of BD and AUD [Itokawa et al., 
2003; Domart et al., 2012]. Two other SNPs in GRIN2A, rs2072450 and rs9924016 showed 
an association with AD, positive family history, an earlier age of onset, risky drinking 
patterns in adolescents and maximum number of drinks for adults [Schumann et al., 2008]. 
GRM8 is located on chromosome 7q31 [Scherer et al., 1996] and encodes a metabotropic 
glutamate receptor. Variation within this gene has previously been associated with AD [Chen 




As a secondary analysis, the larger BD cohort was investigated in terms of the glutamatergic 
and HPA-axis SNPs to determine whether these SNPs were associated with the BD diagnosis. 
As with the BD-AUD group, none of the SNPs were significantly associated with BD after 
correction for multiple testing. However, SNPs in the genes GRIA1 and AKAP2 obtained p-
values less than 0.01 prior to correction for multiple testing. GRIA1 located on chromosome 
5q31.1 encodes an ionotropic glutamate receptor. This gene has previously been implicated in 
BD with psychosis, but this was for SNPs other than those reported in this study [Kerner et 
al., 2009]. Also, the GRIA1 SNP rs2926835 obtained genome-wide significance in a BD 
GWAS. AKAP2 located at chromosome 9q31.3 encodes an A-kinase anchoring protein 
which, as the name suggests, functions as an ―anchor‖ to protein kinase A (PKA), by binding 
to its regulatory subunit, thereby directing it to the appropriate location in the cell for PKA to 
fulfil its function [Colledge and Scott, 1999; Feliciello et al., 2001].  The AKAP2 gene was 
also significantly associated with BD from the gene-based analysis. AKAP2 has not been 
associated with BD before. Although GRIA1 and AKAP2 did not reach statistical significance 
they are still plausible candidates for BD and should be investigated in future studies.   
None of the HPA-axis SNPs obtained even a nominal association with BD-AUD. However, 
from the gene-based analysis for BD only, two genes from the HPA-axis pathway, POMC 
and NR3C2 were associated with BD. POMC, located on chromosome 2p23.3 encodes a 
hormone precursor protein, producing hormones such as ACTH [Chang et al., 1980; Whitfeld 
et al., 1982]. A recent proteomic study found increased levels of the POMC protein in the 
post-mortem pituitary glands of BD patients [Stelzhammer et al., 2015]. Also, the gene-
ontology category of ―hormone activity‖ was found to be over-represented in the significant 
hits from a BD GWAS meta-analysis, and this category included the gene POMC [Holmans 
et al., 2009]. NR3C2, located on chromosome 4q31.1, encodes a mineralocorticoid receptor 
(MR) which is involved in electrolyte homeostasis [Arriza et al., 1987]. The expression of 
this gene was significantly decreased in the anterior cingulate cortex and DLPFC of 
depressed patients [Qi et al., 2013]. SNPs within this gene have been moderately associated 
with BD [Ceulemans et al., 2011]. However, another study did not find an association 
between SNPs within NR3C2 and BD, but found that the GR gene, NR3C1, had an 
association with clinical characteristics of BD [Spijker et al., 2011]. Previous studies have 
found significant evidence for the role of the HPA-axis in BD and alcohol-use phenotypes 




not play a role in the aetiology of BD comorbid with AUD but rather that it may be 
associated with BD, with no comorbidity. 
One of the limitations of this study is the relatively small sample size. An odds ratio of 3.6 is 
required to detect a statistically significant association. For certain psychiatric disorders, 
including BD, it is hypothesised that the underlying aetiology is as a result of multiple 
variants of small effect [Purcell et al., 2009]. The same could be true for psychiatric comorbid 
phenotypes. Thus it is likely that a larger sample size may detect an association between the 
variants of interest and BD-AUD. Another limitation of this study was that the individuals 
under investigation could possibly have had other comorbidities, besides AUD, which they 
were not assessed for. This would have confounded the analysis and future studies should 
have a BD-AUD comorbid group free of other comorbid diagnoses. Also, only two pathways 
were investigated in this study and genotype data was not available for all of the genes 
present in either pathway and were therefore not included in this analysis. Variants not 
investigated in this study could play a role in the aetiology of BD-AUD. Therefore, the 
glutamatergic and HPA-axis pathways could still have a potential role in the aetiology of BD-
AUD. Also, there are several other pathways such as the serotonergic and circadian pathways 
which warrant exploration in terms of BD-AUD comorbidity as these have previously been 
found to have an association with AUD comorbid with BD and depression [Yasseen et al., 
2009; Sjoholm et al., 2010].  
The results from this study indicate that BD-AUD is not genetically distinct from BD in 
terms of the glutamatergic pathways and the HPA-axis. However, PRKCI appears to be an 
interesting candidate gene for follow-up studies for BD-AUD comorbidity. In addition, the 
genes GRIA1, AKAP2, POMC and NR3C2 should be further investigated in terms of BD. In 











Chapter 6: Conclusions  
6.1 Summary of Findings 
The aim of this thesis, in its entirety, was to identify the aetiology of the complex psychiatric 
disorders, BD and AUD, using bioinformatics, high-throughput genomic technologies, brain-
imaging and environmental measures. An additional aim was to assess the genetic aetiology 
of BD-AUD comorbidity. These aims were achieved firstly by performing WGS and whole-
genome linkage analysis in an Afrikaner family with BD. Secondly, the aetiology of AUD 
was investigated by integrating high-throughput genotyping data with brain imaging and 
environmental measures in two adolescent groups: a South African group and an international 
birth cohort. Thirdly, the genetic aetiology of BD-AUD comorbidity was assessed by 
investigating the glutamatergic pathway and HPA-axis using publically-available data on a 
well-established BD cohort. 
In conclusion, this study was unable to identify variants and genes which are highly likely to 
underlie BD and AUD, based on strong statistical evidence. Using the Bonferroni correction 
method to adjust for multiple testing, none of the genetic variants under examination were 
statistically significant. This may reflect, i) that there are no genuine statistical associations 
between the SNPs and phenotypes of interest, or ii) that there is some association and this 
disappears upon correction for multiple testing. The Bonferroni correction decreases Type I 
error (the probability of rejecting the null hypothesis, when it is true). This method is often 
used as it is relatively simple to calculate and can be applied to most multiple-testing 
scenarios [Bender and Lange, 2001]. However, the Bonferroni correction has often been 
criticized as being overly conservative and increases the chances of Type II error (the 
probability of rejecting the alternate hypothesis, when it is true) [Perneger, 1998]. In light of 
this, it is worth re-examining the uncorrected findings for each of the chapters of this thesis.  
The aims of Chapter 2 were to identify susceptibility variants for BD in a large Afrikaner 
family using whole-genome technology. Although no chromosomal regions obtained a 
significant LOD score, using the AxiomTM Genome-wide CEU 1 array plate, the four regions 
which obtained the highest LOD scores, i.e.: 6p25, 10p14-10p15.1, 11q23-11q25, and 13q21-
22 were further investigated. The interrogation of WGS data, while filtering for these four 
regions, identified variants and pathways which may play a role in the aetiology of BD. The 
TCR signalling pathway, which is involved in the immune response, was the most enriched 




identified in psychiatric disorders such as SCZ [Maes et al., 1995; Theodoropoulou et al., 
2001; Steiner et al., 2010]. The exact mechanism as to how a disruption of the immune 
system results in an altered mental state is still unknown, however it is thought to possibly 
occur via several pathways, including the HPA-axis and various neurotransmitter pathways 
[Dantzer et al., 2008]. 
The aims of Chapter 3 were to determine the complex biological interactions underlying 
adolescent AUD using genetic, brain imaging, and environmental data. From the analysis of 
the genetic data, no single SNP was found to be associated with adolescent AUD, after 
correction for multiple testing. However, the SNP with the lowest uncorrected p-value was 
located in the glutamate-receptor gene, GRIK4. Furthermore, the circadian rhythm genes 
NR1D1 and BHLHE41 were associated with AUD in a gene-based test. Childhood trauma 
was shown to be higher in adolescents with AUD compared to matched controls. No 
significant gene x environment interactions were found for lifetime alcohol units consumed. 
Uncorrected findings from the gene-imaging analysis identified a SNP in the glutamate 
receptor gene, GRIN2B, as being associated with brain volume in the left OFC and posterior 
cingulate. These findings indicate that the circadian and glutamatergic pathways may play a 
role in AUD and should be further investigated.  Both the circadian and glutamatergic 
pathways have previously been implicated in BD and suggest a common pathophysiology 
between AUD and BD may exist.  
The aim of Chapter 4 was to determine whether HPA-axis variants were associated with 
alcohol usage in adolescence and whether these variants interact with adverse childhood 
events. An additional aim was to determine whether childhood internalising behaviour was 
associated with alcohol use in adolescence. No single SNP was significantly associated with 
AUDIT scores; however the ―top‖ SNPs from this analysis were located in the genes UCN3 
and POMC. Additionally, from the gene-based analysis, UCN3 was associated with the 
AUDIT scores.  No significant gene x environment interaction was detected and the SDQ-
emotional subscale was not associated with AUDIT score. No association was found between 
life events score and AUDIT scores. None of the HPA-axis genes were associated with the 
SDQ-emotional subscale. These results suggest that the HPA-axis genetic variants may not 
interact with childhood life events to predict adolescent alcohol use. Also, it appears that 




In Chapter 5, the aim was to determine whether BD comorbid with AUD was genetically 
distinct to BD without substance-use comorbidity, in terms of the glutamatergic and HPA-
axis pathways. When analysing genes, PRKCI was found to be associated with BD-AUD 
comorbidity. After correction for multiple testing, no single SNP was associated with BD-
AUD comorbidity. Nonetheless, it is worth noting that the SNPs with the lowest p-values 
were located in the genes PRKCE, GRIN2A, and GRM8. None of the selected HPA-axis 
genes were associated with the BD-AUD phenotype. When examining BD on its own, the 
genes AKAP2, POMC and NR3C2 obtained uncorrected p-values of less than 0.05. 
6.2 Emerging Themes 
This study was able to detect pathways which may be common to BD and AUD. Firstly; 
immune dysfunction may be involved in the pathophysiology of BD. The immune system has 
previously been implicated in BD [Breunis et al., 2003; Ortiz‐Domínguez et al., 2007; 
Brietzke et al., 2009; Drexhage et al., 2011; Wieck et al., 2013; Barbosa et al., 2014]. The 
excessive consumption of alcohol has a negative effect on the immune system which could 
result in immunodeficiency and autoimmunity [Cook, 1998; Szabo and Mandrekar, 2009]. 
Post-mortem brains of individuals with AD showed an increase in expression of a pro-
inflammatory cytokine protein and an increase in microglial markers compared to control 
brains [He and Crews, 2008]. Similarly, another study found differential expression of 
immune-related genes in the post-mortem brains of individuals with AD [Ökvist et al., 2007]. 
Besides the effect of alcohol on the immune system, variants in the immune system genes 
have been shown to play a role in predisposing individuals to AUD. For example, variation 
within interleukin-related genes have been associated with AD [Pastor et al., 2000; Pastor et 
al., 2005; Saiz et al., 2009]. These studies suggest a role for the immune system in AUD and 
further studies are required to investigate the full extent of the association between this 
system and BD and AUD.  
Secondly, circadian dysfunction may underlie the pathophysiology of AUD. This is 
consistent with animal and human evidence that circadian disturbances may be relevant to 
AUDs [Chen et al., 2004; Hatonen et al., 2008]. Due to the observed sleep disturbances 
characterising the BD phenotype, the circadian rhythm has often been investigated in terms of 
BD [Leibenluft et al., 1996; Perlman et al., 2006; Harvey, 2008]. Several circadian rhythm 
genes have previously been associated with BD [Benedetti et al., 2003; Mansour et al., 2006; 
Nievergelt et al., 2006; Shi et al., 2008; Soria et al., 2010; Karthikeyan et al., 2014], BD 




al., 2008].  A post-mortem brain study conducted on individuals with BD found dysregulation 
of expression of circadian rhythm genes in those who abused alcohol [Gonzalez et al., 2014]. 
Therefore, disruption within the circadian rhythm may be a feature which is common to both 
BD and AUD. 
Thirdly, variation within the HPA-axis does not appear to have an effect on the development 
of AUD. However variation within the POMC gene may be involved in the aetiology of AUD 
and BD, separately, but not when these two disorders are comorbid. POMC has quite a close 
relationship with the immune system since immune cells (e.g. lymphocytes) have been shown 
to express POMC [Ottaviani et al., 1995]. POMC mRNA expression was significantly 
increased in inflamed epidermis tissue compared to normal tissue [Kono et al., 2001].  
Similarly, POMC also plays a role in the circadian rhythm [Dickmeis et al., 2007]. Disruption 
of the circadian rhythm of POMC expression in the hypothalamus of rats was observed after 
alcohol administration [Chen et al., 2004]. Thus POMC has an association with the immune 
system and circadian pathways, both of which may play role in the development of BD and 
AUD.     
It is likely that the aetiology of psychiatric phenotypes is as a result of multiple variants 
interacting with the environment [Uher, 2009; Uher, 2014]. Although in this study we were 
unable to detect significant gene x environment interactions for AUD, we were able to 
identify common pathways, possibly interacting with each other, for BD and AUD. The 
immune system has a tight bi-directional relationship with the HPA-axis [Silverman et al., 
2005; Dunn, 2007].  The HPA-axis has a close relationship with circadian rhythms [Dickmeis 
et al., 2007; Nader et al., 2010; Kalsbeek et al., 2012]. In turn, the immune system also has an 
interaction with the circadian pathways [Keller et al., 2009; Scheiermann et al., 2013; Nakao, 
2014]. Thus, it is possible that variants of small effect within these three pathways, which 
were statistically undetectable in this study, interact with each other to produce the complex 
phenotypes of BD and AUD.  
6.3 Future Considerations 
Based on the findings from this study, there are several possible considerations to be made 
for future research in the field of psychiatric genetics. The immune, circadian, and HPA-axis 
pathways should be investigated further in terms of BD and AUD, particularly in terms of 
possible epistatic relationships between variants in the genes constituting these pathways. In 




of the genes constituting these pathways could be obtained from the post-mortem brain tissue 
of individuals with BD and AUD. Another approach would be to investigate the expression 
profiles of microRNAs (miRNAs) which regulate the genes in the immune, circadian, and 
HPA-axis pathways in individuals with BD and AUD. A recent study has found dysregulated 
miRNA expression levels in individuals at a high genetic risk for BD [Walker et al., 2015].  
Further, in this study only SNPs were investigated. Previous studies have shown increased 
prevalence of CNVs in several psychiatric disorders including AD and BD [Lachman et al., 
2007; Zhang et al., 2008; Lin et al., 2012; Ye et al., 2012]. Future studies could investigate 
whether there are an increased number of large structural variants in the genes of the three 
pathways of interest (immune, circadian and HPA-axis) in individuals with BD and AUD. In 
addition to the genetic analysis of the immune, circadian, and HPA-axis pathways, the 
proteomic profiles of these pathways could be explored in individuals with BD and AUD.  
The use of longitudinal studies may aid in identifying environmental risk factors for the 
development of psychiatric disorders.  In the current study, the longitudinal ALSPAC birth 
cohort was investigated. No association was found between adverse childhood events 
collected at a particular time point and adolescent AUD. Also, no significant gene x 
environment interactions were detected for AUD. Future studies should assess traumatic 
events throughout childhood and determine if these environmental factors interact with 
variants in the immune and circadian pathways to predict risk for the development of AUD in 
adolescence and adulthood.  
In this study, statistically significant signals were not detected. Therefore, future studies 
should have larger sample sizes to have adequate power to detect association between genetic 
variation and psychiatric phenotypes. Previous studies conducted on large sample numbers 
(for example 36,989 cases and 113,075 controls) have had success in identifying possible 
causal variants for SCZ [Ripke et al., 2013; Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014].   
As described above, disruption in the immune system has also been associated with AUD. 
The consumption of alcohol affects the immune system [Cook, 1998; Szabo and Mandrekar, 
2009] and genetic variants in immune-related genes may predispose individuals to develop 
AUD [Pastor et al., 2000; Pastor et al., 2005; Saiz et al., 2009], thereby suggesting a bi-
directional relationship between alcohol use and the immune system [Robinson et al., 2014]. 




members of Family 30. It would be interesting to determine whether any members of this 
family had an AUD and whether the immune system would be implicated in this psychiatric 
phenotype. These family members should also be investigated to determine possible 
endophenotypes for BD and if present in this family, AUD. 
Another possible direction for future studies would be to investigate clinical subgroups of BD 
in a case-only manner. In this regard, a previous GWAS found different groups of genes 
associated with two different subtypes of mania: elated and irritable [Greenwood et al., 
2013]. Other studies have found significant associations by stratifying affected individuals by 
symptom dimensions [Labbe et al., 2012; Meier et al., 2012]. 
In the current investigation and in previous studies, NGS technology has been used to 
determine the aetiology of BD and other psychiatric disorders such as SCZ. To date, only one 
WES study has been conducted for an AUD phenotype [Zuo et al., 2013a]. This study found 
that the most promising candidate genes for AD were low density lipoprotein receptor-
related protein 8, apolipoprotein e receptor (APOER2) and ubiquitin associated protein 2 
(UBAP2) [Zuo et al., 2013a]. New genomic technologies, such as WGS and WES may hold 
the key to determining the complex genetic architecture underlying AUD and should be 
pursued further. 
One of the key challenges of studying psychiatric disorders is the absence of an accurate cell 
model. To help overcome this problem, researchers have obtained patient-derived induced 
pluripotent stem cells (iPSCs) to determine in vitro, the mechanism underlying psychiatric 
disorders such as SCZ [Yoon et al., 2014]. A recent study was able to reprogram BD patients‘ 
fibroblast cells to neuronal cells in order to determine the transcriptional profile of these 
individuals compared to controls [Chen et al., 2014]. Thus, this approach appears to be an 
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A1.1 Family Tree (A subset of Family 30). Individuals with numerical identifiers were genotyped and/or sequenced 
 
Figure A1.1: Two branches of family 30. Individuals with numerical identifiers were genotyped and/or sequenced. BDI: bipolar disorder type I, BDNOS: bipolar disorder 




A1.2 Example of Patient Consent Form 
 
 
REQUEST FOR MOLECULAR STUDIES (DNA) 
 
Molecular Laboratory  
Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
IIDMM, LEVEL 3 (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 406 6826 Keep blood in fridge at 4°C until able to send to 
laboratory 
  
 Please DO NOT send specimens on ice or 
frozen. 




New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
 
Number  of children: ______________________________________ 
 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
 




 Duchenne Muscular 
Dys  
 Colonic Carcinoma   
Fragile-X 
Syndrome  









Additional disorders (apparent or previously treated):  ______________________________________________________________ 
 




Physical disability           Mental retardation             Deafness             Impaired vision            Night blindness       
 
Other:  _________________________________________________________________________________________________ 
 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________  Vol.Blood: ________________(ml)     Other: _________________ 
 









I, ____________________________________________________________________  , request that 
an attempt be made using genetic material to assess the probability that:  I /  my child  /  my  unborn 





2. I understand that the genetic material for analysis is to be obtained from:  blood cells/skin 
sample/other (specify) (DELETE WHERE NOT APPLICABLE) :     
  
3. I request that no portion of the sample be stored for later use.   (MARK IF APPLICABLE ) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT 
APPLICABLE): 
 ( a )  possible re-analysis 
 ( b )  analysis for the benefit of members of my immediate family 
 ( c )  research purposes,  subject to the approval of the University of Cape Town Research 
Ethics 
         Committee, provided that any information from such research will remain 
confidential. 
  
4. The results of the analysis carried out on this sample of stored biological material will be made 
known to me,  
via my doctor, in accordance with the relevant protocol,  if and when  available.  
In addition, I authorise that they may be made known to:  (DELETE WHERE NOT APPLICABLE) : 
 other doctors involved in my care 






5. I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide 
relevant clinical details to the Division of Human Genetics, UCT. 
  
6. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and storage of biological 
material and these have been explained to me.  
( b ) the analysis procedure is specific to the genetic condition mentioned above and cannot 
determine the complete genetic makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical confidentiality . 
( d ) genetic analysis may not be informative for some families or family members. 
( e ) even under the best conditions, current technology of this type is not perfect and could 
lead to incorrect results. 
( f ) where biological material is used for research purposes, there may be no direct benefit to 
me. 
  
7. I understand that I may withdraw my consent for any aspect of the above at any time without this 
affecting my future medical care. 
  
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I 
UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
  
    ____________________________    DATE:     
__________________                               
 
 








A1.3 DNA Isolation Protocol  
 Added 900 microlitres (µl) red blood cell lysis solution to microcentrifuge tube 
 Added 500µl whole blood and mixed by inverting 
 Incubated for one minute at room temperature 
 Centrifuged for 20 seconds at 13 000rpm to pellet white blood cells. Discarded 
supernatant 
 Added 300µl cell lysis solution and vortexed 
 Incubated at 37°C for ten minutes 
 Added 100µl protein precipitation solution and inverted 
 Centrifuged for one minute at 13 000rpm 
 Added supernatant to clean microcentrifuge tube with 300µl isopropanol 
 Mixed by inversion until DNA was visible as threads or clumps 
 Centrifuged for one minute at 13 000rpm 
 Discarded supernatant 
 Added 300µl 70% ethanol and inverted several times 
 Centrifuged for one minute 13 000rpm 
 Discarded supernatant 
 Rehydrated with 50µl DNA hydration solution 
 
A1.4 DNA Integrity Check  
For agarose gel electrophoresis, a volume containing 200ng of DNA together with loading 
buffer (Fermentas Life Sciences, Hanover, USA) was loaded onto a 1% agarose gel. To 
estimate integrity of DNA fragments, the first lane of the gel was loaded with a 100bp 
molecular weight marker (MWM) (Fermentas Life Sciences, Hanover, USA). To enable 
DNA visualization, 30ng of ethidium bromide (EtBr) (Sigma, England), a DNA intercalating 
agent, was added to the agarose prior to solidification. Gel electrophoresis was carried out in 
a gel tank with 1x Tris Borate EDTA (TBE) electrophoretic buffer, at 160V for 
approximately 30 minutes. Thereafter, it was placed in the Uvipro Gold transilluminator 
(UVITec, Cambridge, UK) for the illumination and image capture of the DNA fragments. 
 
 




A1.5 WGS Protocol 
WGS consists of three steps: library creation, clustering and sequencing, each of which are 
described below. 
1) Library Creation 
DNA shearing  
- Random DNA shearing on Covaris instrument 
- Switch on machine 1hr before use. Add distilled water to chamber (between 
10 and 15 left-hand side measure) 
- Require temperature to be between 3-4°C 
- Setting at P1 
- De-gas 
- Shearing: duration 40 seconds- should give fragments of 300bp 
Clean-up of fragmented DNA 
- Use Qiagen kit 
End repair (ER) 
- This step gets rid of 3‘ and 5‘ overhangs 
- Consists of: ER control, ER mix, resuspension buffer 
- Use 96-well plate 
- Add 10µl ER control added to each sample 
- Add all DNA sample (~50µl fragmented DNA) 
- Add 40µl ER mix 
- Place seal on plate 
- Place plate in thermal cycler at 30°C for 30 minutes 
Clean-up with AmPure XP beads 
- Shake beads 
- Add 160µl beads to sample 
- Mix well  
- Incubate at room temp for 15 mins 
- Incubate at room temp for 15 mins on magnetic plate (pulls beads to the 
bottom of well) 
- Discard supernatant without disturbing pellet (brown clump of beads) 
- Add 200µl 80% ethanol and incubate for 30 seconds at room temperature 
- Discard supernatant and add 200µl 80% ethanol 





- Add 17.5µl resuspension buffer, mix with pellet (mix well), make sure pellet 
is evenly dispersed and no pellet remains on the walls of the well 
- Incubate at room temperature for 2 minutes 
- Incubate at room temperature for 5 minutes on magnetic plate (or until liquid 
is clear) 
- Transfer 15µl supernatant to clean well 
Adenylate 3’ ends 
- Add 2.5µl A-tailing control 
- Add 12.5µl A-tailing mix 
- Incubate at 37°C on thermal cycler for 30 minutes 
Ligate Adapters 
- Add 2.5µl ligase control to each sample 
- Add 2.5µl ligase mix 
- Add 2.5µl adapter index (different adapter index for each sample) 
- Mix thoroughly 
- Incubate at 30°C for 10 minutes 
Clean-up with AmPure XP beads 
- Shake beads 
- Add 45µl beads to sample 
- Follow protocol as above 
- Transfer 20µl of supernatant to clean well 
Purify products on gel (Invitrogen e-gel) 
- Load 20µl DNA product into each well (x2 for each sample) 
- Load 10µl 50bp MWM 
- Load water into empty wells 
- Add 20µl water into second lane of wells after 400bp fragment reaches second 
lane 
- Collect (pipette from second lane wells) before 500bp fragment reaches 
second lane 
Clean-up with Qiagen kit 
PCR of products 
- Add 5µl PCR primer cocktail to wells in PCR plate 
- Add 25µl PCR master mix 
- Add all of the cleaned up product 




Clean-up PCR products with AmPure XP beads 
- Add 50µl AmPure beads 
- Step 12- take out entire volume. Do not remove any beads 
Check concentration of product: Nanodrop (concentration) and Agilent Analyser 
(size of fragments and molar conc.) 
Agilent analyser 
- Use DNA 1000 chip 
- add 9µl of gel dye mix (from 4°C fridge) in the well marked ―G‖ 
  - Place chip on priming station 
- Push down syringe until chip is locked into position (―pressurising‖ spreads 
gel into capillaries) 
- Add 9µl gel-dye mix into other G-wells 
- load 5µl marker (DNA 1000) into every other well not marked ―G‖ 
- load 1µl ladder into ladder well 
- load 1µl sample into other wells (not G-wells) 
- load 1µl water into empty wells 
- ensure that there are no air bubbles 
- vortex for 1 min 




- Thaw reagent plate and hybridisation buffer at room temp  
 
DNA dilution 
- Need to have a DNA conc. of 10nm 
- Therefore, dilute with elution buffer (EB) and Tween  
- End concentration of DNA= 10nM 
 
Denaturation 
- Starting [DNA]= 10nM 




- Add 2µl DNA template 
- Add 1µl 2N NaOH (always add last) 
- Vortex and centrifuge 
- Incubate at room temperature for 5 minutes 
- Place on ice 
- Final [DNA]= 1pmol/µl 
 
Serial Dilution 
- Add 4µl denatured sample to clean tube 
- Add 496µl hybridisation buffer 
- Vortex and centrifuge 
- Final [DNA]= 8 pmol 
- Add 125µl diluted sample to clean tube 
- Add 208µl hybridisation buffer 
- Vortex and centrifuge 
- Final [DNA]= 3pmol 
- Add 148.5µl diluted sample to 8 strip tubes 
- Add 1.5µl 8pmol phiX control (20µl 20pmol phiX and 30µl hybridisation 
buffer) 
- Put on strip cap, vortex and centrifuge 
 
At cluster station (cBot Illumina) 
- Wash reservoir (blot water/wash buffer) 
- Load reagents (remove red strip) 
- Scan barcode 
- Load flowcell (wash with water beforehand)- rainbow side-up 
- Put on manifold 
- Load template (without strip cap, NB note direction) 
- Do pre-check 
- Start clustering (runs for ~4 hours) 
-  
 
3) Sequencing (Illumina HiSeq 2000) 
 
- Thaw sequencing reagents at 4°C overnight (except dNTPs and polymerase) 
  
Wash instrument  
- Place water bottles in panel (A/B) 
- Change PE reagents to water (optional) 
- Wash ~1hr 
 
Sequencing 
- Place cleavage mix in water at room temperature 
- Add reagent bottles from TruSeq kit to corresponding colours of black rack 




- Add both tubes of long read FFN mix to incorporation mix 
- Add 1.1ml of polymerase to incorporation mix 
- Shake 
- Place cleavage mix in rack 
- Put on caps with holes 
- Add rack to sequencer 
- Prime X2 (only for version 3)  
- Once primed, remove old gaskets and flowcell 
- Wipe flowcell station with alcohol swab 
- Put in flowcell (wash with water, then alcohol swab, then dry with wipe) of 
interest and new gaskets 
- Engage vacuum 
- Wait for first base read (approx. 30 minutes- 1hr) 
 
Paired-end (PE) cluster generation (“turn-around chemistry”) 
- Use PE cluster kit 
- Thaw reagents 
- Prepare 0.1N NaOH (HP3) 
- Add 2.85ml of PW1 to 15ml conical tube 
- Add 150µl HP3 
- Use PE module rack (black, thin rack) 
- Add reagents to module- uncap 
- Scan lot no. of PE kit 
- Add module to PE rack 
- Pull lever down 
 
A1.6 FastQC Results 
 
















































A1.7 Enrichment Analysis Results 
Table A.1.7.1: ConsensusPathDB Results: Pathway Analysis 
Pathway name set size candidates contained p-value q-value 
pathway 
source 
TCR Signaling Pathway 92 6 (6.7%)  0.000448 0.148 Wikipathways 
Nectin/Necl trans heterodimerization 7  2 (28.6%) 0.00241 0.254 Reactome 
TCR signaling in naïve CD8+ T cells 58 4 (7.5%)  0.00265 0.254 PID 
Olfactory transduction - Homo sapiens 
(human) 408 11 (2.7%) 0.00463 0.254 KEGG 
IL12 signaling mediated by STAT4 33 3 (9.4%)  0.00504 0.254 PID 
Pre-NOTCH Expression and Processing 33 3 (9.4%)  0.00504 0.254 Reactome 
TCR signaling in naïve CD4+ T cells 72 4 (6.1%)  0.00585 0.254 PID 
Olfactory Signaling Pathway 426 11 (2.6%) 0.0065 0.254 Reactome 
Trehalose Degradation 12 2 (16.7%) 0.00731 0.254 SMPDB 
lck and fyn tyrosine kinases in initiation of 
tcr activation 14 2 (15.4%) 0.00858 0.254 BioCarta 
 
Table A1.7.2: ConsensusPathDB Results: GO Analysis 





GO:0032623   interleukin-2 production BP 4 54 5 (9.4%)  0.000228 0.0356 
GO:0032616   interleukin-13 production BP 4 13 3 (23.1%) 0.000299 0.0356 
GO:0007155   cell adhesion BP 2 1375 28 (2.1%) 0.00037 0.0299 
GO:0030424   axon CC 4 320 11 (3.5%) 0.000477 0.0229 
GO:0036477   somatodendritic compartment CC 3 562 15 (2.7%) 0.000676 0.0369 
GO:0000981   sequence-specific DNA binding 
RNA polymerase II transcription factor 
activity 
MF 3 512 14 (2.8%) 0.000789 0.0355 
GO:0097458   neuron part CC 2 980 21 (2.2%) 0.000963 0.0211 
GO:0031225   anchored component of 
membrane CC 2 150 7 (4.7%)  0.000995 0.0211 
GO:0042105   alpha-beta T cell receptor 
complex CC 4 5  2 (40.0%) 0.00107 0.0257 
GO:0098742   cell-cell adhesion via plasma-




GO:0098609   cell-cell adhesion BP 3 201 8 (4.0%)  0.00121 0.243 
GO:0043005   neuron projection CC 3 796 18 (2.3%) 0.00125 0.0369 
GO:0005886   plasma membrane CC 2 4776 67 (1.5%) 0.00155 0.0211 
GO:0071944   cell periphery CC 2 4870 68 (1.4%) 0.00162 0.0211 
GO:0042608   T cell receptor binding MF 4 7  2 (28.6%) 0.00221 0.126 
GO:0048731   system development BP 3 4093 59 (1.5%) 0.00224 0.243 
GO:0098602   single organism cell adhesion BP 2 721 16 (2.3%) 0.00298 0.0967 
GO:0043025   neuronal cell body CC 3 350 10 (2.9%) 0.00326 0.064 
GO:0006099   tricarboxylic acid cycle BP 3 29 3 (10.3%) 0.00338 0.243 
GO:0007275   multicellular organismal 
development BP 3 4621 64 (1.4%) 0.00379 0.243 
GO:0016337   single organismal cell-cell 
adhesion BP 4 679 15 (2.3%) 0.00411 0.253 
GO:0044707   single-multicellular organism 
process BP 2 6462 84 (1.3%) 0.00415 0.0967 
GO:0004984   olfactory receptor activity MF 4 425 11 (2.6%) 0.00485 0.138 
GO:0005911   cell-cell junction CC 2 370 10 (2.8%) 0.00485 0.0505 
GO:0008038   neuron recognition BP 4 34 3 (9.1%)  0.0049 0.253 
GO:0042107   cytokine metabolic process BP 4 110 5 (4.8%)  0.00496 0.253 
GO:0031224   intrinsic component of 
membrane CC 2 5571 73 (1.4%) 0.00615 0.0533 
GO:0045058   T cell selection BP 2 40 3 (8.1%)  0.00677 0.0967 
GO:0051606   detection of stimulus BP 2 712 15 (2.1%) 0.00689 0.0967 
GO:0008037   cell recognition BP 3 116 5 (4.4%)  0.007 0.358 
GO:0048856   anatomical structure 
development BP 2 4828 65 (1.4%) 0.00716 0.0967 
GO:0044297   cell body CC 2 399 10 (2.6%) 0.00806 0.0599 
GO:0060055   angiogenesis involved in 
wound healing BP 4 14 2 (14.3%) 0.00914 0.308 
GO:0042101   T cell receptor complex CC 4 14 2 (14.3%) 0.00914 0.146 
GO:0034109   homotypic cell-cell adhesion BP 4 476 11 (2.4%) 0.00919 0.308 
GO:0042110   T cell activation BP 4 412 10 (2.5%) 0.00922 0.308 
GO:0050907   detection of chemical stimulus 




Table A1.7.3: ConsensusPathDB Results: Protein complex Analysis 
complex name set size 
candidates 
contained p-value q-value 
complex 
source 
CD3 epsilon: CD3 gamma with phosphorylated 
ITAM 2  2 (100.0%) 0.000169 0.00339 Reactome 
TCR/CD3/MHC II/CD4/LCK/CBL/Ubiquitin 12 3 (27.3%) 0.000332 0.00339 PID 
TCR/CD3/MHC I/CD8/LCK/ZAP-
70/CBL/ubiquitin 14 3 (23.1%) 0.000564 0.00339 PID 
TCR/CD3/MHC II/CD4/LCK/ZAP-70/CBL/SLAP-
2/Ubiquitin 14 3 (23.1%) 0.000564 0.00339 PID 
HTR3:5HT 5  2 (40.0%) 0.00165 0.00792 Reactome 
Monovalent TCR/CD3 6  2 (33.3%) 0.00245 0.00982 PID 
MHC II/TCR-CD3 8  2 (25.0%) 0.0045 0.0122 BioCarta 
TCR-CD3/MHC II/CD4 9  2 (22.2%) 0.00574 0.0122 BioCarta 
TCR/CD3/MHC II/CD4 10 2 (22.2%) 0.00574 0.0122 PID 
CD3Z antigen zeta polypeptide/MHC class II 
alpha/CD4/LCK/CD3Z antigen zeta 
polypeptide/TCR-alpha/TCR-beta/CD3G antigen 
gamma polypeptide/CD3E antigen epsilon 
polypeptide/CD3E antigen epsilon 
polypeptide/CD3D antigen delta polypeptide/MHC 
IIb 
10 2 (20.0%) 0.00712 0.0122 BioCarta 
TCR/CD3/MHC I/CD8 11 2 (20.0%) 0.00712 0.0122 PID 
TCR/CD3/MHC II/CD4/LCK 11 2 (20.0%) 0.00712 0.0122 PID 
TCR/CD3/MHC II/CD4/Fyn 12 2 (20.0%) 0.00712 0.0122 PID 
TCR-CD3/MHC II/CD4/LCK/ZAP70 11 2 (18.2%) 0.00863 0.0122 BioCarta 
TCR/CD3/MHC I/CD8/LCK 12 2 (18.2%) 0.00863 0.0122 PID 
TCR/CD3/MHC II/CD4/LCK/ZAP-70 12 2 (18.2%) 0.00863 0.0122 PID 








A1.8 Novel Variants  
Chromos
ome position Allele 1 Allele 2 Gene 
10 10136103 G A N/A 
10 10179737 A AG N/A 
10 10200514 C CA N/A 
10 10296609 GT G N/A 
10 10456021 G C N/A 
10 10548263 G GTATC N/A 
10 10621683 C T N/A 
10 10646657 T TG N/A 
10 10650108 C CA N/A 
10 10960713 G T N/A 
10 11061555 CA C CELF2 
10 11237125 A AAT CELF2 
10 11264087 C CTG CELF2 
10 11278801 C T CELF2 
10 11296849 A ATCCCATCTCTCCCCTTCCTG CELF2 
10 11424854 A G N/A 
10 11428568 T C N/A 
10 11620617 A AT USP6NL 
10 11801381 A AC N/A 
10 12126317 TA T N/A 
10 12161027 T C DHTKD1 
10 12186107 T C SEC61A2 
10 6745418 A C N/A 
10 6763972 TAC T N/A 
10 6765464 A G N/A 
10 6856462 C CAAATT 
LINC0070
7 








10 6896099 GA G N/A 
10 6953742 C CTT 
RP11-
799O21.2 
10 6963347 T TTTTGTTTG 
RP11-
799O21.2 
10 7011013 C CAA N/A 
10 7057102 A ATTG N/A 
10 7136671 GTGCCA G N/A 
10 7143901 CTTG C N/A 
10 7159479 G GATTT N/A 
10 7425807 C T SFMBT2 
10 7468055 C CAG N/A 






10 7533074 A G N/A 
10 7561766 T A N/A 
10 7625453 A G ITIH5 
10 7631534 A G ITIH5 
10 7686459 AT A ITIH5 
10 7686493 GAT G ITIH5 
10 7686511 GAT G ITIH5 
10 7686876 CAT C ITIH5 
10 8154863 G GAC N/A 
10 8165301 C CT N/A 
10 8193066 TTA T N/A 
10 8229754 CT C N/A 
10 8423492 T A N/A 
10 8496602 A G 
RP11-
543F8.2 
10 8716466 GA G N/A 
10 8721113 T TTA N/A 
10 8746686 G GTTA N/A 
10 8812576 G GA N/A 
10 8931548 G GA N/A 
10 8932280 TTA T N/A 
10 8939670 T TA 
RP11-
428L9.1 
10 8948220 A AGATAT 
RP11-
428L9.1 
10 8971599 CA C N/A 
10 9002088 G GAA N/A 
10 9020005 T C N/A 
10 9027420 T TA N/A 
10 9109503 CTTCT C N/A 
10 9219127 TG T N/A 
10 9347135 GT G N/A 
10 9349704 CA C N/A 
10 9398543 AAAAAG A N/A 
10 9407739 G GTTC N/A 
10 9501148 C CTAAG N/A 
10 9518661 C CT N/A 
10 9641099 T TA N/A 
10 9642117 A AAATT N/A 
10 9658016 T C N/A 
10 9727305 TA T N/A 
10 9783562 CA C N/A 
10 9864575 T TTTTTC N/A 
10 9925608 A C N/A 
11 110920370 C CT N/A 




11 112125748 GC G C11orf34 
11 114420611 ATAAAAT A NXPE1 
11 114420618 AT A NXPE1 
11 114420624 AATC A NXPE1 
11 114422786 GT G NXPE1 
11 114506823 C CTT N/A 
11 114677167 GA G N/A 
11 115239741 A ATCT CADM1 
11 115322872 TGGTGGGGTGGGGG T CADM1 
11 116817836 TA T SIK3 
11 118292682 A AAG ATP5L 
11 119440683 TA T N/A 
11 120555425 CT C GRIK4 
11 121583989 
CAAACAAACAAACA
AACA C N/A 
11 122638014 T TTTTTGTTTTG UBASH3B 
11 125345171 T TACAC FEZ1 
11 125389250 
CGCTTGCATCCCCCA
GTGCTCAGCA C N/A 
11 125602506 TG T N/A 
11 125682372 C CT N/A 
11 125690149 C CA N/A 
11 125763566 TC T HYLS1 
11 125875199 
AAAAAAAAAAAAAA
ACAAACAAACAAAC A CDON 
11 126511290 T TA KIRREL3 
11 126524686 A AT 
RP11-
115C10.1 
11 126576836 C CT N/A 
11 130151678 ACGGGGTTTCGC A ZBTB44 
11 130168727 GAC G ZBTB44 
11 130180792 T C ZBTB44 
11 130499624 C T N/A 
11 130613172 C T N/A 
11 130746519 GT G SNX19 
11 131134998 T TATATATCTC 
AP002856.
5 
11 131527043 C CAA NTM 
11 131657248 G GATT NTM 
11 132505486 C CA OPCML 
11 132635994 TA T OPCML 
11 132714860 AT A OPCML 
11 132935913 C T OPCML 
11 133297113 A G OPCML 
11 133496502 A G N/A 
11 133517583 A T N/A 




13 55820910 GT G N/A 
13 56043847 A AAT N/A 
13 56134064 A AC N/A 
13 56469135 AAC A N/A 
13 57675873 T TA N/A 
13 57682228 G GA N/A 
13 57859067 CT C N/A 
13 57898337 CAT C N/A 
13 57929785 C CT N/A 
13 58557942 C CA N/A 
13 60084333 AT A N/A 
13 60157779 CAT C N/A 
13 61437085 G GT N/A 
13 61567690 A ACTTCTATCCAAACACCTTCT N/A 
13 61608564 AT A N/A 
13 61816277 TA T N/A 
13 62212434 G GT N/A 
13 62455649 CT C N/A 
13 62458899 TA T N/A 
13 62465242 A ATTAT N/A 
13 62491661 T TA N/A 
13 62506143 G GA N/A 
13 63262572 AAT A 
LINC0044
8 
13 63462506 TAA T N/A 
13 63602845 AG A N/A 
13 63603386 G 
GAAAACCACCATTTCACAATT
CCACTTGTA N/A 
13 63617372 GTCTGA G N/A 
13 63621303 CT C N/A 
13 63630283 T TTTG N/A 
13 63631658 AT A N/A 
13 63632180 TTA T N/A 
13 63633294 TTA T N/A 
13 63636191 T TA N/A 
13 63637865 A AT N/A 
13 63640749 CAAT C N/A 
13 63643708 TAC T N/A 
13 63643733 G GAC N/A 
13 63645763 CA C N/A 
13 63647632 AAAAT A N/A 
13 63647877 CT C N/A 
13 63949360 G GA N/A 
13 64855636 T TACAAGGAACTTAA N/A 






13 65406800 CTTTAAA C N/A 
13 66023171 GTA G N/A 
13 66038243 ACTGT A N/A 
13 66190671 ATG A N/A 
13 66770329 G GAT N/A 
13 68028753 A AC N/A 
13 68181900 GAT G N/A 
13 68182036 A AAT N/A 
13 70534839 TTGAG T KLHL1 
13 70542462 GATATATTTGC G KLHL1 
13 70734955 ATATATT A N/A 
13 71748804 AAAAT A N/A 
13 72072799 A AAG DACH1 
13 72309226 CAT C DACH1 
13 72767168 C CTG N/A 
13 73912075 
CATATGTGTGTGTGT
AT C N/A 
13 74383497 C CG KLF12 
13 75384338 A G N/A 
13 76011735 C CT TBC1D4 
13 76138056 C CTGTGTG UCHL3 
13 76512262 CAT C N/A 
13 77645372 G GTGTA MYCBP2 
13 78116534 CAACA C SCEL 
6 1512884 A AAAAG 
RP11-
157J24.1 
6 1531653 C CT N/A 
6 1653790 G T GMDS 
6 1793139 A G GMDS 
6 1940990 T C GMDS 
6 2016301 TA T GMDS 
6 258665 AT A N/A 
6 2781978 G A WRNIP1 
6 2878456 C G 
RP11-
420G6.4 
6 3321342 G GTCCAGGC SLC22A23 
6 3440941 AG A SLC22A23 
6 3627192 A T N/A 
6 3684277 C CTTGAA N/A 
6 380640 A G N/A 
6 3836105 T A 
RP11-
420L9.4 
6 438817 T A N/A 
6 5318630 AAAAC A FARS2 
6 5337300 CT C FARS2 




6 5432761 T TA FARS2 
6 5853542 A AAC 
RP3-
380B8.4 
6 6742716 A AG N/A 
6 780554 TA T 
RP11-
532F6.5 
6 904746 TTATC T 
RP5-
1077H22.2 
6 974400 T 
TGTGTGTGTATATATATATAT
ACCATG N/A 
6 982448 GT G N/A 
 
Appendix 2  
A2.1 Childhood Trauma Questionnaire  
Instructions: These questions ask about some of your experiences growing up as a child and a 
teenager. For each question, circle the number that best describes how you feel. 1 = Never True 2 = 
Rarely True 3 = Sometimes True 4 = Often True 5 = Very Often True. Although some of these 
questions are of a personal nature, please try to answer as honestly as you can. Your answers will be 
kept confidential. 
 
1. When I was growing up, I didn‘t have enough to eat. 1 2 3 4 5 
2. When I was growing up, I knew that there was someone to take care of me and protect 
me. 
1 2 3 4 5 
3. When I was growing up, people in my family called me things like ―stupid‖, ―lazy‖ or 
―ugly‖. 
1 2 3 4 5 
4. When I was growing up, my parents were too drunk or high to take care of the family. 1 2 3 4 5 
5. When I was growing up, there was some one in my family who helped me feel that I was 
important or special 
1 2 3 4 5 
6. When I was growing up, I had to wear dirty clothes. 1 2 3 4 5 
7. When I was growing up, I felt that I was loved. 1 2 3 4 5 
8. When I was growing up, I thought my parents wished I had never been born. 1 2 3 4 5 
9. When I was growing up, I got hit so hard by someone in my family that I had to see a 
doctor or go to the hospital. 
1 2 3 4 5 
10. When I was growing up, people in my family hit me so hard that it left bruises or marks. 1 2 3 4 5 





12. When I was growing up, there was nothing I wanted to change about my family. 1 2 3 4 5 
13. When I was growing up, people in my family looked out for each other. 1 2 3 4 5 
14. When I was growing up, people in my family said hurtful or insulting things to me. 1 2 3 4 5 
15. When I was growing up, I believe that I was physically abused. 1 2 3 4 5 
16. When I was growing up, I got hit or beaten so badly that it was noticed by someone like 
a teacher, neighbour or doctor. 
1 2 3 4 5 
17. When I was growing up, I felt that someone in my family hated me. 1 2 3 4 5 
18. When I was growing up, people in my family felt close to each other. 1 2 3 4 5 
19. When I was growing up, someone tried to touch me in a sexual way, or tried to make me 
touch them. 
1 2 3 4 5 
20. When I was growing up, someone threatened to hurt me or tell lies about me unless I did 
something sexual with them. 
1 2 3 4 5 
21. When I was growing up, I had the perfect childhood. 1 2 3 4 5 
22. When I was growing up, someone tried to make me do sexual things or watch sexual 
things. 
1 2 3 4 5 
23. When I was growing up, someone molested me. 1 2 3 4 5 
24. When I was growing up, I believe that I was emotionally abused. 1 2 3 4 5 
25. When I was growing up, there was someone to take me to the doctor if I needed it. 1 2 3 4 5 
26. When I was growing up, I had the best family in the world. 1 2 3 4 5 
27. When I was growing up, I believe that I was sexually abused. 1 2 3 4 5 








A2.2 Single SNP Association Results (uncorrected p-value less than 0.05) 
Chromosome SNP Minor allele Odds Ratio t-statistic p-value 
11 rs7105258 A 3.091 3.12 0.001807 
17 rs2071570 A 0.3624 -3.077 0.002093 
11 rs11030119 A 0.4038 -3.034 0.00241 
5 rs10515806 A 0.1805 -2.971 0.002964 
5 rs10515805 A 0.1805 -2.971 0.002964 
22 rs5993882 C 2.225 2.897 0.003767 
3 rs11925572 A 3.356 2.896 0.00378 
12 rs3809140 G 0.4546 -2.892 0.003828 
10 rs10509117 A 2.771 2.886 0.003906 
11 rs528833 A 0.3552 -2.857 0.004274 
5 rs752266 G 0.3441 -2.848 0.004398 
3 rs1503079 A 2.144 2.781 0.005422 
6 rs3025035 A 0.2992 -2.776 0.005498 
3 rs16823934 A 0.4083 -2.769 0.005624 
22 rs5993883 A 0.4762 -2.765 0.005689 
23 rs5906729 C 0.3862 -2.759 0.005802 
10 rs2420941 C 0.4699 -2.752 0.005921 
11 rs7105286 A 2.17 2.747 0.00601 
2 rs309180 A 2.316 2.742 0.006111 
11 rs4936556 A 2.535 2.739 0.006171 
1 rs2487453 G 0.4915 -2.717 0.006594 
5 rs1042713 A 2.185 2.701 0.006919 
23 rs4570308 A 0.4007 -2.7 0.006935 
23 rs1465108 G 0.4007 -2.7 0.006935 
4 rs10026568 A 0.4498 -2.696 0.007013 
22 rs1063311 A 2.091 2.683 0.007307 
3 rs2668196 T 2.162 2.679 0.007377 
22 rs174675 A 2.01 2.679 0.007381 
7 rs3793243 G 2.086 2.672 0.00754 
2 rs590557 A 2.29 2.652 0.008011 
2 rs12185692 A 2.63 2.647 0.008129 
5 rs12654778 A 2.313 2.641 0.008255 
8 rs4907376 T 2.746 2.625 0.008657 
11 rs2276310 A 2 2.616 0.008886 
11 rs11030108 A 0.4549 -2.59 0.009591 
8 rs17053612 A 1.892 2.589 0.009626 
5 rs6888306 A 0.5173 -2.589 0.009635 




11 rs11030121 A 0.5019 -2.576 0.01001 
22 rs933271 G 1.941 2.575 0.01003 
5 rs393795 A 0.4628 -2.565 0.01031 
11 rs2030324 G 1.983 2.565 0.01032 
11 rs10835215 A 1.983 2.565 0.01032 
13 rs1536375 G 0.3261 -2.55 0.01078 
23 rs7883073 G 2.4 2.518 0.0118 
4 rs10000512 A 2.435 2.505 0.01226 
10 rs1649200 G 0.4926 -2.497 0.01252 
11 rs2276319 A 2.046 2.492 0.01271 
7 rs10226318 A 1.969 2.491 0.01274 
3 rs6771393 A 0.4404 -2.484 0.01298 
10 rs1801253 C 0.442 -2.47 0.01352 
11 rs10767665 A 1.935 2.466 0.01367 
9 rs10511887 G 0.359 -2.459 0.01392 
22 rs740603 A 0.5466 -2.45 0.01428 
6 rs9497515 T 0.5218 -2.45 0.01429 
6 rs827677 C 0.5255 -2.445 0.0145 
8 rs3912537 C 2.041 2.442 0.01459 
11 rs1800497 A 0.4746 -2.438 0.01476 
23 rs5925079 A 0.3049 -2.438 0.01477 
12 rs555044 A 1.926 2.437 0.01482 
2 rs3771827 G 1.982 2.426 0.01526 
1 rs1538974 A 2.17 2.424 0.01535 
13 rs2148656 G 2.031 2.416 0.0157 
11 rs11214775 A 2.115 2.413 0.01583 
5 rs1364043 C 0.5236 -2.395 0.01662 
20 rs2427430 C 0.5014 -2.385 0.01706 
23 rs7890174 A 2.182 2.385 0.0171 
22 rs2283793 G 1.948 2.383 0.01718 
17 rs12103667 G 4.172 2.383 0.0172 
11 rs7128320 A 1.982 2.378 0.01738 
4 rs17483979 C 3.393 2.377 0.01747 
9 rs2073837 A 0.5427 -2.37 0.01778 
8 rs7016275 G 2.464 2.367 0.01792 
16 rs1070487 A 0.5252 -2.365 0.01805 
5 rs11953285 C 3.364 2.358 0.01836 
11 rs3133846 G 0.5148 -2.352 0.01869 
6 rs6900017 A 0.4031 -2.351 0.01872 
11 rs12225735 A 0.4352 -2.345 0.01905 




1 rs6587924 A 0.5501 -2.335 0.01955 
11 rs7103873 G 1.864 2.334 0.0196 
11 rs2049046 A 1.864 2.334 0.0196 
5 rs13171967 A 0.533 -2.333 0.01966 
16 rs837692 A 1.924 2.332 0.01969 
23 rs6579495 A 0.5192 -2.327 0.01999 
3 rs6763202 G 0.547 -2.324 0.02011 
4 rs3898050 A 0.4177 -2.319 0.0204 
8 rs1563945 C 0.457 -2.312 0.02076 
2 rs3828275 A 2.007 2.31 0.02087 
11 rs17614942 A 0.3192 -2.304 0.02123 
14 rs4645856 G 0.4064 -2.302 0.02134 
2 rs4988235 A 2.481 2.3 0.02147 
2 rs182549 A 2.481 2.3 0.02147 
8 rs3802281 G 1.783 2.294 0.02182 
5 rs6892282 A 0.5561 -2.288 0.02214 
3 rs2029127 A 0.4346 -2.282 0.02251 
10 rs9420317 G 2.158 2.279 0.02266 
10 rs17156146 A 0.4764 -2.277 0.02278 
8 rs979148 G 2.193 2.269 0.02327 
8 rs351784 G 0.56 -2.262 0.02368 
4 rs4695226 C 0.5223 -2.256 0.02407 
6 rs1343796 G 1.872 2.255 0.02415 
3 rs4481143 T 0.5393 -2.254 0.02422 
10 rs6413419 A 0.3666 -2.249 0.0245 
23 rs518147 G 1.849 2.245 0.02474 
2 rs755503 G 1.795 2.244 0.02484 
8 rs13270574 G 0.5535 -2.243 0.0249 
3 rs1563382 G 0.5323 -2.243 0.02492 
11 rs6589846 C 2.098 2.235 0.02539 
8 rs472151 A 1.74 2.231 0.0257 
5 rs12656106 G 1.904 2.226 0.02599 
10 rs10788154 C 1.889 2.223 0.0262 
11 rs2155258 G 1.833 2.222 0.02631 
11 rs962369 G 0.5069 -2.218 0.02658 
11 rs2282586 A 1.942 2.213 0.02688 
10 rs6479700 A 1.788 2.211 0.02706 
11 rs674246 G 0.5648 -2.209 0.02717 
7 rs4721415 A 2.454 2.206 0.02735 
22 rs4485648 G 1.818 2.204 0.02754 




11 rs7127507 G 0.5582 -2.2 0.0278 
2 rs3771811 A 0.5084 -2.187 0.02877 
11 rs3793993 C 0.458 -2.185 0.02886 
11 rs1464896 G 0.3774 -2.181 0.02916 
8 rs488323 A 0.5815 -2.176 0.02955 
11 rs2212449 C 0.5776 -2.168 0.03014 
4 rs6447528 A 1.785 2.159 0.03085 
8 rs1050275 G 2.269 2.157 0.03097 
12 rs3741775 C 1.999 2.153 0.03134 
12 rs2730891 G 0.5813 -2.149 0.03161 
4 rs6837710 G 0.5586 -2.139 0.03242 
6 rs7770710 A 0.4644 -2.132 0.03301 
4 rs6857487 A 0.5769 -2.13 0.03315 
1 rs6688165 A 0.5274 -2.129 0.03325 
12 rs3021530 C 0.3919 -2.123 0.03373 
5 rs7737796 G 1.756 2.123 0.03374 
23 rs3027458 A 1.981 2.122 0.03385 
2 rs356643 A 1.705 2.121 0.03396 
4 rs1800855 A 0.6014 -2.12 0.03401 
12 rs10875749 A 0.452 -2.117 0.03429 
23 rs2269416 C 1.881 2.116 0.03436 
23 rs498207 G 1.77 2.114 0.03449 
23 rs12843268 G 0.4857 -2.111 0.03476 
23 rs3027405 T 2.038 2.1 0.03569 
23 rs12394221 G 1.944 2.097 0.03596 
3 rs1698042 C 0.5855 -2.091 0.03653 
11 rs12273363 G 0.3371 -2.082 0.0373 
10 rs4148913 G 1.737 2.078 0.03771 
22 rs174690 A 0.5173 -2.077 0.03776 
8 rs7006334 G 0.4406 -2.075 0.03801 
23 rs3810709 A 0.4796 -2.074 0.03805 
23 rs5905859 A 0.4796 -2.074 0.03805 
23 rs2072744 G 0.4796 -2.074 0.03805 
22 rs3810608 A 2.738 2.068 0.0386 
12 rs10444584 A 1.796 2.065 0.03896 
1 rs2780816 C 0.5951 -2.063 0.03914 
4 rs2000978 G 2.425 2.062 0.03922 
16 rs10500336 G 1.842 2.059 0.03949 
16 rs2939960 A 2.57 2.052 0.04013 
1 rs2295633 A 1.722 2.047 0.04063 




18 rs1944545 G 1.991 2.042 0.04113 
11 rs12800734 A 1.74 2.04 0.0413 
12 rs10746075 A 0.5705 -2.04 0.04136 
11 rs4430518 C 1.799 2.04 0.04137 
11 rs4910306 A 1.733 2.04 0.04139 
1 rs6424922 A 1.703 2.037 0.04167 
16 rs17498325 A 0.4063 -2.036 0.04176 
11 rs1491851 G 0.5671 -2.036 0.04178 
12 rs711159 A 1.589 2.029 0.04251 
11 rs10892643 A 1.767 2.024 0.04296 
12 rs2269355 G 0.5932 -2.02 0.04342 
11 rs3758987 G 0.5555 -2.018 0.04361 
11 rs3132780 G 0.3817 -2.016 0.0438 
6 rs806379 T 0.6032 -2.01 0.04443 
7 rs2066992 A 2.181 2.008 0.04466 
11 rs1076562 A 1.704 2.007 0.04476 
1 rs3024498 G 2.498 1.999 0.04562 
1 rs16824627 G 1.741 1.994 0.04616 
5 rs874083 A 2.462 1.994 0.04618 
11 rs4274224 A 1.645 1.989 0.04673 
4 rs10021525 G 1.673 1.984 0.04727 
8 rs2927385 C 0.5946 -1.982 0.04746 
11 rs2027760 A 1.655 1.978 0.04797 
3 rs1837205 A 1.923 1.971 0.04871 
3 rs4687002 G 1.65 1.97 0.04883 
7 rs3917550 A 2.163 1.97 0.04886 
5 rs11167557 G 0.6331 -1.969 0.04896 
5 rs6884105 A 0.6176 -1.966 0.04932 
10 rs10886849 A 0.5122 -1.963 0.04965 
11 rs2883187 A 1.754 1.962 0.04974 




A2.3 Gene-Based Results 
SET NSNP NSIG ISIG EMP1 SNPS 
Per3 13 0 0 1 NA 
MTHFR 1 0 0 1 NA 
OPRD1 18 0 0 1 NA 
JUN 2 0 0 1 NA 
NFIA 1 0 0 1 NA 
PTGER3 2 0 0 1 NA 
NRAS 1 0 0 1 NA 
NGFB 12 0 0 1 NA 
S100A10 5 0 0 1 NA 
CHRNB2 5 0 0 1 NA 
CRP 1 0 0 1 NA 
RGS4 8 0 0 1 NA 
F5 11 0 0 1 NA 
AVPR1B 7 0 0 1 NA 
PLXNA2 6 0 0 1 NA 
IL1B 16 0 0 1 NA 
NTSR2 5 0 0 1 NA 
POMC 11 0 0 1 NA 
FOSL2 8 0 0 1 NA 
PRKCE 19 0 0 1 NA 
REG3A 1 0 0 1 NA 
ADRA2B 3 0 0 1 NA 
IL1R2 13 0 0 1 NA 
IL1A 7 0 0 1 NA 
IL1RN 2 0 0 1 NA 
DBI 6 0 0 1 NA 
NR4A2 4 0 0 1 NA 
STAT1 10 0 0 1 NA 
FZD7 4 0 0 1 NA 
CREB 8 0 0 1 NA 
FEV 4 0 0 1 NA 
DNAJB2 1 0 0 1 NA 
HTR2B 5 0 0 1 NA 
HES6 3 0 0 1 NA 
Per2 22 0 0 1 NA 
BHLHB2 7 0 0 1 NA 
GRM7 2 0 0 1 NA 
OXTR 21 0 0 1 NA 
SLC6A1 16 0 0 1 NA 
RAF1 3 0 0 1 NA 
RBMS3 0 0 0 1 NA 




DRD3 24 0 0 1 NA 
GSK3B 11 0 0 1 NA 
LRRC31 1 0 0 1 NA 
FGFR3 1 0 0 1 NA 
ADRA2C 5 0 0 1 NA 
DRD5 2 0 0 1 NA 
GABRA2 20 0 0 1 NA 
REST 8 0 0 1 NA 
AMTN 0 0 0 1 NA 
IL8 1 0 0 1 NA 
ADH1A 0 0 0 1 NA 
NFKB1 9 0 0 1 NA 
IL2 2 0 0 1 NA 
FGF2 11 0 0 1 NA 
NPY2R 3 0 0 1 NA 
GLRB 8 0 0 1 NA 
NPY1R 12 0 0 1 NA 
NPY5R 4 0 0 1 NA 
PRLR 2 0 0 1 NA 
CART 0 0 0 1 NA 
CRHBP 13 0 0 1 NA 
IL5 1 0 0 1 NA 
IL4 1 0 0 1 NA 
FGF1 21 0 0 1 NA 
CSNK1A1 7 0 0 1 NA 
PPARGC1B 1 0 0 1 NA 
SLC6A7 7 0 0 1 NA 
GABRB2 30 0 0 1 NA 
GABRA6 12 0 0 1 NA 
GABRA1 8 0 0 1 NA 
GABRG2 2 0 0 1 NA 
DRD1 12 0 0 1 NA 
TFAP2A 7 0 0 1 NA 
DTNBP1 2 0 0 1 NA 
PRL 3 0 0 1 NA 
GABBR1 9 0 0 1 NA 
LTA 2 0 0 1 NA 
TNFA 6 0 0 1 NA 
GRM4 13 0 0 1 NA 
TULP1 1 0 0 1 NA 
VEGF 5 0 0 1 NA 
SLC29A1 5 0 0 1 NA 
IL17 2 0 0 1 NA 




HTR1B 13 0 0 1 NA 
HTR1E 1 0 0 1 NA 
SYNE1 47 0 0 1 NA 
OPRM1 65 0 0 1 NA 
ACHE 5 0 0 1 NA 
NPY 15 0 0 1 NA 
CREB5 2 0 0 1 NA 
CRHR2 18 0 0 1 NA 
DDC 21 0 0 1 NA 
EGFR 5 0 0 1 NA 
GRM3 14 0 0 1 NA 
TAC1 5 0 0 1 NA 
NRCAM 6 0 0 1 NA 
LEP 2 0 0 1 NA 
CSMD1 4 0 0 1 NA 
CLDN23 4 0 0 1 NA 
SLC18A1 15 0 0 1 NA 
ADRB3 5 0 0 1 NA 
FGFR1 2 0 0 1 NA 
ADAM18 3 0 0 1 NA 
PENK 5 0 0 1 NA 
CALB1 2 0 0 1 NA 
SLC1A1 3 0 0 1 NA 
JAK2 5 0 0 1 NA 
MPDZ 11 0 0 1 NA 
ALDH1A1 13 0 0 1 NA 
RORB 2 0 0 1 NA 
NTRK2 36 0 0 1 NA 
NFIL3 3 0 0 1 NA 
GRIN1 6 0 0 1 NA 
GAD2 20 0 0 1 NA 
ADRA2A 10 0 0 1 NA 
SLC18A2 30 0 0 1 NA 
DRD1IP 4 0 0 1 NA 
DRD4 4 0 0 1 NA 
TH 9 0 0 1 NA 
ARNTL 30 0 0 1 NA 
TPH1 11 0 0 1 NA 
CAT 0 0 0 1 NA 
CRY2 7 0 0 1 NA 
DRD4 15 0 0 1 NA 
FOSL1 3 0 0 1 NA 
ADRBK1 3 0 0 1 NA 




IL18 4 0 0 1 NA 
HTR3A 14 0 0 1 NA 
CACNA1C 44 0 0 1 NA 
TNFRSF1A 3 0 0 1 NA 
SCNN1A 1 0 0 1 NA 
GRIN2B 76 0 0 1 NA 
PDE6H 0 0 0 1 NA 
timeless 4 0 0 1 NA 
TPH2 79 0 0 1 NA 
KCNC2 2 0 0 1 NA 
SYT1 20 0 0 1 NA 
SLC6A15 30 0 0 1 NA 
ALDH2 6 0 0 1 NA 
NOS1 2 0 0 1 NA 
CIT 2 0 0 1 NA 
P2RX7 15 0 0 1 NA 
FGF9 8 0 0 1 NA 
HTR2A 54 0 0 1 NA 
DAOA 9 0 0 1 NA 
MAMDC1 26 0 0 1 NA 
GPHN 16 0 0 1 NA 
GABRB3 0 0 0 1 NA 
SLC12A6 12 0 0 1 NA 
AP3B2 8 0 0 1 NA 
MAPK3 2 0 0 1 NA 
ADCY7 14 0 0 1 NA 
NET1 40 0 0 1 NA 
ARRB2 7 0 0 1 NA 
PER1 13 0 0 1 NA 
VAMP2 3 0 0 1 NA 
SLC6A4 42 0 0 1 NA 
CDK5R1 3 0 0 1 NA 
PPP1R1B 4 0 0 1 NA 
PNMT 0 0 0 1 NA 
HCRT 1 0 0 1 NA 
STAT5 0 0 0 1 NA 
ACE1 14 0 0 1 NA 
GRIN2C 3 0 0 1 NA 
GALR2 2 0 0 1 NA 
CSNK1D 0 0 0 1 NA 
MC2R 4 0 0 1 NA 
MYO5B 3 0 0 1 NA 
TCF4 3 0 0 1 NA 




SerpinB2 0 0 0 1 NA 
SerpinB10 4 0 0 1 NA 
SerpinB8 11 0 0 1 NA 
CDH7 6 0 0 1 NA 
EPOR 1 0 0 1 NA 
APOE 8 0 0 1 NA 
PDYN 10 0 0 1 NA 
OXT 16 0 0 1 NA 
SNAP25 45 0 0 1 NA 
SLC32A1 2 0 0 1 NA 
CHRNA4 15 0 0 1 NA 
OPRL1 6 0 0 1 NA 
GRIK1 46 0 0 1 NA 
DIP2 3 0 0 1 NA 
ADRBK2 14 0 0 1 NA 
XBP1 2 0 0 1 NA 
SYN3 2 0 0 1 NA 
GALR3 0 0 0 1 NA 
CSNK1E 14 0 0 1 NA 
GLRA2 12 0 0 1 NA 
GPR50 9 0 0 1 NA 
GABRA3 20 0 0 1 NA 
GABRQ 6 0 0 1 NA 
NR1D1 5 1 1 0.0032 rs2071570 
BHLHB3 4 1 1 0.005799 rs3809140 
BCHE 11 2 2 0.0113 rs11925572|rs2668196 
STX1A 5 1 1 0.0188 rs3793243 
ARRB1 10 2 2 0.0225 rs528833|rs2276310 
ADRB2 11 2 1 0.0236 rs1042713 
HES1 4 1 1 0.0283 rs6771393 
ADRB1 4 1 1 0.0352 rs1801253 
DISC1 5 2 2 0.0372 rs2487453|rs1538974 
ADRA1B 15 7 5 0.0457 rs10515805|rs752266|rs6888306|rs11953285|rs6892282 
VEGFA 11 2 2 0.0468 rs3025035|rs6900017 
GRIK4 67 6 5 0.05139 rs7105258|rs7105286|rs4936556|rs2276319|rs3133846 
MAOB 18 4 1 0.05469 rs7883073 
HTR1A 7 1 1 0.05569 rs1364043 
FOS 3 1 1 0.05879 rs4645856 
WFS1 5 1 1 0.06719 rs3898050 
TSPAN8 2 1 1 0.06979 rs10444584 
SLC6A3 45 1 1 0.07379 rs393795 
MAOA 21 8 2 0.07459 rs5906729|rs3027405 
MAPK1 15 3 2 0.07669 rs1063311|rs3810608 




GAD1 19 2 2 0.08529 rs12185692|rs3828275 
AP3M2 4 2 2 0.08529 rs13270574|rs1050275 
ANK3 49 2 2 0.09779 rs10509117|rs6479700 
SLC6A13 16 1 1 0.1036 rs555044 
GRM1 18 1 1 0.1044 rs9497515 
CYP2E1 6 1 1 0.1047 rs6413419 
OPRK1 12 2 2 0.1123 rs7016275|rs3802281 
COMT 36 7 5 0.1143 rs5993882|rs5993883|rs740603|rs4485648|rs174690 
PNOC 9 2 2 0.1155 rs1563945|rs351784 
RGS2 17 1 1 0.1169 rs1342809 
CLOCK 32 2 2 0.1185 rs10000512|rs6837710 
GRIN2A 9 2 2 0.1207 rs1070487|rs837692 
NTSR1 14 1 1 0.1212 rs2427430 
GABRE 8 2 2 0.1271 rs5925079|rs2269416 
GABRD 3 1 1 0.1272 rs16824627 
GALNTL4 5 1 1 0.1308 rs4910306 
DGKH 26 1 1 0.1324 rs2148656 
CRHR1 31 1 1 0.1445 rs12103667 
BDNF 41 13 5 0.1489 rs11030119|rs2030324|rs1464896|rs12273363|rs1491851 
CCKBR 9 1 1 0.1528 rs3793993 
HTR2C 37 3 2 0.1652 rs6579495|rs518147 
MAPK14 8 1 1 0.1721 rs7770710 
DAO 9 1 1 0.1794 rs3741775 
CRY1 6 1 1 0.1954 rs10746075 
IL10 15 1 1 0.1997 rs3024498 
GAP43 31 2 2 0.2037 rs16823934|rs1837205 
GLRA1 8 1 1 0.2158 rs11167557 
GNB3 7 1 1 0.2164 rs2269355 
CCKAR 10 2 2 0.2178 rs1800855|rs2000978 
NR3C2 51 3 3 0.2185 rs10026568|rs17483979|rs6857487 
HTR3B 21 3 3 0.2266 rs11214775|rs17614942|rs3758987 
JAK1 14 1 1 0.2355 rs2780816 
AVPR1A 17 1 1 0.2447 rs3021530 
SLC6A11 21 1 1 0.2618 rs4481143 
TACR1 29 2 2 0.2689 rs3771827|rs3771811 
GALR1 9 1 1 0.2713 rs1944545 
NR3C1 36 1 1 0.285 rs12656106 
FAAH 11 1 1 0.3018 rs2295633 
CNR1 11 1 1 0.3141 rs806379 
SLC9A9 43 1 1 0.3308 rs6763202 
IL6 15 1 1 0.337 rs2066992 
FGFR2 64 5 5 0.3398 rs2420941|rs1649200|rs9420317|rs10788154|rs10886849 
DBH 31 2 2 0.3834 rs2073837|rs3025369 




GABRB1 36 2 2 0.4365 rs4695226|rs6447528 
CRH 33 1 1 0.4427 rs7006334 
FKBP5 98 1 1 0.4617 rs1343796 
PON1 21 1 1 0.499 rs3917550 
NRG1 45 1 1 0.514 rs3757930 
NPAS2 34 1 1 0.5301 rs356643 
CAMK2A 24 1 1 0.557 rs874083 
DRD2 36 2 2 0.5597 rs1076562|rs4274224 
ADRA1A 56 3 2 0.6272 rs472151|rs526302 
LPHN3 31 1 1 0.6833 rs10021525 
 
Appendix 3 
A3.1 Genes and SNPs 
Gene SNP Gene SNP 
CRHR2 rs1003929 CRHR1 rs241027 
CRHR2 rs10271509 CRHR1 rs241030 
UCN3 rs10400011 CRHR1 rs241031 
CRHR2 rs107540 CRHR1 rs241033 
CRHR2 rs1076292 CRHR1 rs241035 
UCN3 rs10795268 CRHR1 rs241036 
UCN3 rs10904479 CRHR1 rs241039 
UCN3 rs10904481 CRHR2 rs255100 
CRHR1 rs110402 CRHR2 rs255102 
UCN3 rs11253130 CRHR2 rs255105 
UCN3 rs11591351 CRHR2 rs255106 
CRHR2 rs12701020 CRHR2 rs255108 
CRH rs12721510 CRHR2 rs255110 
UCN3 rs12768198 CRHR2 rs255112 
UCN3 rs12783734 CRHR2 rs255113 
UCN2 rs13319651 CRHR2 rs255115 
CRHR1 rs171440 CRHR2 rs255121 
CRHR1 rs171441 CRHR2 rs255122 
CRHR2 rs17159371 CRH rs3176921 
CRHR2 rs17159372 CRHR1 rs3418 
CRHR1 rs173365 POMC rs3769671 
CRHR2 rs2014663 CRHR2 rs3779250 
CRHR2 rs2190242 CRHR2 rs4722999 
CRHR2 rs2240403 CRHR2 rs4723000 
CRHR2 rs2240404 CRHR2 rs4723002 
CRHR2 rs2251002 CRHR2 rs4723003 
CRHR2 rs2267710 CRHR2 rs6462219 




CRHR2 rs2267715 POMC rs6545975 
CRHR2 rs2267716 UCN3 rs6601952 
CRHR2 rs2267717 POMC rs6713532 
CRHR2 rs2284216 CRH rs6982394 
CRHR2 rs2284217 CRH rs6999780 
CRHR2 rs2284218 CRHR2 rs733453 
CRHR2 rs2284219 POMC rs7565427 
CRHR2 rs2284220 POMC rs7565877 
CRHR1 rs241022 CRHR2 rs7812133 
CRHR1 rs241023 CRHR1 rs81189 
CRHR1 rs241026 CRHR2 rs929377 
POMC rs934778 CRHR2 rs975537 























































7 0.8502 0.4279 -0.1952 0.1798 2.253 0.02429 
7 rs255100 0.7212 0.3825 -0.1732 0.1592 2.159 0.03087 
7 
rs107629
2 0.5794 0.3683 -0.226 0.1541 2.017 0.04365 
7 
rs225100
2 0.5794 0.3683 -0.226 0.1541 2.017 0.04365 
7 
rs171593
71 1.127 0.7061 -0.2369 0.2837 1.792 0.07307 
7 
rs171593
72 1.271 0.7648 -0.1628 0.3085 1.739 0.08206 
7 rs107540 0.5768 0.3644 -0.08987 0.1515 1.689 0.09116 
7 rs255122 0.5168 0.3552 -0.1098 0.1489 1.627 0.1037 
7 
rs228421
9 0.4105 0.3622 -0.2274 0.1516 1.625 0.1043 
7 rs733453 0.4105 0.3622 -0.2223 0.1516 1.612 0.107 
7 
rs226771
5 0.4105 0.3622 -0.2223 0.1516 1.612 0.107 
7 
rs228421
8 0.386 0.3626 -0.2321 0.1515 1.573 0.1157 
7 rs255115 0.4937 0.354 -0.09809 0.1487 1.541 0.1233 
7 rs255113 0.471 0.3546 -0.1132 0.1502 1.517 0.1293 
7 rs255112 0.4604 0.3565 -0.1084 0.1501 1.471 0.1414 
7 rs975537 0.6072 0.4257 -0.04953 0.1778 1.423 0.1546 
2 
rs671353
2 0.6058 0.4074 -0.01121 0.1712 1.396 0.1627 
7 
rs377925
0 0.3997 0.3806 -0.1257 0.153 1.281 0.2002 
7 
rs226771
2 0.5778 0.5018 -0.1031 0.2132 1.249 0.2117 
7 
rs646221
9 0.5778 0.5018 -0.1031 0.2132 1.249 0.2117 
7 
rs201466
3 0.5778 0.5018 -0.1031 0.2132 1.249 0.2117 
8 
rs127215
10 0.8856 0.6439 0.02541 0.3004 1.21 0.2261 
7 rs255108 0.4179 0.3508 -0.04093 0.1451 1.209 0.2268 
7 
rs228422
0 0.5185 0.5009 -0.1139 0.2131 1.162 0.2453 
7 
rs100392
9 0.5185 0.5009 -0.1139 0.2131 1.162 0.2453 
7 rs255106 0.3929 0.3513 -0.04395 0.1453 1.149 0.2504 
7 
rs472299
9 0.4106 0.3948 -0.07582 0.1579 1.144 0.2526 
7 
rs226771
0 0.4106 0.3948 -0.07195 0.1579 1.135 0.2564 






09 0.4079 0.3821 0.004651 0.1594 0.9741 0.33 
17 rs173365 -0.2721 0.3436 0.07394 0.1441 -0.9286 0.3531 
7 
rs226771
6 0.1488 0.4227 -0.2276 0.1758 0.8222 0.411 
7 
rs219024
2 0.1615 0.4305 -0.2092 0.1799 0.7945 0.4269 
7 rs255121 0.289 0.592 -0.2215 0.2542 0.7924 0.4281 
7 
rs472300
3 -0.6989 0.6339 -0.1613 0.2576 -0.7856 0.4321 
2 
rs756542
7 0.01557 0.5046 0.44 0.2201 -0.7708 0.4408 
2 
rs756587
7 0.0905 0.5462 -0.3629 0.2331 0.7634 0.4452 
8 
rs317692
1 0.5693 0.6586 0.06115 0.2445 0.7233 0.4695 
8 
rs699978
0 0.5693 0.6586 0.06115 0.2445 0.7233 0.4695 
8 
rs647225
7 0.5693 0.6586 0.06115 0.2445 0.7233 0.4695 
7 rs929377 0.1476 0.3961 -0.1608 0.1627 0.7202 0.4714 
10 
rs109044
79 -0.3871 0.3942 -0.08743 0.1624 -0.7029 0.4821 
7 rs973002 0.3336 0.4676 0.01813 0.1973 0.6216 0.5342 
7 
rs472300
2 -0.5708 0.6467 -0.1613 0.2576 -0.5883 0.5564 
2 rs934778 0.3021 0.3579 0.07771 0.1571 0.574 0.566 
7 rs255105 0.1665 0.3634 -0.05159 0.1504 0.5546 0.5792 
17 rs81189 -0.09253 0.3472 0.1085 0.144 -0.5349 0.5927 
17 rs171440 -0.09253 0.3472 0.08929 0.1443 -0.4836 0.6287 
7 
rs228421
6 0.07005 0.6977 -0.212 0.2701 0.377 0.7061 
10 
rs109044
81 -0.212 0.3881 -0.06231 0.1593 -0.3568 0.7212 
10 
rs112531
30 -0.1904 0.3983 -0.04523 0.1629 -0.3373 0.7359 
10 
rs660195
2 -0.2071 0.3884 -0.07365 0.159 -0.3179 0.7506 
7 
rs224040
4 -0.1315 0.544 -0.3065 0.2301 0.2962 0.7671 
10 
rs107952
68 -0.1393 0.4002 -0.01401 0.1645 -0.2895 0.7722 
2 
rs654597
5 0.2213 0.3286 0.3147 0.1477 -0.2591 0.7955 
10 
rs115913
51 0.2584 0.3853 0.3639 0.1694 -0.2507 0.802 
10 
rs104000
11 -0.1365 0.4003 -0.03172 0.1645 -0.2422 0.8087 
7 rs255110 0.06193 0.3759 -0.0329 0.1603 0.232 0.8165 
7 
rs224040
3 -0.4275 0.689 -0.2634 0.2679 -0.222 0.8243 
7 
rs226771
7 0.2292 0.5712 0.106 0.231 0.2 0.8415 
10 
rs127837
34 0.3111 0.3875 0.3948 0.1706 -0.1976 0.8434 







0 -0.226 0.5399 -0.3205 0.2311 0.1609 0.8722 
7 
rs127010
20 -0.2376 0.4605 -0.1578 0.1988 -0.159 0.8737 
17 rs241030 -0.1779 0.3937 -0.1455 0.1623 -0.07608 0.9394 
17 rs241039 -0.1405 0.3979 -0.1229 0.1646 -0.04099 0.9673 
17 rs3418 -0.1405 0.3979 -0.1229 0.1646 -0.04099 0.9673 
17 rs241036 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241035 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241033 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241031 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241027 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241026 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241023 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 
17 rs241022 -0.1405 0.3979 -0.133 0.1642 -0.01755 0.986 





Appendix 4  
A4.1 Genes and SNPs 
Gene SNP Gene SNP Gene SNP Gene SNP 
AKAP1 rs15944 GRIK4 rs10502240 GRM8 rs1008260 GRIK3 rs544932 
AKAP1 rs2058578 GRIK4 rs10790394 GRM8 rs1008906 GRIK3 rs547390 
AKAP1 rs2160115 GRIK4 rs10790395 GRM8 rs1008907 GRIK3 rs553719 
AKAP1 rs2230772 GRIK4 rs10790400 GRM8 rs10232001 GRIK3 rs569858 
AKAP1 rs2301702 GRIK4 rs10790402 GRM8 rs1024380 GRIK3 rs571524 
AKAP1 rs3095505 GRIK4 rs10892599 GRM8 rs10254233 GRIK3 rs6687320 
AKAP1 rs3785484 GRIK4 rs10892612 GRM8 rs10256873 GRIK3 rs7517274 
AKAP1 rs3826296 GRIK4 rs10892629 GRM8 rs10274867 GRIK3 rs7531813 
AKAP1 rs4583 GRIK4 rs10892631 GRM8 rs10487463 GRIK3 rs7555221 
AKAP1 rs7209653 GRIK4 rs10892640 GRM8 rs10487466 PRKCH rs4312236 
AKAP1 rs721427 GRIK4 rs10892643 GRM8 rs1155597 PRKCH rs4899050 
AKAP1 rs998113 GRIK4 rs10892648 GRM8 rs1155657 PRKCH rs4902046 
AKAP10 rs119672 GRIK4 rs11217956 GRM8 rs11563302 PRKCH rs4902069 
AKAP10 rs17604987 GRIK4 rs11217973 GRM8 rs11563486 PRKCH rs6573385 
AKAP10 rs203457 GRIK4 rs11217974 GRM8 rs11563496 PRKCH rs7155214 
AKAP10 rs203466 GRIK4 rs11218005 GRM8 rs11563701 PRKCH rs7158720 
AKAP10 rs2108978 GRIK4 rs11218016 GRM8 rs11563720 PRKCH rs767755 
AKAP10 rs850622 GRIK4 rs11218029 GRM8 rs11563773 PRKCH rs8008798 
AKAP11 rs9525607 GRIK4 rs11218032 GRM8 rs11563801 PRKCH rs8013398 
AKAP11 rs9594724 GRIK4 rs11218067 GRM8 rs11763603 PRKCH rs8019776 




AKAP12 rs12195960 GRIK4 rs11218071 GRM8 rs1204515 PRKCH rs991110 
AKAP12 rs12202922 GRIK4 rs11218072 GRM8 rs1204516 PRKCI rs1392366 
AKAP12 rs17080959 GRIK4 rs11218078 GRM8 rs1204556 PRKCI rs1684885 
AKAP12 rs17081113 GRIK4 rs11603586 GRM8 rs1204578 PRKCI rs2291930 
AKAP12 rs2294796 GRIK4 rs11607732 GRM8 rs1204585 PRKCI rs2292386 
AKAP12 rs2786748 GRIK4 rs12226536 GRM8 rs1204590 PRKCI rs7620870 
AKAP12 rs4870006 GRIK4 rs12284730 GRM8 rs1211384 PRKCQ rs2453 
AKAP12 rs4870007 GRIK4 rs2004676 GRM8 rs12154960 PRKCQ rs4750439 
AKAP12 rs6557123 GRIK4 rs2155258 GRM8 rs12706735 PRKCQ rs582052 
AKAP12 rs6907228 GRIK4 rs2298723 GRM8 rs12706739 PRKCZ rs262641 
AKAP12 rs7742224 GRIK4 rs2850808 GRM8 rs12706740 PRKCZ rs3107146 
AKAP12 rs7764018 GRIK4 rs2852212 GRM8 rs13222700 PRKCZ rs3107157 
AKAP12 rs926557 GRIK4 rs2852241 GRM8 rs13240418 PRKCZ rs3128309 
AKAP12 rs9322311 GRIK4 rs3824978 GRM8 rs13240504 PRKCZ rs3753242 
AKAP12 rs9383875 GRIK4 rs3901285 GRM8 rs1361981 PRKCZ rs385039 
AKAP12 rs9383876 GRIK4 rs4414232 GRM8 rs1361990 PRKCZ rs626479 
AKAP12 rs9383877 GRIK4 rs4451741 GRM8 rs1419442 PRKCZ rs7513222 
AKAP12 rs9383882 GRIK4 rs4526780 GRM8 rs1419484 SERPINA6 rs10141408 
AKAP13 rs10520589 GRIK4 rs4582985 GRM8 rs1419496 SERPINA6 rs11160168 
AKAP13 rs10520594 GRIK4 rs4635090 GRM8 rs1419508 SERPINA6 rs11160169 
AKAP13 rs10520595 GRIK4 rs4936566 GRM8 rs1419521 SERPINA6 rs12437224 
AKAP13 rs10520596 GRIK4 rs499804 GRM8 rs17150350 SERPINA6 rs1956177 
AKAP13 rs10520599 GRIK4 rs645156 GRM8 rs17612819 SERPINA6 rs1998056 
AKAP13 rs11073403 GRIK4 rs646543 GRM8 rs17627206 SERPINA6 rs2144834 
AKAP13 rs11074223 GRIK4 rs658696 GRM8 rs17683462 SERPINA6 rs7161521 
AKAP13 rs1111107 GRIK4 rs6589833 GRM8 rs17691394 SERPINA6 rs8005533 
AKAP13 rs11631660 GRIK4 rs6589846 GRM8 rs1981696 SERPINA6 rs941599 
AKAP13 rs11633893 GRIK4 rs669397 GRM8 rs1989850 SLC1A1 rs10491731 
AKAP13 rs11634177 GRIK4 rs7104543 GRM8 rs2023735 SLC1A1 rs10758629 
AKAP13 rs11634651 GRIK4 rs7116106 GRM8 rs2066902 SLC1A1 rs10814993 
AKAP13 rs11635711 GRIK4 rs7128009 GRM8 rs2106190 SLC1A1 rs10814997 
AKAP13 rs11637726 GRIK4 rs7128320 GRM8 rs2106193 SLC1A1 rs10974616 
AKAP13 rs11638762 GRIK4 rs751368 GRM8 rs2106200 SLC1A1 rs10974623 
AKAP13 rs12101598 GRIK4 rs751369 GRM8 rs2106353 SLC1A1 rs10974624 
AKAP13 rs12440599 GRIK4 rs751370 GRM8 rs2157752 SLC1A1 rs12342908 
AKAP13 rs12442591 GRIK4 rs7925270 GRM8 rs2188187 SLC1A1 rs12551465 
AKAP13 rs12708553 GRIK5 rs3785906 GRM8 rs2237776 SLC1A1 rs17812372 




AKAP13 rs12909648 GRIN2A rs10500373 GRM8 rs2237786 SLC1A1 rs2072657 
AKAP13 rs13379755 GRIN2A rs10518151 GRM8 rs2237790 SLC1A1 rs3780414 
AKAP13 rs16940997 GRIN2A rs1070476 GRM8 rs2237794 SLC1A1 rs3824259 
AKAP13 rs16941653 GRIN2A rs1070484 GRM8 rs2283061 SLC1A1 rs4742003 
AKAP13 rs16942698 GRIN2A rs1070548 GRM8 rs2283062 SLC1A1 rs4742008 
AKAP13 rs16943236 GRIN2A rs1102972 GRM8 rs2283064 SLC1A1 rs4742009 
AKAP13 rs16943741 GRIN2A rs11074502 GRM8 rs2283079 SLC1A1 rs6476878 
AKAP13 rs16977800 GRIN2A rs11074546 GRM8 rs2283092 SLC1A1 rs7022369 
AKAP13 rs16977810 GRIN2A rs11074547 GRM8 rs2299476 SLC1A1 rs7022772 
AKAP13 rs17552700 GRIN2A rs11074593 GRM8 rs2299492 SLC1A1 rs7031998 
AKAP13 rs17552971 GRIN2A rs11074605 GRM8 rs2299500 SLC1A1 rs7849913 
AKAP13 rs17553734 GRIN2A rs11074613 GRM8 rs2299503 SLC1A1 rs7871243 
AKAP13 rs17553790 GRIN2A rs11644367 GRM8 rs2299536 SLC1A1 rs928209 
AKAP13 rs17575933 GRIN2A rs11644461 GRM8 rs2299537 SLC1A1 rs9886720 
AKAP13 rs17618909 GRIN2A rs11645379 GRM8 rs2299546 SLC1A1 rs9918970 
AKAP13 rs17623915 GRIN2A rs11647369 GRM8 rs2299555 SYNGAP1 rs411136 
AKAP13 rs17632140 GRIN2A rs11647877 GRM8 rs2299556 UCN2 rs171440 
AKAP13 rs17635450 GRIN2A rs11648615 GRM8 rs2402820 UCN2 rs171441 
AKAP13 rs17638001 GRIN2A rs11859693 GRM8 rs3808122 UCN3 rs11253130 
AKAP13 rs17638180 GRIN2A rs11862776 GRM8 rs3808142 
  AKAP13 rs1861856 GRIN2A rs11866328 GRM8 rs4141410 
  AKAP13 rs2062234 GRIN2A rs11866385 GRM8 rs4731330 
  AKAP13 rs2169876 GRIN2A rs12596342 GRM8 rs6467092 
  AKAP13 rs2241267 GRIN2A rs12920919 GRM8 rs6947960 
  AKAP13 rs2291048 GRIN2A rs12924396 GRM8 rs6950264 
  AKAP13 rs2430832 GRIN2A rs12932835 GRM8 rs6951546 
  AKAP13 rs2448026 GRIN2A rs12934281 GRM8 rs6951643 
  AKAP13 rs338507 GRIN2A rs12935101 GRM8 rs6958658 
  AKAP13 rs338515 GRIN2A rs13331514 GRM8 rs6961760 
  AKAP13 rs338518 GRIN2A rs13336632 GRM8 rs6975541 
  AKAP13 rs338520 GRIN2A rs1345424 GRM8 rs6975798 
  AKAP13 rs338540 GRIN2A rs1420040 GRM8 rs728600 
  AKAP13 rs338554 GRIN2A rs1448262 GRM8 rs766239 
  AKAP13 rs3743321 GRIN2A rs1550961 GRM8 rs7784231 
  AKAP13 rs3765096 GRIN2A rs1650420 GRM8 rs7792592 
  AKAP13 rs414374 GRIN2A rs16956781 GRM8 rs7794734 
  AKAP13 rs4240775 GRIN2A rs16966731 GRM8 rs7796391 
  AKAP13 rs4281668 GRIN2A rs17570793 GRM8 rs7805944 
  AKAP13 rs4360875 GRIN2A rs17671033 GRM8 rs7806403 
  AKAP13 rs4407021 GRIN2A rs17682922 GRM8 rs886176 
  AKAP13 rs4536419 GRIN2A rs17682940 GRM8 rs929174 
  AKAP13 rs4638530 GRIN2A rs17750208 GRM8 rs952912 
  AKAP13 rs4842888 GRIN2A rs17793917 GRM8 rs9942681 





AKAP13 rs4843094 GRIN2A rs1875205 IDO1 rs3739319 
  AKAP13 rs6496055 GRIN2A rs1875207 MAPK1 rs17759598 
  AKAP13 rs6497117 GRIN2A rs1875208 MAPK1 rs2276005 
  AKAP13 rs7165772 GRIN2A rs1900718 MAPK1 rs2276006 
  AKAP13 rs7168345 GRIN2A rs194355 MAPK1 rs2283792 
  AKAP13 rs7169429 GRIN2A rs2034369 MAPK1 rs2298432 
  AKAP13 rs7170370 GRIN2A rs2267772 MAPK1 rs2298434 
  AKAP13 rs7171364 GRIN2A rs2267786 MAPK1 rs363437 
  AKAP13 rs7182210 GRIN2A rs2267787 MAPK1 rs5755694 
  AKAP13 rs725686 GRIN2A rs2267792 MAPK1 rs5999515 
  AKAP13 rs730372 GRIN2A rs2352740 MAPK1 rs5999521 
  AKAP13 rs730439 GRIN2A rs2353434 MC2R rs1940907 
  AKAP13 rs8025492 GRIN2A rs2442098 MC2R rs4308014 
  AKAP13 rs8035127 GRIN2A rs2650434 MC2R rs4519393 
  AKAP13 rs8036310 GRIN2A rs2937030 MC2R rs4519394 
  AKAP13 rs8041467 GRIN2A rs3104704 MC2R rs4797824 
  AKAP13 rs870689 GRIN2A rs3743833 MC2R rs4797825 
  AKAP13 rs900573 GRIN2A rs3848332 NR3C1 rs10051292 
  AKAP14 rs2428236 GRIN2A rs3852745 NR3C1 rs10063711 
  AKAP3 rs10774250 GRIN2A rs3852746 NR3C1 rs10428525 
  AKAP3 rs1860342 GRIN2A rs3905837 NR3C1 rs10482642 
  AKAP3 rs6416316 GRIN2A rs4780717 NR3C1 rs10515522 
  AKAP3 rs7316317 GRIN2A rs4780746 NR3C1 rs12187799 
  AKAP6 rs10134827 GRIN2A rs4780751 NR3C1 rs12189303 
  AKAP6 rs10135053 GRIN2A rs4780817 NR3C1 rs12656580 
  AKAP6 rs10146478 GRIN2A rs4782108 NR3C1 rs13158686 
  AKAP6 rs10151252 GRIN2A rs4782258 NR3C1 rs13354365 
  AKAP6 rs1028537 GRIN2A rs4782263 NR3C1 rs1363668 
  AKAP6 rs10431651 GRIN2A rs4782265 NR3C1 rs1366082 
  AKAP6 rs10431652 GRIN2A rs4782266 NR3C1 rs1373999 
  AKAP6 rs10483416 GRIN2A rs4782271 NR3C1 rs1422874 
  AKAP6 rs10872865 GRIN2A rs4782275 NR3C1 rs1445873 
  AKAP6 rs11156742 GRIN2A rs4998386 NR3C1 rs153516 
  AKAP6 rs11627566 GRIN2A rs6416623 NR3C1 rs153518 
  AKAP6 rs12435388 GRIN2A rs6497523 NR3C1 rs1644431 
  AKAP6 rs12818068 GRIN2A rs6497732 NR3C1 rs17100309 
  AKAP6 rs12878600 GRIN2A rs6497738 NR3C1 rs17100323 
  AKAP6 rs12882489 GRIN2A rs7173923 NR3C1 rs17100330 
  AKAP6 rs12887176 GRIN2A rs7188291 NR3C1 rs17100416 
  AKAP6 rs12889349 GRIN2A rs7190716 NR3C1 rs17100498 
  AKAP6 rs12897283 GRIN2A rs7191698 NR3C1 rs17100500 
  AKAP6 rs17091663 GRIN2A rs7195891 NR3C1 rs17100506 
  AKAP6 rs17098884 GRIN2A rs7196708 NR3C1 rs17100739 





AKAP6 rs17099285 GRIN2A rs7204654 NR3C1 rs17287758 
  AKAP6 rs17099538 GRIN2A rs7205594 NR3C1 rs17339831 
  AKAP6 rs17414154 GRIN2A rs7499321 NR3C1 rs17342167 
  AKAP6 rs17484233 GRIN2A rs8044064 NR3C1 rs17346995 
  AKAP6 rs1805261 GRIN2A rs8045712 NR3C1 rs17348257 
  AKAP6 rs1885721 GRIN2A rs8055598 NR3C1 rs17348488 
  AKAP6 rs1950702 GRIN2A rs8060093 NR3C1 rs17401682 
  AKAP6 rs1956210 GRIN2A rs8060992 NR3C1 rs181786 
  AKAP6 rs1957015 GRIN2A rs837692 NR3C1 rs184458 
  AKAP6 rs1957030 GRIN2A rs837694 NR3C1 rs2028833 
  AKAP6 rs2300831 GRIN2A rs837696 NR3C1 rs2398660 
  AKAP6 rs2300832 GRIN2A rs837698 NR3C1 rs247623 
  AKAP6 rs2300833 GRIN2A rs837703 NR3C1 rs2918417 
  AKAP6 rs2383302 GRIN2A rs844395 NR3C1 rs2963154 
  AKAP6 rs2383340 GRIN2A rs884918 NR3C1 rs325258 
  AKAP6 rs4981990 GRIN2A rs971035 NR3C1 rs325262 
  AKAP6 rs4981991 GRIN2A rs971036 NR3C1 rs431647 
  AKAP6 rs6571548 GRIN2A rs9922383 NR3C1 rs4912927 
  AKAP6 rs7146377 GRIN2A rs9922871 NR3C1 rs4912933 
  AKAP6 rs7146681 GRIN2A rs9924226 NR3C1 rs6580287 
  AKAP6 rs7146994 GRIN2A rs9932138 NR3C1 rs6859024 
  AKAP6 rs7149335 GRIN2A rs9933832 NR3C1 rs6869469 
  AKAP6 rs7151141 GRIN2B rs10492132 NR3C1 rs6871843 
  AKAP6 rs7151681 GRIN2B rs10492134 NR3C1 rs6879079 
  AKAP6 rs7159519 GRIN2B rs10492136 NR3C1 rs6898504 
  AKAP6 rs7160156 GRIN2B rs10492141 NR3C1 rs7714402 
  AKAP6 rs7160301 GRIN2B rs10492142 NR3C1 rs7719351 
  AKAP6 rs8004777 GRIN2B rs10772694 NR3C1 rs7727865 
  AKAP6 rs8016916 GRIN2B rs10845809 NR3C1 rs7728928 
  AKAP6 rs8021057 GRIN2B rs10845814 NR3C1 rs867924 
  AKAP6 rs926771 GRIN2B rs10845826 NR3C1 rs9285657 
  AKAP6 rs9322889 GRIN2B rs10845831 NR3C1 rs953723 
  AKAP6 rs9322896 GRIN2B rs10845838 NR3C1 rs17403174 
  AKAP6 rs9322899 GRIN2B rs10845852 NR3C1 rs17403503 
  AKAP6 rs941746 GRIN2B rs10845856 NR3C1 rs17413134 
  AKAP6 rs9635189 GRIN2B rs10845858 NR3C1 rs17414396 
  AKAP7 rs1190788 GRIN2B rs10845861 NR3C2 rs10010766 
  AKAP7 rs1190791 GRIN2B rs10845863 NR3C2 rs10031194 
  AKAP7 rs1190806 GRIN2B rs11055556 NR3C2 rs10032020 
  AKAP7 rs11965549 GRIN2B rs11055557 NR3C2 rs1040288 
  AKAP7 rs1534624 GRIN2B rs11055593 NR3C2 rs10434100 
  AKAP7 rs17182683 GRIN2B rs11055594 NR3C2 rs10519951 
  AKAP7 rs1729549 GRIN2B rs11055597 NR3C2 rs10519952 





AKAP7 rs17573187 GRIN2B rs11055626 NR3C2 rs10519963 
  AKAP7 rs17787339 GRIN2B rs11055628 NR3C2 rs11099678 
  AKAP7 rs1881573 GRIN2B rs11055664 NR3C2 rs11099681 
  AKAP7 rs2204732 GRIN2B rs11055670 NR3C2 rs11099694 
  AKAP7 rs3777478 GRIN2B rs11055681 NR3C2 rs11725509 
  AKAP7 rs3777483 GRIN2B rs11055699 NR3C2 rs11737660 
  AKAP7 rs3777486 GRIN2B rs11611183 NR3C2 rs11936376 
  AKAP7 rs3777489 GRIN2B rs12305339 NR3C2 rs13116332 
  AKAP7 rs3903759 GRIN2B rs12313659 NR3C2 rs13116347 
  AKAP7 rs6917207 GRIN2B rs12317299 NR3C2 rs13133240 
  AKAP7 rs6937607 GRIN2B rs12371702 NR3C2 rs13137823 
  AKAP7 rs6942184 GRIN2B rs12422385 NR3C2 rs13142954 
  AKAP7 rs9321275 GRIN2B rs12809496 NR3C2 rs1403142 
  AKAP8 rs12611023 GRIN2B rs1362816 NR3C2 rs1403143 
  AKAP9 rs10234071 GRIN2B rs16909348 NR3C2 rs1512335 
  AKAP9 rs10281556 GRIN2B rs16909619 NR3C2 rs1512342 
  AKAP9 rs10488509 GRIN2B rs17220663 NR3C2 rs1512343 
  AKAP9 rs12530646 GRIN2B rs172677 NR3C2 rs16998733 
  AKAP9 rs12531366 GRIN2B rs17760842 NR3C2 rs17024387 
  AKAP9 rs12536529 GRIN2B rs17760889 NR3C2 rs17024443 
  AKAP9 rs12537846 GRIN2B rs17833759 NR3C2 rs17024482 
  AKAP9 rs12540055 GRIN2B rs17833849 NR3C2 rs1858416 
  AKAP9 rs13231578 GRIN2B rs17833908 NR3C2 rs1879827 
  AKAP9 rs2282971 GRIN2B rs1805199 NR3C2 rs1994624 
  AKAP9 rs2299231 GRIN2B rs1805476 NR3C2 rs2070949 
  AKAP9 rs2299233 GRIN2B rs1805490 NR3C2 rs2070950 
  AKAP9 rs3753107 GRIN2B rs1805525 NR3C2 rs2070951 
  AKAP9 rs6942649 GRIN2B rs1805543 NR3C2 rs2293162 
  AKAP9 rs7785095 GRIN2B rs1805546 NR3C2 rs2883930 
  CAMK2
A rs1432833 GRIN2B rs1805553 NR3C2 rs3846307 
  CAMK2
A rs17111079 GRIN2B rs1806191 NR3C2 rs3846329 
  CAMK2
A rs3822606 GRIN2B rs2160402 NR3C2 rs3887856 
  CAMK2
A rs4958467 GRIN2B rs2193150 NR3C2 rs3910044 
  CAMK2
A rs4958468 GRIN2B rs2193151 NR3C2 rs3910046 
  CAMK2
A rs4958469 GRIN2B rs219872 NR3C2 rs3910054 
  CAMK2
A rs874083 GRIN2B rs219886 NR3C2 rs4027073 
  CAMK2
B rs1890135 GRIN2B rs219904 NR3C2 rs4260521 
  CAMK2
B rs3934888 GRIN2B rs219909 NR3C2 rs4835128 







D rs10009286 GRIN2B rs219921 NR3C2 rs4835493 
  CAMK2
D rs10023113 GRIN2B rs220578 NR3C2 rs4835514 
  CAMK2
D rs10461194 GRIN2B rs2268129 NR3C2 rs5522 
  CAMK2
D rs1047187 GRIN2B rs2268132 NR3C2 rs5525 
  CAMK2
D rs10488891 GRIN2B rs2268133 NR3C2 rs6535577 
  CAMK2
D rs10488894 GRIN2B rs2268135 NR3C2 rs6535584 
  CAMK2
D rs11098193 GRIN2B rs2284410 NR3C2 rs6535594 
  CAMK2
D rs11946664 GRIN2B rs2284415 NR3C2 rs6810951 
  CAMK2
D rs12508566 GRIN2B rs2284428 NR3C2 rs6811001 
  CAMK2
D rs12644009 GRIN2B rs2300241 NR3C2 rs6828665 
  CAMK2
D rs13144613 GRIN2B rs2300242 NR3C2 rs6849903 
  CAMK2
D rs17046126 GRIN2B rs2300245 NR3C2 rs7687754 
  CAMK2
D rs17446453 GRIN2B rs2300266 NR3C2 rs7693077 
  CAMK2
D rs17592426 GRIN2B rs2300268 NR3C2 rs9307847 
  CAMK2
D rs17593296 GRIN2B rs4140764 NR3C2 rs17483833 
  CAMK2
D rs17629820 GRIN2B rs4763358 NR3C2 rs17484259 
  CAMK2
D rs17630012 GRIN2B rs7295850 NR3C2 rs17484678 
  CAMK2
D rs17630328 GRIN2B rs7296762 NR3C2 rs17484873 
  CAMK2
D rs17630766 GRIN2B rs7311519 NR3C2 rs17581311 
  CAMK2
D rs1859148 GRIN2B rs7313149 NR3C2 rs17581884 
  CAMK2
D rs1859150 GRIN2B rs7314871 NR3C2 rs17620330 
  CAMK2
D rs1859152 GRIN2B rs7952915 NR3C2 rs17620822 
  CAMK2




























































































G rs7080350 GRIN3A rs12708308 
PALM2-
AKAP2 rs260221 
  CREB1 rs2551920 GRIN3A rs1323412 PALM2-AKAP2 rs491356 
  CREB1 rs2709393 GRIN3A rs1323420 PALM2-AKAP2 rs491730 
  CREB1 rs6785 GRIN3A rs1323421 PALM2-AKAP2 rs496709 
  CRHBP rs7721799 GRIN3A rs1323430 PALM2-AKAP2 rs4978870 
  CRHR1 rs17689471 GRIN3A rs1407877 PALM2-AKAP2 rs4978875 
  CRHR1 rs17689824 GRIN3A rs1535633 PALM2-AKAP2 rs525681 
  CRHR1 rs17689882 GRIN3A rs16920504 PALM2-AKAP2 rs545955 
  CRHR1 rs17762769 GRIN3A rs17189275 PALM2-AKAP2 rs6477737 
  CRHR1 rs17763104 GRIN3A rs17189604 PALM2-AKAP2 rs6477740 





CRHR1 rs241033 GRIN3A rs17774987 PALM2-AKAP2 rs7028076 
  CRHR1 rs242939 GRIN3A rs1853447 PALM2-AKAP2 rs7038399 
  CRHR1 rs413778 GRIN3A rs2146801 PALM2-AKAP2 rs7847333 
  CRHR1 rs422112 GRIN3A rs2417286 PALM2-AKAP2 rs7847354 
  CRHR1 rs4277389 GRIN3A rs2485523 PALM2-AKAP2 rs7861341 
  CRHR1 rs453997 GRIN3A rs2506351 PALM2-AKAP2 rs7863709 
  CRHR1 rs4640231 GRIN3A rs2506362 PALM2-AKAP2 rs7865972 
  CRHR1 rs8072451 GRIN3A rs2506363 PALM2-AKAP2 rs914356 
  CRHR2 rs1003929 GRIN3A rs301434 PALM2-AKAP2 rs914358 
  CRHR2 rs2190242 GRIN3A rs4742823 POMC rs6545975 
  CRHR2 rs2240404 GRIN3A rs7023041 POMC rs7565427 
  CRHR2 rs2267710 GRIN3A rs7849782 POMC rs7565877 
  CRHR2 rs255121 GRM1 rs1014878 POMC rs934778 
  CRHR2 rs4723003 GRM1 rs10484860 PRKACB rs1016379 
  CRHR2 rs929377 GRM1 rs10872583 PRKACB rs10493750 
  CRHR2 rs973002 GRM1 rs11155451 PRKACB rs11163905 
  CRHR2 rs975537 GRM1 rs12202357 PRKACB rs12405120 
  DICER1 rs10498642 GRM1 rs1331639 PRKACB rs12723299 
  DICER1 rs6575499 GRM1 rs1331645 PRKACB rs2134646 
  DLG4 rs2239340 GRM1 rs1543349 PRKACB rs2134648 
  FKBP5 rs1475774 GRM1 rs17075834 PRKACB rs2139931 
  FKBP5 rs16878806 GRM1 rs2268663 PRKACB rs2642186 
  FKBP5 rs16879378 GRM1 rs2268666 PRKACB rs589373 
  FKBP5 rs2766533 GRM1 rs2300620 PRKACB rs603939 
  FKBP5 rs2817032 GRM1 rs2300631 PRKACB rs6661411 
  FKBP5 rs4713899 GRM1 rs2814863 PRKACB rs6701486 
  FKBP5 rs755658 GRM1 rs362818 PRKAR1A rs16972996 
  FKBP5 rs9368881 GRM1 rs362840 PRKAR1A rs2952275 
  FKBP5 rs9462104 GRM1 rs362842 PRKAR1A rs4265886 
  GLS rs3771316 GRM1 rs362844 PRKAR1A rs8076465 
  GLS rs6434429 GRM1 rs362845 PRKAR2A rs9859473 
  GLS rs867637 GRM1 rs362847 PRKAR2B rs10272371 
  GRIA1 rs10035262 GRM1 rs362848 PRKAR2B rs12154324 
  GRIA1 rs10035289 GRM1 rs362851 PRKAR2B rs13224682 
  GRIA1 rs10060095 GRM1 rs362852 PRKAR2B rs17153823 
  GRIA1 rs10070447 GRM1 rs362855 PRKAR2B rs17340577 
  GRIA1 rs10073988 GRM1 rs362894 PRKAR2B rs17425839 
  GRIA1 rs10477084 GRM1 rs362949 PRKAR2B rs2049900 





GRIA1 rs10515692 GRM1 rs4896861 PRKAR2B rs6960708 
  GRIA1 rs11167640 GRM1 rs56566 PRKAR2B rs9656135 
  GRIA1 rs11738883 GRM1 rs6570746 PRKCA rs10451280 
  GRIA1 rs11739206 GRM1 rs6570747 PRKCA rs10491200 
  GRIA1 rs11742223 GRM1 rs6570757 PRKCA rs12450569 
  GRIA1 rs11747180 GRM1 rs6914813 PRKCA rs12600582 
  GRIA1 rs11955628 GRM1 rs7741271 PRKCA rs12601850 
  GRIA1 rs12152942 GRM1 rs7743911 PRKCA rs1355984 
  GRIA1 rs12153489 GRM1 rs7750018 PRKCA rs16959216 
  GRIA1 rs12153765 GRM1 rs7772919 PRKCA rs16959229 
  GRIA1 rs12515520 GRM1 rs863820 PRKCA rs16959236 
  GRIA1 rs12515561 GRM1 rs9322052 PRKCA rs16959238 
  GRIA1 rs12515563 GRM1 rs9390374 PRKCA rs16959447 
  GRIA1 rs13354399 GRM1 rs9497485 PRKCA rs16959450 
  GRIA1 rs1363677 GRM1 rs9497521 PRKCA rs16959508 
  GRIA1 rs1461232 GRM1 rs979775 PRKCA rs16959510 
  GRIA1 rs1463747 GRM3 rs10238436 PRKCA rs16959514 
  GRIA1 rs1493389 GRM3 rs10952891 PRKCA rs16959593 
  GRIA1 rs1493395 GRM3 rs12704286 PRKCA rs16959604 
  GRIA1 rs1493403 GRM3 rs12704289 PRKCA rs16959714 
  GRIA1 rs1540383 GRM3 rs16888204 PRKCA rs16959880 
  GRIA1 rs1552837 GRM3 rs16888210 PRKCA rs16960077 
  GRIA1 rs17096210 GRM3 rs17160978 PRKCA rs16960114 
  GRIA1 rs17114692 GRM3 rs17161024 PRKCA rs17643302 
  GRIA1 rs17114703 GRM3 rs17697445 PRKCA rs17686174 
  GRIA1 rs17114836 GRM3 rs17697609 PRKCA rs17686720 
  GRIA1 rs17114975 GRM3 rs2158786 PRKCA rs17688050 
  GRIA1 rs17115017 GRM3 rs2189812 PRKCA rs17710992 
  GRIA1 rs17115020 GRM3 rs2237553 PRKCA rs17771145 
  GRIA1 rs17115039 GRM3 rs2237554 PRKCA rs227915 
  GRIA1 rs17356099 GRM3 rs2237559 PRKCA rs228884 
  GRIA1 rs17515380 GRM3 rs2237563 PRKCA rs3803821 
  GRIA1 rs17518831 GRM3 rs2299221 PRKCA rs3803822 
  GRIA1 rs17519054 GRM3 rs2299224 PRKCA rs3888658 
  GRIA1 rs17519558 GRM3 rs274621 PRKCA rs4381631 
  GRIA1 rs17519656 GRM3 rs2888551 PRKCA rs4536508 
  GRIA1 rs17523221 GRM3 rs4294091 PRKCA rs4622543 
  GRIA1 rs17525192 GRM3 rs6955452 PRKCA rs4630584 
  GRIA1 rs17591636 GRM3 rs6955917 PRKCA rs4630585 
  GRIA1 rs1873906 GRM3 rs723631 PRKCA rs4644888 
  GRIA1 rs1973372 GRM3 rs7788115 PRKCA rs4791051 
  GRIA1 rs2216649 GRM3 rs7804907 PRKCA rs6504424 
  GRIA1 rs2452801 GRM3 rs802437 PRKCA rs6504425 





GRIA1 rs2963957 GRM3 rs802441 PRKCA rs6967 
  GRIA1 rs2964018 GRM3 rs802459 PRKCA rs7207097 
  GRIA1 rs4273649 GRM3 rs802467 PRKCA rs7207345 
  GRIA1 rs4336409 GRM4 rs1109654 PRKCA rs7211524 
  GRIA1 rs4424038 GRM4 rs13196449 PRKCA rs7217618 
  GRIA1 rs4958351 GRM4 rs2499690 PRKCA rs7219499 
  GRIA1 rs4958676 GRM4 rs2499714 PRKCA rs7221805 
  GRIA1 rs524905 GRM4 rs7751882 PRKCA rs7225164 
  GRIA1 rs541518 GRM4 rs9368793 PRKCA rs7405806 
  GRIA1 rs545098 GRM4 rs937039 PRKCA rs7502206 
  GRIA1 rs574071 GRM4 rs9380406 PRKCA rs8066055 
  GRIA1 rs6580024 GRM4 rs9394187 PRKCA rs8068129 
  GRIA1 rs6580032 GRM4 rs9469693 PRKCA rs8069142 
  GRIA1 rs6580039 GRM5 rs1000061 PRKCA rs8069859 
  GRIA1 rs6870761 GRM5 rs10501694 PRKCA rs8075066 
  GRIA1 rs6889794 GRM5 rs10501696 PRKCA rs8080727 
  GRIA1 rs6889909 GRM5 rs10741500 PRKCA rs956952 
  GRIA1 rs6891142 GRM5 rs10765186 PRKCA rs980346 
  GRIA1 rs7708391 GRM5 rs10831251 PRKCA rs9891403 
  GRIA1 rs7709884 GRM5 rs11018448 PRKCA rs9893560 
  GRIA1 rs7711124 GRM5 rs11018463 PRKCA rs9895580 
  GRIA1 rs7714428 GRM5 rs11020781 PRKCA rs9896549 
  GRIA1 rs7727515 GRM5 rs11020938 PRKCA rs9896922 
  GRIA1 rs7735696 GRM5 rs11021034 PRKCA rs9897124 
  GRIA1 rs778816 GRM5 rs11021035 PRKCA rs9898205 
  GRIA1 rs812389 GRM5 rs11021132 PRKCA rs9900205 
  GRIA1 rs889060 GRM5 rs11021266 PRKCA rs9900353 
  GRIA1 rs9324751 GRM5 rs1116378 PRKCA rs990082 
  GRIA1 rs9686702 GRM5 rs11606431 PRKCA rs990083 
  GRIA2 rs17035916 GRM5 rs11828996 PRKCA rs9900927 
  GRIA2 rs17035959 GRM5 rs12290410 PRKCA rs9901804 
  GRIA2 rs4392549 GRM5 rs12787863 PRKCA rs9903792 
  GRIA3 rs10521718 GRM5 rs12802146 PRKCA rs9904266 
  GRIA3 rs11260421 GRM5 rs1391873 PRKCA rs9908167 
  GRIA3 rs12396914 GRM5 rs1391874 PRKCA rs9908953 
  GRIA3 rs12557782 GRM5 rs1391875 PRKCA rs9911259 
  GRIA3 rs2157272 GRM5 rs1391878 PRKCA rs9912468 
  GRIA3 rs2353721 GRM5 rs1391954 PRKCA rs9915719 
  GRIA3 rs4825476 GRM5 rs1499026 PRKCB rs1013316 
  GRIA3 rs4825836 GRM5 rs1499030 PRKCB rs1014632 
  GRIA3 rs498126 GRM5 rs1499185 PRKCB rs10852256 
  GRIA3 rs503118 GRM5 rs1499188 PRKCB rs10852263 
  GRIA3 rs550640 GRM5 rs1508688 PRKCB rs11074583 





GRIA3 rs5911548 GRM5 rs16914739 PRKCB rs120908 
  GRIA3 rs5911590 GRM5 rs16915130 PRKCB rs12932420 
  GRIA3 rs5911622 GRM5 rs17184781 PRKCB rs1468130 
  GRIA3 rs593293 GRM5 rs1846442 PRKCB rs1557671 
  GRIA3 rs5956542 GRM5 rs1846443 PRKCB rs16940401 
  GRIA3 rs637574 GRM5 rs1903848 PRKCB rs16973180 
  GRIA3 rs652582 GRM5 rs1903851 PRKCB rs16973277 
  GRIA3 rs6608067 GRM5 rs2047512 PRKCB rs174828 
  GRIA3 rs6608068 GRM5 rs2221108 PRKCB rs17809041 
  GRIA3 rs6608087 GRM5 rs2387412 PRKCB rs17810486 
  GRIA3 rs687577 GRM5 rs2892290 PRKCB rs195996 
  GRIA3 rs695214 GRM5 rs308879 PRKCB rs196004 
  GRIA3 rs7052603 GRM5 rs308880 PRKCB rs198142 
  GRIA3 rs7058062 GRM5 rs4107263 PRKCB rs198182 
  GRIA3 rs762993 GRM5 rs4121738 PRKCB rs198200 
  GRIA3 rs970665 GRM5 rs4488199 PRKCB rs198201 
  GRIA3 rs970666 GRM5 rs4604887 PRKCB rs198202 
  GRIA3 rs989638 GRM5 rs4604888 PRKCB rs1989647 
  GRIA3 rs989639 GRM5 rs4753731 PRKCB rs2188355 
  GRIA4 rs10502061 GRM5 rs640211 PRKCB rs2188356 
  GRIA4 rs10502062 GRM5 rs6483397 PRKCB rs2188360 
  GRIA4 rs10502063 GRM5 rs6483399 PRKCB rs2238493 
  GRIA4 rs10750733 GRM5 rs7121916 PRKCB rs2340988 
  GRIA4 rs10791767 GRM5 rs719182 PRKCB rs2470688 
  GRIA4 rs10791773 GRM5 rs723859 PRKCB rs2560402 
  GRIA4 rs10895849 GRM5 rs7396702 PRKCB rs2560406 
  GRIA4 rs10895850 GRM5 rs7396713 PRKCB rs375624 
  GRIA4 rs10895875 GRM5 rs7483940 PRKCB rs377133 
  GRIA4 rs11226828 GRM5 rs7935922 PRKCB rs3785380 
  GRIA4 rs11226856 GRM5 rs7943357 PRKCB rs3785394 
  GRIA4 rs1267444 GRM5 rs8181526 PRKCB rs3785403 
  GRIA4 rs17104596 GRM5 rs904462 PRKCB rs381901 
  GRIA4 rs17104715 GRM5 rs961689 PRKCB rs3826260 
  GRIA4 rs17104747 GRM5 rs973716 PRKCB rs400066 
  GRIA4 rs17104835 GRM5 rs982010 PRKCB rs405322 
  GRIA4 rs17482908 GRM5 rs992259 PRKCB rs4238948 
  GRIA4 rs1938961 GRM6 rs17078852 PRKCB rs437545 
  GRIA4 rs1939148 GRM6 rs17078862 PRKCB rs4787291 
  GRIA4 rs1940964 GRM6 rs2645341 PRKCB rs4788423 
  GRIA4 rs2155045 GRM7 rs10222587 PRKCB rs6497704 
  GRIA4 rs2186598 GRM7 rs10490857 PRKCB rs7192816 
  GRIA4 rs495498 GRM7 rs10510353 PRKCB rs7196543 
  GRIA4 rs505829 GRM7 rs10510354 PRKCB rs7197785 





GRIA4 rs545184 GRM7 rs10510364 PRKCB rs8047317 
  GRIA4 rs552767 GRM7 rs10510370 PRKCB rs8051531 
  GRIA4 rs601480 GRM7 rs1066658 PRKCB rs8051700 
  GRIA4 rs602098 GRM7 rs1083801 PRKCB rs8055831 
  GRIA4 rs610160 GRM7 rs1106486 PRKCB rs8056879 
  GRIA4 rs622178 GRM7 rs11131064 PRKCB rs8063762 
  GRIA4 rs631002 GRM7 rs11131069 PRKCB rs886114 
  GRIA4 rs632100 GRM7 rs11131078 PRKCB rs9806904 
  GRIA4 rs638099 GRM7 rs1143740 PRKCB rs9925126 
  GRIA4 rs646007 GRM7 rs1155966 PRKCB rs9930905 
  GRIA4 rs658965 GRM7 rs11706732 PRKCB rs9938298 
  GRIA4 rs661329 GRM7 rs11708019 PRKCB rs9940479 
  GRIA4 rs668120 GRM7 rs11710946 PRKCD rs13084863 
  GRIA4 rs682708 GRM7 rs11711367 PRKCD rs1483185 
  GRIA4 rs7102566 GRM7 rs11713266 PRKCD rs17052826 
  GRIA4 rs7122727 GRM7 rs11716647 PRKCE rs10166692 
  GRIA4 rs748353 GRM7 rs11717471 PRKCE rs10179954 
  GRIA4 rs994575 GRM7 rs11717750 PRKCE rs10188306 
  GRIK1 rs1016700 GRM7 rs11915789 PRKCE rs10189339 
  GRIK1 rs1029224 GRM7 rs11918634 PRKCE rs10201978 
  GRIK1 rs11088125 GRM7 rs12489041 PRKCE rs10202504 
  GRIK1 rs11701584 GRM7 rs12494654 PRKCE rs1020445 
  GRIK1 rs12627201 GRM7 rs12497688 PRKCE rs10210199 
  GRIK1 rs16985084 GRM7 rs12637466 PRKCE rs10211547 
  GRIK1 rs1735072 GRM7 rs13070476 PRKCE rs10490341 
  GRIK1 rs2142161 GRM7 rs13072518 PRKCE rs10490342 
  GRIK1 rs2244881 GRM7 rs1351938 PRKCE rs10865208 
  GRIK1 rs2249140 GRM7 rs1356268 PRKCE rs11125038 
  GRIK1 rs2252974 GRM7 rs1485167 PRKCE rs11125041 
  GRIK1 rs2268206 GRM7 rs1485171 PRKCE rs11125048 
  GRIK1 rs2832417 GRM7 rs1485172 PRKCE rs11690929 
  GRIK1 rs2832442 GRM7 rs1485174 PRKCE rs11691705 
  GRIK1 rs2832445 GRM7 rs1499079 PRKCE rs11903923 
  GRIK1 rs2832448 GRM7 rs1499161 PRKCE rs12464563 
  GRIK1 rs2832449 GRM7 rs1499199 PRKCE rs12465869 
  GRIK1 rs2832457 GRM7 rs1499204 PRKCE rs12616328 
  GRIK1 rs2832464 GRM7 rs1504047 PRKCE rs12712963 
  GRIK1 rs2832465 GRM7 rs1532544 PRKCE rs13003856 
  GRIK1 rs2832473 GRM7 rs1605705 PRKCE rs13016869 
  GRIK1 rs2832477 GRM7 rs162802 PRKCE rs13036100 
  GRIK1 rs2832488 GRM7 rs17046231 PRKCE rs13404973 
  GRIK1 rs2832489 GRM7 rs17046322 PRKCE rs13405086 
  GRIK1 rs2832493 GRM7 rs17047073 PRKCE rs13424270 





GRIK1 rs307943 GRM7 rs17047199 PRKCE rs1448219 
  GRIK1 rs363442 GRM7 rs17047734 PRKCE rs1522987 
  GRIK1 rs363457 GRM7 rs17234886 PRKCE rs17033965 
  GRIK1 rs363495 GRM7 rs17235018 PRKCE rs17034571 
  GRIK1 rs363497 GRM7 rs17288561 PRKCE rs17034573 
  GRIK1 rs363501 GRM7 rs17655560 PRKCE rs17034576 
  GRIK1 rs363515 GRM7 rs17664833 PRKCE rs17034610 
  GRIK1 rs363516 GRM7 rs17665113 PRKCE rs17034641 
  GRIK1 rs363526 GRM7 rs17673467 PRKCE rs17034719 
  GRIK1 rs363528 GRM7 rs17694650 PRKCE rs17799476 
  GRIK1 rs363529 GRM7 rs17697853 PRKCE rs1868271 
  GRIK1 rs363566 GRM7 rs17717959 PRKCE rs1868272 
  GRIK1 rs388700 GRM7 rs17723289 PRKCE rs1868273 
  GRIK1 rs398989 GRM7 rs17751439 PRKCE rs1868390 
  GRIK1 rs402280 GRM7 rs17824866 PRKCE rs1868392 
  GRIK1 rs406191 GRM7 rs1857697 PRKCE rs1966813 
  GRIK1 rs408151 GRM7 rs1872394 PRKCE rs1982366 
  GRIK1 rs408302 GRM7 rs1872397 PRKCE rs2005271 
  GRIK1 rs415336 GRM7 rs1872400 PRKCE rs2029087 
  GRIK1 rs441426 GRM7 rs1876614 PRKCE rs2034360 
  GRIK1 rs453238 GRM7 rs1878164 PRKCE rs2053797 
  GRIK1 rs455354 GRM7 rs1909397 PRKCE rs2204204 
  GRIK1 rs455804 GRM7 rs1963265 PRKCE rs2218660 
  GRIK1 rs456784 GRM7 rs2069062 PRKCE rs2255091 
  GRIK1 rs458470 GRM7 rs2116711 PRKCE rs2255094 
  GRIK1 rs459617 GRM7 rs2133450 PRKCE rs2278777 
  GRIK1 rs460583 GRM7 rs2291867 PRKCE rs2285024 
  GRIK1 rs462393 GRM7 rs2324122 PRKCE rs2345178 
  GRIK1 rs463021 GRM7 rs2875257 PRKCE rs2345625 
  GRIK1 rs463360 GRM7 rs329044 PRKCE rs2345955 
  GRIK1 rs463479 GRM7 rs332938 PRKCE rs2594491 
  GRIK1 rs464576 GRM7 rs340657 PRKCE rs2595213 
  GRIK1 rs464668 GRM7 rs340659 PRKCE rs2595222 
  GRIK1 rs467028 GRM7 rs3749380 PRKCE rs2711286 
  GRIK1 rs467155 GRM7 rs3749448 PRKCE rs2711292 
  GRIK1 rs7277926 GRM7 rs3792452 PRKCE rs2711293 
  GRIK1 rs7283968 GRM7 rs3792460 PRKCE rs2711295 
  GRIK1 rs932250 GRM7 rs3804850 PRKCE rs281469 
  GRIK2 rs10457942 GRM7 rs3804857 PRKCE rs281471 
  GRIK2 rs12182308 GRM7 rs3804867 PRKCE rs281472 
  GRIK2 rs12192251 GRM7 rs3804883 PRKCE rs281508 
  GRIK2 rs12193068 GRM7 rs3804886 PRKCE rs2881068 
  GRIK2 rs13195038 GRM7 rs3804904 PRKCE rs3754566 





GRIK2 rs1338167 GRM7 rs3804928 PRKCE rs3768747 
  GRIK2 rs1361450 GRM7 rs3804945 PRKCE rs3768751 
  GRIK2 rs1415483 GRM7 rs3828472 PRKCE rs3795863 
  GRIK2 rs17054628 GRM7 rs3846161 PRKCE rs3820732 
  GRIK2 rs17054632 GRM7 rs3864076 PRKCE rs3886870 
  GRIK2 rs1832413 GRM7 rs4095095 PRKCE rs4557033 
  GRIK2 rs1832415 GRM7 rs4143516 PRKCE rs4952771 
  GRIK2 rs1890278 GRM7 rs4441639 PRKCE rs4952787 
  GRIK2 rs2245817 GRM7 rs456835 PRKCE rs4952805 
  GRIK2 rs2248660 GRM7 rs4686101 PRKCE rs4953254 
  GRIK2 rs2255496 GRM7 rs4686102 PRKCE rs4953262 
  GRIK2 rs2518150 GRM7 rs4686119 PRKCE rs4953269 
  GRIK2 rs2518203 GRM7 rs4686145 PRKCE rs4953273 
  GRIK2 rs2518204 GRM7 rs4686146 PRKCE rs4953279 
  GRIK2 rs2518296 GRM7 rs4686148 PRKCE rs4953288 
  GRIK2 rs2518313 GRM7 rs576913 PRKCE rs4953290 
  GRIK2 rs2579938 GRM7 rs6443090 PRKCE rs4953305 
  GRIK2 rs2749052 GRM7 rs6443099 PRKCE rs4953321 
  GRIK2 rs2749054 GRM7 rs6443100 PRKCE rs505310 
  GRIK2 rs2764226 GRM7 rs6764411 PRKCE rs556650 
  GRIK2 rs2782892 GRM7 rs6769814 PRKCE rs563601 
  GRIK2 rs2782920 GRM7 rs6771606 PRKCE rs612717 
  GRIK2 rs2786239 GRM7 rs6772333 PRKCE rs637889 
  GRIK2 rs2787566 GRM7 rs6775424 PRKCE rs6544843 
  GRIK2 rs2852571 GRM7 rs6777701 PRKCE rs6544873 
  GRIK2 rs2852584 GRM7 rs6777970 PRKCE rs656823 
  GRIK2 rs2852604 GRM7 rs6778030 PRKCE rs666334 
  GRIK2 rs2852605 GRM7 rs6781223 PRKCE rs667747 
  GRIK2 rs4112793 GRM7 rs6782528 PRKCE rs6705717 
  GRIK2 rs4839801 GRM7 rs6799329 PRKCE rs6719779 
  GRIK2 rs4840195 GRM7 rs6801970 PRKCE rs6725257 
  GRIK2 rs4840196 GRM7 rs6803027 PRKCE rs6732900 
  GRIK2 rs4840197 GRM7 rs6808554 PRKCE rs6742742 
  GRIK2 rs4840202 GRM7 rs6810141 PRKCE rs6743119 
  GRIK2 rs6905533 GRM7 rs712775 PRKCE rs6746467 
  GRIK2 rs6918619 GRM7 rs712777 PRKCE rs6748375 
  GRIK2 rs6919217 GRM7 rs712779 PRKCE rs6750700 
  GRIK2 rs6928180 GRM7 rs712782 PRKCE rs6751349 
  GRIK2 rs7749722 GRM7 rs712785 PRKCE rs6760363 
  GRIK2 rs7754131 GRM7 rs7340751 PRKCE rs753572 
  GRIK2 rs9322608 GRM7 rs752300 PRKCE rs7557421 
  GRIK2 rs9322609 GRM7 rs7621537 PRKCE rs7558342 
  GRIK2 rs9377274 GRM7 rs7622749 PRKCE rs7563379 





GRIK2 rs9390779 GRM7 rs7635212 PRKCE rs7577273 
  GRIK2 rs9399726 GRM7 rs7650218 PRKCE rs7582320 
  GRIK2 rs9404115 GRM7 rs779694 PRKCE rs7593255 
  GRIK2 rs9404120 GRM7 rs779699 PRKCE rs7593800 
  GRIK2 rs9404125 GRM7 rs779705 PRKCE rs7598174 
  GRIK2 rs9485549 GRM7 rs779733 PRKCE rs7602129 
  GRIK2 rs9498701 GRM7 rs779741 PRKCE rs7604415 
  GRIK2 rs954765 GRM7 rs779742 PRKCE rs878812 
  GRIK3 rs1032722 GRM7 rs779749 PRKCE rs884400 
  GRIK3 rs11263956 GRM7 rs781393 PRKCE rs935656 
  GRIK3 rs1160752 GRM7 rs908465 PRKCE rs935672 
  GRIK3 rs12133182 GRM7 rs9311976 PRKCE rs938661 
  GRIK3 rs12736276 GRM7 rs951557 PRKCG rs443239 
  GRIK3 rs16823702 GRM7 rs9812630 PRKCH rs10134093 
  GRIK3 rs3738085 GRM7 rs9814809 PRKCH rs10483742 
  GRIK3 rs3767066 GRM7 rs9814881 PRKCH rs10483743 
  GRIK3 rs3767101 GRM7 rs9819314 PRKCH rs1088673 
  GRIK3 rs4652931 GRM7 rs9819987 PRKCH rs11621346 
  GRIK3 rs4653233 GRM7 rs9823996 PRKCH rs11621877 
  GRIK3 rs471710 GRM7 rs9826424 PRKCH rs12590817 
  GRIK3 rs476894 GRM7 rs9836538 PRKCH rs12881922 
  GRIK3 rs480495 GRM7 rs9837019 PRKCH rs12883769 
  GRIK3 rs484017 GRM7 rs9837834 PRKCH rs17098278 
  GRIK3 rs493243 GRM7 rs9837989 PRKCH rs17098279 
  GRIK3 rs499230 GRM7 rs9849147 PRKCH rs17098351 
  GRIK3 rs501832 GRM7 rs9860274 PRKCH rs17098356 
  GRIK3 rs507460 GRM7 rs9860560 PRKCH rs17098382 
  GRIK3 rs517969 GRM7 rs9870018 PRKCH rs17098514 
  GRIK3 rs522481 GRM7 rs9870241 PRKCH rs17098542 
  GRIK3 rs527442 GRM7 rs9870680 PRKCH rs1957907 
  GRIK3 rs527631 GRM7 rs9875041 PRKCH rs2181987 
  GRIK3 rs535620 GRM7 rs989126 PRKCH rs2184634 
  GRIK3 rs535876 GRM7 rs9990013 PRKCH rs4281621 
   
 
A4.2 Single SNP Association (BD-AUD) 
Chromosome SNP Minor allele Odds ratio 
t-
statistic p-value 
2 rs2594491 C 0.6677 -3.066 0.002172 
16 rs3104704 T 0.5604 -2.986 0.002823 
16 rs1875205 C 0.6155 -2.864 0.004178 
7 rs2299556 G 1.549 2.668 0.007641 




7 rs1419442 A 1.425 2.556 0.01058 
3 rs1392366 C 1.468 2.49 0.01276 
2 rs4953262 A 1.375 2.456 0.01403 
7 rs2299546 A 1.403 2.451 0.01425 
11 rs7925270 A 1.394 2.438 0.01475 
7 rs2299536 A 1.377 2.415 0.01576 
5 rs6898504 C 0.6967 -2.409 0.01601 
14 rs1998056 G 1.37 2.406 0.01613 
21 rs2832448 C 1.419 2.393 0.01673 
5 rs1463747 C 0.7258 -2.388 0.01695 
3 rs17047149 G 0.08411 -2.374 0.01759 
6 rs10457942 A 0.6329 -2.37 0.01777 
2 rs667747 T 0.4858 -2.369 0.01784 
11 rs973716 T 0.6356 -2.368 0.01788 
21 rs2244881 C 1.41 2.351 0.01874 
16 rs2352740 A 1.366 2.337 0.01944 
21 rs2832449 T 1.403 2.318 0.02043 
5 rs1493389 T 0.5659 -2.308 0.02097 
5 rs2452801 C 0.7271 -2.308 0.02099 
11 rs10790400 T 1.354 2.292 0.0219 
14 rs11160168 T 1.392 2.275 0.02289 
6 rs12192251 G 0.6276 -2.268 0.02332 
5 rs1973372 A 0.5783 -2.242 0.02495 
2 rs563601 A 1.37 2.238 0.02525 
2 rs17034641 T 1.555 2.233 0.02552 
4 rs17035959 C 1.364 2.23 0.02577 
16 rs2239340 A 0.7105 -2.227 0.02593 
16 rs2188360 T 0.7211 -2.22 0.0264 
11 rs6589833 C 1.35 2.214 0.0268 
16 rs3785394 C 1.343 2.203 0.02759 
16 rs6416623 T 1.342 2.2 0.02778 
4 rs17035916 T 1.357 2.186 0.0288 
5 rs17518831 T 0.748 -2.18 0.02929 
7 rs2188187 C 1.365 2.163 0.03053 
4 rs2107172 C 1.323 2.16 0.03076 
9 rs16920504 A 0.6944 -2.144 0.03203 
2 rs17034719 G 2.182 2.141 0.03229 
7 rs2237790 G 0.7192 -2.139 0.0324 
7 rs6975798 A 0.7561 -2.118 0.03414 
2 rs637889 C 1.336 2.109 0.03495 
5 rs2398660 G 0.7506 -2.098 0.03593 
16 rs7404005 A 0.7251 -2.093 0.03636 
2 rs2218660 C 1.344 2.064 0.03904 




14 rs12437224 A 1.443 2.061 0.03932 
11 rs7116106 A 1.316 2.04 0.04137 
6 rs362851 G 0.7757 -2.036 0.04172 
7 rs4141410 G 0.7615 -2.035 0.04182 
16 rs195996 A 1.301 2.026 0.04279 
6 rs9380406 T 1.306 2.022 0.04316 
2 rs2711295 T 1.63 2.015 0.04385 
4 rs11936376 A 1.352 2.015 0.04391 
16 rs4782271 G 1.392 2.003 0.04518 
6 rs4112793 C 0.459 -1.99 0.04659 
17 rs7225164 A 0.7666 -1.976 0.04816 
7 rs952912 G 1.365 1.967 0.04916 
 
A4.3 Single SNP Association (BD) 
Chromosome SNP 
Minor 
allele Odds Ratio t-statistic p-value 
5 rs812389 G 1.565 3.112 0.001858 
9 rs10980210 G 2.381 3.077 0.002093 
12 rs16909348 A 0.3075 -3.003 0.002672 
4 rs4027073 C 1.5 2.867 0.00414 
9 rs10816924 A 1.676 2.843 0.004462 
2 rs7565427 A 0.4937 -2.833 0.004615 
2 rs10865208 G 1.45 2.742 0.006098 
16 rs2239340 A 1.501 2.738 0.006186 
17 rs16959593 T 1.823 2.716 0.006607 
3 rs9823996 G 1.463 2.702 0.006895 
4 rs13142954 A 1.494 2.692 0.007092 
12 rs11055557 A 1.408 2.564 0.01035 
16 rs8044064 A 1.422 2.54 0.01108 
16 rs16973277 C 0.4203 -2.498 0.01249 
12 rs1805543 C 1.391 2.462 0.01381 
6 rs6557123 G 0.7005 -2.454 0.01412 
16 rs1900718 G 0.7173 -2.441 0.01466 
3 rs779749 T 0.6986 -2.435 0.01489 
12 rs1362816 T 1.641 2.429 0.01515 
2 rs2595222 T 0.7095 -2.425 0.01532 
6 rs10457871 G 0.7054 -2.418 0.01561 
2 rs13003856 C 0.711 -2.416 0.01571 
16 rs4998386 T 0.5173 -2.407 0.01609 
3 rs1155966 G 1.73 2.402 0.01631 
14 rs10498642 G 1.592 2.389 0.01692 
4 rs3815072 C 1.483 2.386 0.01705 
16 rs9924226 G 0.717 -2.353 0.01861 




3 rs1963265 T 1.396 2.344 0.01906 
2 rs4952771 T 1.389 2.314 0.02069 
3 rs6771606 G 1.406 2.304 0.02125 
16 rs2238493 G 0.5248 -2.291 0.02199 
3 rs1106486 C 0.7152 -2.261 0.02376 
3 rs6769814 G 1.375 2.259 0.02391 
5 rs10070447 T 0.7165 -2.256 0.02408 
17 rs17604987 A 0.6752 -2.246 0.02471 
16 rs7190716 A 0.5398 -2.246 0.02473 
11 rs646543 G 0.672 -2.245 0.02476 
17 rs850622 T 0.6758 -2.243 0.02488 
11 rs719182 T 1.449 2.238 0.0252 
16 rs10852263 T 0.655 -2.226 0.02603 
4 rs17024387 T 1.367 2.208 0.02724 
11 rs7128009 T 0.6636 -2.207 0.02728 
3 rs3804945 T 0.7287 -2.2 0.02781 
2 rs6751349 A 0.5969 -2.195 0.02818 
16 rs7205594 T 0.732 -2.188 0.0287 
3 rs13070476 C 0.6768 -2.175 0.02961 
16 rs11644367 T 0.7418 -2.173 0.02975 
6 rs9485549 G 1.917 2.171 0.02989 
16 rs2267786 A 1.372 2.167 0.03023 
16 rs6497732 T 1.339 2.158 0.03092 
2 rs6732900 T 0.7351 -2.156 0.03107 
3 rs7628504 G 0.68 -2.153 0.03135 
12 rs12422385 G 1.592 2.145 0.03193 
12 rs10492136 C 0.5461 -2.13 0.03315 
3 rs3792460 C 1.365 2.128 0.03331 
7 rs2299233 C 0.7451 -2.126 0.03353 
16 rs13336632 C 0.5846 -2.123 0.03372 
16 rs2267772 C 0.733 -2.113 0.03459 
2 rs7573407 T 0.7391 -2.11 0.03483 
16 rs13331514 T 0.5867 -2.11 0.03486 
16 rs7188291 G 0.5872 -2.103 0.0355 
9 rs7022772 A 0.7042 -2.102 0.03553 
3 rs1351938 A 0.7502 -2.102 0.03558 
16 rs17671033 T 0.5879 -2.098 0.0359 
12 rs10845863 T 2.245 2.096 0.03605 
12 rs1805199 T 0.6647 -2.096 0.03612 
16 rs1070476 A 1.324 2.084 0.03719 
12 rs11055628 A 1.363 2.078 0.03771 
14 rs7159519 T 1.329 2.076 0.03793 
16 rs10518151 G 0.5917 -2.075 0.03796 




7 rs13240504 T 1.467 2.071 0.03838 
16 rs9922383 T 0.592 -2.07 0.03848 
17 rs8069859 G 1.404 2.068 0.03859 
12 rs2160402 A 0.5558 -2.064 0.03904 
17 rs203457 A 0.7426 -2.062 0.03918 
2 rs6719779 G 1.332 2.061 0.03928 
17 rs119672 G 0.7443 -2.05 0.04036 
5 rs4958676 A 0.6749 -2.048 0.04055 
4 rs17484259 A 0.6656 -2.046 0.04071 
4 rs11936376 A 0.6876 -2.036 0.04173 
17 rs2108978 T 0.7463 -2.031 0.04226 
16 rs971035 C 1.342 2.009 0.04451 
17 rs7209653 G 0.7235 -2.005 0.04491 
4 rs7684265 G 0.5778 -2.002 0.04532 
21 rs363497 G 0.2403 -1.988 0.04684 
3 rs3804904 A 1.331 1.973 0.04854 
16 rs11644461 C 1.307 1.968 0.04901 
7 rs10488509 G 1.316 1.968 0.04912 
2 rs7563379 C 0.7564 -1.967 0.04914 
 
A4.4 Gene-Based Results (BD-AUD) 
Gene NSNP NSIG ISIG EMP1 SNPS 
PRKCZ 8 0 0 1 NA 
GRIK3 34 0 0 1 NA 
PRKAR2A 1 0 0 1 NA 
PRKCD 3 0 0 1 NA 
CAMK2A 7 0 0 1 NA 
GRM6 3 0 0 1 NA 
SYNGAP1 1 0 0 1 NA 
AKAP12 19 0 0 1 NA 
CAMK2B 2 0 0 1 NA 
GRM3 31 0 0 1 NA 
AKAP9 15 0 0 1 NA 
PRKAR2B 10 0 0 1 NA 
IDO1 1 0 0 1 NA 
SLC1A1 26 0 0 1 NA 
PALM2-
AKAP2 40 0 0 1 NA 
PRKCQ 3 0 0 1 NA 
GRIA4 43 0 0 1 NA 
AKAP3 4 0 0 1 NA 
GRIN2B 90 0 0 1 NA 
AKAP6 57 0 0 1 NA 




AKAP13 82 0 0 1 NA 
AKAP10 6 0 0 1 NA 
AKAP1 12 0 0 1 NA 
PRKCA 80 0 0 1 NA 
PRKAR1A 4 0 0 1 NA 
GRIK5 1 0 0 1 NA 
PRKCG 1 0 0 1 NA 
MAPK1 10 0 0 1 NA 
POMC 4 0 0 1 NA 
UCN 0 0 0 1 NA 
CRH 0 0 0 1 NA 
CRHR2 9 0 0 1 NA 
UCN3 1 0 0 1 NA 
UCN2 2 0 0 1 NA 
CRHR1 14 0 0 1 NA 
AVP 0 0 0 1 NA 
AVPR1B 0 0 0 1 NA 
CRHBP 1 0 0 1 NA 
FKBP5 9 0 0 1 NA 
MC2R 6 0 0 1 NA 
NR3C2 51 0 0 1 NA 
AKAP11 2 0 0 1 NA 
AKAP14 1 0 0 1 NA 
AKAP4 0 0 0 1 NA 
AKAP5 0 0 0 1 NA 
AKAP7 21 0 0 1 NA 
AKAP8 1 0 0 1 NA 
ARC 0 0 0 1 NA 
CREB1 3 0 0 1 NA 
DICER1 2 0 0 1 NA 
DUSP1 0 0 0 1 NA 
GLS 3 0 0 1 NA 
GRIA3 31 0 0 1 NA 
GRIN2C 2 0 0 1 NA 
GRIN3B 0 0 0 1 NA 
GRM2 0 0 0 1 NA 
MAPK3 0 0 0 1 NA 
PRKACA 0 0 0 1 NA 
PRKACB 13 0 0 1 NA 
PRKACG 0 0 0 1 NA 
STX1A 0 0 0 1 NA 
SYP 0 0 0 1 NA 
GRIK2 58 3 2 0.5219 rs10457942|rs4112793 




GRIA1 80 6 2 0.2885 rs1463747|rs1493389 
GRIN3A 30 1 1 0.331 rs16920504 
GRIA2 3 2 1 
0.0605
5 rs17035959 
GRM7 170 1 1 0.468 rs17047149 
CAMK2G 5 1 1 0.1688 rs17631000 
SERPINA6 10 4 3 0.1023 rs1956177|rs1998056|rs12437224 
CAMK2D 39 1 1 0.4019 rs2107172 
DLG4 1 1 1 0.0259 rs2239340 
GRM8 103 7 5 0.2676 rs2299556|rs1419442|rs2299546|rs2237790|rs6975798 
GRIN2D 4 1 1 0.1483 rs2380121 
PRKCE 129 5 5 0.2728 rs2594491|rs4953262|rs667747|rs17034641|rs563601 
GRIK1 64 4 2 0.495 rs2832448|rs307943 
GRIN2A 111 5 3 0.1824 rs3104704|rs2352740|rs4782271 
GRM1 43 1 1 0.4751 rs362851 
PRKCB 62 5 2 0.475 rs3785394|rs2188360 
NR3C1 37 2 2 0.3114 rs6898504|rs2398660 
GRIK4 57 4 1 0.2089 rs7925270 
GRM4 10 1 1 0.2788 rs9380406 
GRM5 67 1 1 0.193 rs973716 
 










PRKCZ 8 0 0 1 NA 
GRIK3 34 0 0 1 NA 
PRKCD 3 0 0 1 NA 
CAMK2A 7 0 0 1 NA 
GRM6 3 0 0 1 NA 
SYNGAP1 1 0 0 1 NA 
GRM4 10 0 0 1 NA 
CAMK2B 2 0 0 1 NA 
GRM3 31 0 0 1 NA 
PRKAR2B 10 0 0 1 NA 
IDO1 1 0 0 1 NA 
GRIN3A 30 0 0 1 NA 
PRKCQ 3 0 0 1 NA 
CAMK2G 5 0 0 1 NA 
GRIA4 43 0 0 1 NA 
AKAP3 4 0 0 1 NA 
PRKCH 33 0 0 1 NA 
AKAP13 82 0 0 1 NA 
PRKAR1A 4 0 0 1 NA 




UCN 0 0 0 1 NA 
CRH 0 0 0 1 NA 
CRHR2 9 0 0 1 NA 
UCN3 1 0 0 1 NA 
UCN2 2 0 0 1 NA 
CRHR1 14 0 0 1 NA 
AVP 0 0 0 1 NA 
AVPR1B 0 0 0 1 NA 
CRHBP 1 0 0 1 NA 
FKBP5 9 0 0 1 NA 
MC2R 6 0 0 1 NA 
NR3C1 37 0 0 1 NA 
SERPINA6 10 0 0 1 NA 
AKAP11 2 0 0 1 NA 
AKAP14 1 0 0 1 NA 
AKAP4 0 0 0 1 NA 
AKAP5 0 0 0 1 NA 
AKAP7 21 0 0 1 NA 
AKAP8 1 0 0 1 NA 
ARC 0 0 0 1 NA 
CREB1 3 0 0 1 NA 
DUSP1 0 0 0 1 NA 
GLS 3 0 0 1 NA 
GRIA2 3 0 0 1 NA 
GRIA3 31 0 0 1 NA 
GRIN2C 2 0 0 1 NA 
GRIN2D 4 0 0 1 NA 
GRIN3B 0 0 0 1 NA 
GRM1 43 0 0 1 NA 
GRM2 0 0 0 1 NA 
MAPK3 0 0 0 1 NA 
PRKACA 0 0 0 1 NA 
PRKACB 13 0 0 1 NA 
PRKACG 0 0 0 1 NA 
PRKCI 5 0 0 1 NA 
DICER1 2 1 1 
0.033
4 rs10498642 




AKAP2 40 2 2 
0.020
2 rs10980210|rs10816924 
GRM8 103 1 1 
0.759
8 rs13240504 











PRKCB 62 3 2 
0.304
7 rs16973277|rs10852263 
AKAP10 6 5 1 0.05 rs17604987 
AKAP9 15 2 2 
0.137
7 rs2299233|rs10488509 
GRIK1 64 1 1 
0.718
8 rs363497 
CAMK2D 39 2 2 
0.375
4 rs3815072|rs7684265 
NR3C2 51 1 1 
0.026
2 rs4027073 
GRIK4 57 2 1 
0.417
1 rs646543 
AKAP12 19 2 1 
0.112
4 rs6557123 
SLC1A1 26 1 1 
0.411
3 rs7022772 
AKAP6 57 1 1 
0.712
1 rs7159519 
GRM5 67 1 1 
0.376
6 rs719182 
AKAP1 12 1 1 
0.298
7 rs7209653 
POMC 4 1 1 
0.011
7 rs7565427 
GRIN2A 111 9 5 
0.328
7 rs8044064|rs1900718|rs4998386|rs2267786|rs6497732 
GRIA1 80 4 3 
0.145
3 rs812389|rs4958351|rs4958676 
GRIK2 58 1 1 
0.602
6 rs9485549 
GRM7 170 9 5 0.441 rs9823996|rs779749|rs1155966|rs6771606|rs13070476 
 
